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Abstract 
Introduction 
Lactase in addition to its role in the digestion of lactose available in milk and dairy products is implicated in the 
metabolism of a range of phenolic phytochemicals in the gut. Experiments with Caco-2 cells have shown that 
these cells which mimic the intestinal mucosa indicate that quercetin glucosides and quercetin aglycone (widely 
consumed in onions and apples) block glucose uptake from the gut by competing with glucose for the sodium-
dependent SGLT-1 and sodium-independent GLUT-2 transporters respectively (Johnston et al., 2005a, Schulze 
et al., 2015). It has been suggested that dietary phenolics that block glucose uptake from the gut may reduce the 
risk of type 2 diabetes. However, the ability of quercetin glucosides to block SGLT-1 is lost or reduced when the 
glucoside moiety is cleaved off during lactase hydrolysis. It is currently unknown if lactose-tolerant individuals 
deglycosylate quercetin to a greater extent than lactose-intolerant individuals and therefore are less able to reduce 
glucose uptake from the intestine. The aim of in vitro study was to model human gut condition for glucose 
transport by using Caco-2 cell models and to model role of human intestinal LPH by incubation of Caco-2 cells 
with quercetin flavonoids and purified β-galactosidases and in vivo was to investigate whether lactose-tolerant 
and lactose-intolerant subjects show differences in the uptake of glucose. 
Methods 
Caco-2 cells were cultured in DMEM full medium in 24 well plates. Thereafter, glucose uptake assay was 
conducted by using 3H-glucose in the presence and absence of sodium, to assess the effect of flavonoids such as 
phloridzin, quercetin 4́-glucoside, quercetin 3,4́-diglucoside, quercetin 3́-glucoside, and quercetin aglycone on 
glucose uptake. Transwell inserts were also used to demonstrate the bidirectional permeability through Caco-2 
monolayers, transport of glucose from apical (SGLT-1) to basolateral side (GLUT-2). -galactosidase enzyme 
assay was conducted by using -galactosidase from Aspergillus oryzae, Caco-2 cells were treated with 100 µM 
quercetin glucosides, 25% w/v onion extract and -galactosidase in order to model the hydrolysis of flavonoids 
by lactase in the small intestine. HPLC was carried out to determine if quercetin glucosides are found in onion 
extract and test whether -galactosidase is active and result in deglycosylation of substrates such as individual 
quercetin glucosides and quercetin glucosides in onion extract. For the clinical study, lactose intolerance was 
identified by the hydrogen breath test (Gastrolyzer), and blood glucose levels were measured by taking finger-
prick blood samples in several intervals (0, 15, 30, 60, 90, 120) minutes using an EKF glucose analyser. 
Results 
Findings from the current in vitro research confirm that phloridzin is an inhibitor of sodium-dependent conditions 
(SGLT-1) transporter with 80% reduction, this therefore was used as a positive control. Quercetin 4́-glucoside 
and quercetin 3,4́-diglucoside at (100µM) significantly decreased the uptake of glucose in the presence of sodium 
with up to 75% reduction compared to control p < 0.01. However, no significant glucose inhibition was found 
from these quercetin glucosides in the absence of sodium condition (p > 0.5), whilst quercetin aglycone 
significantly inhibited the glucose uptake with 50% reduction compared to control at significance levels of (p = 
0.02). HPLC data identified quercetin 3,4́-diglucoside and quercetin 4́-glucoside with RT = 4.082 min and 11.392 
min in the onion extract by showing peaks at similar ranges with RT= 4.114 min and 11.385 min with their 
standards, and the concentration of quercetin 4́-glucoside was measured as the highest level (42µg/ml) in onion 
extract compared to 3,4́-glucoside and quercetin 3-glucoside. Further HPLC illustrated that, after incubation of 
quercetin glucosides and onion extract with -galactosidase Aspergillus oryzae for 20, 40 and 60 minutes, the 
peaks occurred at similar RT =16.453 min and 16.441 min respectively in accordance with standard quercetin 
(RT=16.239 min), suggesting the deglycosylation of these compounds with -galactosidase from Aspergillus 
oryzae. According to findings from the clinical study, reduction of peak glucose levels by an onion meal was 
higher in lactose-intolerant people than lactose-tolerant people (44.2% versus 19.3%, p = 0.042). Also, the area 
under the blood glucose curve was reduced more in lactose-intolerant people compared to lactose-tolerant people, 
however was not statistically significant (54.5% versus 42.1%, p = 0.425). 
Discussion 
Our result suggests that quercetin 4́-glucoside and quercetin 3,4-́diglucosides and onion extract were the main 
inhibitors of glucose uptake in sodium-dependent conditions (SGLT-1). Whereas, quercetin aglycone inhibited 
GLUT-2 glucose transport on Caco-2 cell monolayers under sodium independent conditions. Our findings were 
in accordance to several previous studies (Boyer et al., 2005, Kwon et al., 2007, Schulze et al., 2015). Notably, in 
vitro studies were conducted to model whether the in vivo study is likely to succeed or not. Findings from our 
human study showed that glucose uptake was blocked by the onion solution and a diet containing quercetin 
glucosides (onion meal) may be of greater benefit for glycaemic control in lactose-intolerant people than in 
lactose-tolerant people. 
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1. CHAPTER ONE – GENERAL INTRODUCTION 
1.1. Diabetes, Type 1 and Type 2 
There are two major types of diabetes, which are dependent upon the secretion and sensitivity 
to insulin. Type 1 diabetes mellitus is an autoimmune disease, in which the immune system 
starts destroying the β-cells of the pancreas, and therefore exogenous insulin is required due to 
the lack of insulin level. The second type of diabetes is non-insulin dependent diabetes in which 
adequate amounts of insulin may be available. However, cells cannot use it effectively because 
of insulin resistance (Chang-Chen et al., 2008).  
Type 1 diabetes accounts for only 5 to 10% of all diabetic cases, whereas type 2 diabetes, which 
is the most common type of diabetes, accounts for more than 90% of all diabetic patients (Yach 
et al., 2006). The main factors contributing to the risk of type 2 diabetes could be genetic factors, 
peripheral insulin resistance, ageing, and also possible changes in the source of food, quantity 
of carbohydrates, as well as lack of physical activity (Schulze and Hu, 2005). For instance, the 
key factor in the development of hyperglycaemia could be the result of a high intake of 
carbohydrates in the form of beverages and snacks that contain a great amount of sugar. 
Therefore, high glucose absorption will result in permanent stimulation of insulin secretion 
(Yach et al., 2006). 
In 2014, the estimated number of people with diabetes mellitus was almost 422 million adults 
worldwide and it is anticipated to reach 552 million cases in 2030 (WHO, 2016). According to 
the new figures released by Diabetes UK 2016, the population of people living with diabetes 
in the UK has reached over 4 million.  
According to a report, 709,000 deaths from stroke and 1,490,000 deaths from ischaemic heart 
diseases were linked to high blood glucose levels (above optimum), and an indication that 13% 
and 21% of all deaths resulted from these conditions (Danaei et al., 2006). It is noteworthy that 
the rate of mortality of diabetics is over 4 million, which is comparable with the mortality rate 
from smoking (4.8 million), high cholesterol (3.9 million) and obesity (2.4 million). This is 
based on data from 52 countries provided by investigators, systematic reviews and individual-
level records in population health surveys (Danaei et al., 2006). Moreover, several studies have 
also found that association of isolated post-challenge hyperglycaemia with the risk of 
cardiovascular and atherosclerosis in type 2 diabetic patients is much greater than in isolated 
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fasting hyperglycaemia (Balkau et al., 1999, Bonora, 2002). The postprandial hyperglycaemia 
causes a 50% greater risk of CVD in impaired glucose-tolerance (IGT) patients who have not 
undergone therapy, compared to those who have (Esposito et al., 2004).  
Metabolic syndrome is highly prevalent among the patients with type 2 diabetes and is reported 
as a major risk factor for development of cardiovascular diseases and dyslipidaemia as a result 
of function of increasing BMI. Insulin resistance is present in majority of individuals with 
metabolic syndrome, it is correlated with the risk of type 2 diabetes and cardiovascular diseases. 
Moreover, elevated blood pressure associates with obesity and glucose intolerance and usually 
occurs in insulin resistance individuals (Alberti et al., 2006). Adiponectin is an adipokine that 
is modulated through expression of AdipoR1 and AdipoR2 receptors, leading to the activation 
of AMPK pathway which is positively associated with insulin sensitivity and altered by various 
environmental, genetic factors and pathological conditions. Thus, monitoring levels of 
adiponectin is a good predictable marker for type 2 diabetes and metabolic syndrome 
(Kadowaki et al., 2006). 
Increased oxidative stress has been found as one of the major concerns of diabetes. Thus, 
elevated levels of free radicals or reactive oxygen species (ROS) may cause stimulation of 
oxidised low-density lipoprotein (Ox-LDL). Consequently, sustained hyperglycaemia and high 
levels of oxidative stress are the major contributors in the development of diabetes. Retaining 
a balance between antioxidants and ROS is a key mechanism in avoiding damage from 
oxidative stress (Khaki et al., 2010). 
1.1.1. Management of Diabetes 
The recommended major therapy for patients with type 2 diabetes are lifestyle changes, such 
as dietary changes, weight reduction and physical activity (Lindahl et al., 2009, Roumen et al., 
2008). For maintaining blood glucose levels, lifestyle intervention may not be enough; 
therefore, patients with type 2 diabetes will additionally need antihyperglycaemic medications 
such as metformin in combination with or without subcutaneous insulin injections. The 
possible limitations regarding the use of antidiabetic drugs have resulted in undesirable side 
effects, as well as contraindications due to the presence of co-morbid diseases including 
hypertension and dyslipidaemia in patients (Tschope et al., 2013). Therefore, the demand for 
antihyperglycaemic agents with minor side effects is required.  
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Food can be powerful in preventing and reversing diabetes. However, dietary approaches have 
changed as we have learned more about the disease (Roumen et al., 2008). The traditional 
approach to diabetes focuses on limiting refined sugars and foods that release sugars during 
digestion-starches, breads and fruits. With carbohydrates reduced, the diet may contain an 
unhealthful amount of fat and protein. Therefore, diabetes experts have taken care to limit fats, 
especially saturated fats that can raise cholesterol levels, and to limit protein for people with 
impaired kidney function (Asif, 2014).  
A recent report has concluded that there is strong evidence that a low glycaemic index (GI) 
diet decreases the risk of type 2 diabetes and coronary heart disease, and also is most likely to 
reduce the risk of obesity and several cancers (Augustin et al., 2015a). There is growing 
evidence that secondary plant metabolites, particularly polyphenols (flavonoids), control 
postprandial increase in levels of blood glucose. For instance, phloridzin, a dihydrochalcone, 
which is highly found in apples and onions, has long been known as a very effective natural 
SGLT-1 inhibitor (Ehrenkranz et al., 2005). Moreover, several pharmaceutical companies have 
made SGLT-2 (glucose transporter) inhibitors that stop reabsorption of glucose from the kidney, 
thus improving the hyperglycaemia in type 2 diabetic patients. The approved SGLT-2 inhibitor 
in Europe is called dapagliflozin, which is used for type 2 diabetes treatment (Kilov et al., 
2013).  
Fruits and vegetables are high in insoluble fibre. Diets that are high in fibre may be able to help 
in the management of diabetes. Soluble fibre delays glucose absorption from the small intestine, 
and thus may help prevent the spike in blood glucose levels that follow a meal or snack (Asif, 
2014). 
1.2. Intestinal Glucose Transport and Absorption 
Glucose is the prime energy source for the majority of energy-dependent processes in living 
organisms. Glucose is an essential metabolic substrate of all mammalian cells. It is not only a 
precursor of glycoproteins, triglycerides, and glycogen, glucose metabolism governs many 
functions, because the oxidation of glucose generates a major source of metabolic energy in 
eukaryotic cells (Boyer et al., 2005). These functions are secondary to glucose uptake. Glucose 
is a hydrophilic compound; it cannot pass through the lipid bilayer by passive diffusion, and 
therefore requires specific carrier proteins to mediate its specific transport into the cytosol 
(Gray, 2010). When glucose is metabolised in the presence of oxygen, the process leads to 
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mitochondrial citric acid cycle, cytoplasmic glycolysis and oxidative phosphorylation. 
Following digestion of glucose, it enters the blood stream and then into cells which mostly take 
up glucose in an insulin dependent manner. Insulin is produced by the pancreas as a result of 
increased glucose levels (Song et al., 2005). 
There are two types of membrane proteins for the transport of glucose and other 
monosaccharides across cell membranes through the body. The glucose uptake is regulated by 
the action of facilitative glucose transporters (GLUTs), coded by the solute carrier (SLC) 2 
gene family, on the cell surface. There are three classes of GLUT isoforms: class I consists of 
GLUT1-4; class II, GLUT6, 8, 10 and 12; and class III, GLUT5, 9 and 11. Several studies with 
knockout or transgenic mice established the main role of these transporters in the regulation of 
glucose uptake and storage (Hanhineva et al., 2010b, Bauche et al., 2007).  
GLUT-1 and GLUT-3 control the glucose uptake at the basal membrane. GLUT-4 is expressed 
through kidney and muscle cells and remains stored in insulin-responsive compartments within 
the cells until insulin has facilitated its localisation on the cell surface (Hanhineva et al., 2010b). 
The second glucose membrane proteins are sodium-coupled glucose cotransporters (SGLTS) 
encoded by SLC5 gene family (Scheepers et al., 2004). While GLUTs passively and selectively 
allow monosaccharides to transport a concentration gradient, the uptake of glucose by SGLTs 
is mediated in a secondary active manner together with Na+-ions (Joost and Thorens, 2001, 
Uldry and Thorens, 2004). The SGLT family of transporters transport sugars against the 
concentration gradient utilising the sodium-electrochemical gradient (Roder et al., 2014). The 
GLUT family are facilitative transporters that transport sugars along the concentration gradient. 
After glucose enters normal cells, it is converted into pyruvate through glycolysis. 
Subsequently, pyruvate is transformed into acetyl-CoA, which is used as substrate in 
mitochondria to generate ATP (Szablewski, 2013). 
1.2.1. The classical model of glucose transport via SGLT-1 and GLUT-2 
The classical model of glucose transport is mediated by two classes of hexose transporters: 
SGLT-1 expressed at apical membrane (AM) and GLUT-2 expressed at basolateral membrane 
(BLM). Colon cells like Caco-2 are the most recognised cell line on presenting the two main 
transporters of glucose; one is the sodium dependent (in the presence of sodium) glucose 
transporter (SGLT-1), which is located in the apical membrane of the enterocyte. It is believed 
that it is a high affinity, low capacity active transport protein. Whereas, GLUT-2 transporter is 
not a sodium dependent glucose transporter and has a low affinity, high capacity and facilitated 
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protein transport. GLUT-2 is located on the basolateral membrane, and thus mediates glucose 
transport into the portal venous system (Zheng et al., 2011).  
 
Figure 1.1: Demonstration of glucose and fructose absorption in the small intestine (Shirazi-Beechay et al., 
2010). 
In enterocytes, the SGLT-1 is responsible for the transport of Na+ (two) coupled with glucose 
or galactose and water (Drozdowski and Thomson, 2006). This transporter is facilitated 
through Na+/K+ ATPase activity in the basal membrane. The facilitative transporter GLUT-2 
transports sugars across the basolateral membrane. Besides SGLT-1, the facilitative glucose 
transporter GLUT-5 is expressed at the apical membrane (Gray, 2010) (Figure 1.1). GLUT-5 
proteins exhibit no transport activity for glucose; however, it carries fructose into the 
enterocytes (Corpe et al., 2002). The exit of glucose, galactose and fructose from the 
enterocytes cytosol into the blood circulation is mediated by facilitative diffusion through 
GLUT-2 in the basolateral membrane (Miyamoto et al., 1992).  
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Figure 1.2: SGLT-1 and GLUT-2 mediated glucose transport at low luminal glucose concentrations (30-50 
mmol/L). 
Figure 1.2 shows 1) SGLT-1 transported the glucose along with two sodium ions. 2) The 
SGLT-1 is maintained by a Na+/K+ ATPase at the enterocytes basolateral membrane. 3) 
Glucose at intracellular level can be utilised for metabolism or is effluxed through basal GLUT-
2, in the presence of sodium conditions, apical GLUT-2 is located in subapical vesicles and 
does not transport glucose; notably, at low levels of glucose, no GLUT-2 is translocated into 
the apical membrane (Diez-Sampedro et al., 2004, Williamson, 2013). 
Glucose is transported through the apical enterocyte membrane by SGLT-1; facilitated glucose 
transport through the basolateral membrane is entirely mediated by GLUT-2 (Kellet et al., 
2008). Interestingly, GLUT-2 could be associated with the transport of glucose across the 
apical membrane at the high luminal glucose levels (Kellet and Brot-Laroche, 2005). However, 
the initial glucose transport via SGLT-1 is required for the GLUT-2 translocation into the apical 
membrane. Therefore it is evident that SGLT-1 is the prime component in the absorption of 
glucose and a target in hyperglycaemia management (Gouyon et al., 2003, Mace et al., 2009).  
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Figure 1.3: Activation of the apical GLUT-2 pathway of glucose transport across enterocyte at high 
concentrations (200 mmol/L). 
Figure 1.3 demonstrates 1) SGLT-1 mediated glucose and sodium influx increased. 2) The high 
concentrations of glucose and sodium content at intracellular level inhibits the basolateral 
Na+/K+ ATPase. The high intracellular content results in the rearrangement of cytoskeleton, 
leading to protein trafficking, followed by depolarisation of apical membrane, and is ready for 
GLUT-2 insertion from the subapical vesicles. 3) High influx of glucose derived from apical 
GLUT-2 activity, and therefore there is a greater release of glucose into circulation from 
basolateral membrane GLUT-2 (Goestemeyer et al., 2007, Williamson, 2013). 
GLUT-2 is rapidly transported to the apical membrane within a few minutes at elevated glucose 
levels. As the glucose concentration drops due to transport or at the end of the meal, the GLUT-
2 transporters moves away from the apical membrane ready for the next incidence of high 
glucose concentration (Williamson, 2013). After absorption of glucose into the blood from the 
intestine, it enters β-cells followed by phosphorylation of glucose and insulin secretion. Insulin 
reaches muscle and adipose cells, which thus leads to relocation of GLUT-4 to the cell 
membrane, and therefore stimulates glucose uptake into these tissues and consequential 
clearance from blood. In support of this, a study conducted by Kellet et al., 2008 showed that 
GLUT-2 was the main transporter of glucose mass absorption across the apical membrane at 
high luminal glucose concentrations (Kellet et al., 2008). It is suggested that GLUT-2 was 
translocated from an internal vesicle pool into the apical membrane in relation to an activation 
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of protein kinase CβII, initiated by SGLT-1 mediated transport across the apical membrane 
(Gouyon et al., 2003, Mace et al., 2009).  
Although the exact mechanisms of glucose absorption at high luminal levels is still uncertain, 
it is noteworthy that SGLT-1 also acts as an important pathway in the uptake of glucose levels 
in the intestine, since SGLT-1 deficient mice developed a severe malabsorption when fed 
galactose and glucose (Powell et al., 2013). This is in agreement with the glucose and galactose 
malabsorption syndrome available in humans with mutations in SLCA1-gene (Wright et al., 
2007). Whereas, mice heterozygous for SGLT-1 illustrated no adverse effects of growth 
retardation on a glucose containing diet (Powell et al., 2013), suggesting that a partial decrease 
in glucose uptake levels via SGLT-1 may be a potential therapeutic agent to prevent high 
concentrations of postprandial blood glucose in patients with impaired glucose tolerance and 
type 2 diabetes (Zheng et al., 2011). 
SGLT-1 transporter can transport the glucose and galactose with greatest abundance in the 
apical membrane of the proximal part of the small intestine (duodenum and proximal jejunum) 
(Zhou et al., 2003, Yoshikawa et al., 2011). In addition to glucose and galactose, other hexoses 
such as α-methyl-glucopyranoside (α-MDG) and 3-O-methlyglucose (3-OMG) could be used 
as substrates for SGLT-1 (Hediger and Rhoads, 1994). Also, SGLT-1 is found in the renal 
tubes at the proximal S3-segment (Lee et al., 1994), as well as in other tissues such as the brain 
and heart (Yu et al., 2013, Zhou et al., 2003). It is suggested that the apparent Km which is 
defined as the substrate concentration at ½ the maximum velocity for glucose through SGLT-
1 in vivo studies, is between 6-23 mM, whereas it is only 2-6 mM for in vitro studies (Hirayama 
et al., 1996, Ferraris et al., 1990).  
On the other hand, GLUT-2 with Km of approximately 17 mM (Thorens, 1996), in addition to 
being expressed in the small intestine, is also expressed in the pancreatic β-cells, kidney and 
liver, that need low affinity systems to determine accurate influx at physiological glucose levels 
(Thorens, 2001). According to the research conducted by (Wright and Turk, 2004), in the 
intestinal transport cells and kidney, GLUT-2 mediated absorption or reabsorption of glucose. 
Moreover, GLUT-2 is required for stimulation of insulin secretion from pancreatic β-cells, thus 
playing as a glucose sensor. This was followed by low levels of GLUT-2 expression in the 
brain, suggesting that GLUT-2 in the brain may cause a similar sensing function (Arluison et 
al., 2004).  
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1.2.2. Other mechanisms involved in the transport of glucose  
Several studies have shown that GLUT-2 deficient mice had no changes in the kinetic of 
glucose absorption in the intestine after an oral glucose tolerance test (OGTT) (Stumpel et al., 
2001), similar to subjects carrying mutations in SLC2A2 gene at GLUT-2, the Fanconi-Bickel 
syndrome condition (Santer et al., 2003). Moreover, another report failed to detect any activity 
of GLUT-2 in apical membrane vesicles from healthy and/or diabetic cases showing that 
GLUT-2 is not permanently expressed at the luminal side of the small intestine of diabetic 
patients (Dyer et al., 2002). Interestingly, Stumpel (et al., 2001) suggested another possible 
transcellular route as a crucial pathway for transport of glucose across the basolateral 
membrane that does not need functional GLUT-2. In this pathway the glucose is moved to the 
apical membrane through SGLT-1 into the enterocyte, followed by phosphorylation to glucose-
6-phosphate (G6P) and access into the endoplasmic reticulum (ER). Then, G6P is hydrolysed 
into glucose and phosphate, and free glucose is realised across the basolateral membrane 
through exocytosis (Stumpel et al., 2001). 
There are several other theories, which have been suggested to demonstrate transepithelial 
transport of glucose at high luminal glucose concentrations. For example, the solvent drag 
theory suggested that passive paracellular flux, which involves absorption of glucose 
predominantly by a passive diffusional process, results in bulk glucose absorption (Mullen et 
al., 1985). This idea supports the possible passive component of glucose transport through an 
increase in paracellular permeability, because of widening of tight junctions activated either by 
SGLT-1, or by the high luminal glucose level, thus allowing great quantities of solvent or other 
nutrients moving to the paracellular space, followed by dragging glucose with them and thus 
diffusing into the portal system (Pappenheimer and Reiss, 1987). On the other hand, animal 
studies conducted on non-membrane permeable substrates, such as L-glucose in the presence 
of high luminal sugar levels, showed a slight increase in the levels of these substrates in the 
blood, illustrating that paracellular transport does not contribute to glucose bulk absorption at 
high luminal concentrations (Schwartz et al., 1995). 
1.2.3. SGLT-1 and GLUT-2 role on Diabetes and Hyperglycaemia  
It should be noted that high levels of glucose transporters in type 2 diabetes and obesity could 
develop a greater absorption rate of glucose in relation to a sugar-rich meal, thus resulting in 
greater postprandial blood glucose peak compared to non-diabetic cases. In support of this, a 
study observed that the rate of glucose absorption was approximately threefold faster in type 2 
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diabetics tissues as compared to control subjects (Dyer et al., 1997). Several studies have 
investigated the effect of different dietary monosaccharides on expression of SGLT-1 in the 
small intestine. They have illustrated an upregulation when different sugars were present in the 
small intestine, suggesting that neither transport through SGLT-1 nor metabolism is essential 
to induce gene expression of SGLT-1 (Dyer et al., 2003, Shirazi-Beechey et al., 1994). 
Moreover, in a study on diabetic mice, they showed that upregulation of SGLT-1 is activated 
through sweet taste receptors (T1R2 + T1R3) in the intestine through G-protein α-gustducin or 
the sweet receptor subunit TR13, and determined no upregulation of SGLT-1 expression in 
relation to dietary sugars and artificial sweeteners as found in wild-type mice (Margolskee et 
al., 2007).  
Co-overexpression of RS1 (Regulatory subunit 1) and SGLT-1 in Xenopus oocytes, in the renal 
epithelial cell line LLC-PK1 reduced SGLT-1 mRNA, SGLT-1 protein in addition to the 
amount of SGLT-1-mediated glucose uptake (Korn et al., 2001). In fact, in mice lacking RS1, 
the expression level of SGLT-1 in addition to postprandial glucose absorption in luminal 
intestine highly increased; therefore, there was a greater peak in blood glucose concentrations 
in the portal glucose sensing compared to wild-type mice (Osswald et al., 2005).  
Reduction in the protein abundance of SGLT-1 caused a significant decrease in the absorption 
levels of intestinal hexose for the gastrointestinal peptide cholecystokinin (Hirsh and 
Cheeseman, 1998), similarly for leptin that reaches the intestinal lumen after its release by 
mucosal gastric cells (Ducroc et al., 2005). Therefore, both these hormones could act as main 
targets for changes in expression of SGLT-1 detected in type 2 diabetes patients (Dyer et al., 
1997) as well as obesity cases in animal models (Huang et al., 2012, Jurowich et al., 2013). 
Downregulation of SGLT-1 expression in changing the levels of GLP-1 and GIP, contributes 
to the fast improvement of glycaemic control obtained post Roux-en Y gastric bypass surgery 
(RYGB) in patients with type 2 diabetes and obesity (Jurowich et al., 2013, Stearns et al., 2009). 
Moreover, another study showed that, in mice with RS1, which is a membrane-associated 
intracellular protein that inhibits trafficking of intracellular vesicles possessing SGLT-1 from 
the trans-Golgi network to the plasma membrane, have regulated the postprandial 
hyperglycaemia (Kroiss et al., 2006). 
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In diabetes, several transporters and enzymes responsible for glucose uptake in the intestine 
are upregulated. For example, SGLT-1 levels increased up to fourfold in the gut of type 2 
diabetics, and GLUT-2 mRNA also increased threefold. It is believed that brush border vesicles 
from duodenal biopsies from diabetic subjects take up glucose almost three fold faster than the 
equivalent from the control subjects (Williamson, 2013). 
1.3. Dietary Polyphenols  
1.3.1. Structure  
Polyphenol is a compound possessing more than one phenolic hydroxyl group (Hoffman and 
Gerber, 2012). More than 8000 polyphenolic compounds have been recognised in literature, 
ranging from simple molecules, such as phenolic acids, to highly polymerised structures, like 
tannins (Crozier et al., 2009). Polyphenols can be divided into several types, dependent on the 
number of phenolic rings and the structural elements binding these rings. The two main 
subclasses include flavonoids and non-flavonoids (D'Archivio et al., 2007). Flavonoids, which 
are the most known types of polyphenols, depending on the variation in the type of heterocycle 
involved, are divided into six major subclasses: flavonols, flavanones, flavanols, flavones, 
anthocyanins and isoflavones (Pandey and Rizvi, 2009), and non-flavonoids such as phenolic 
acids, cinnamic acid derivatives, stilbenes and lignans (Hoffman and Gerber, 2012).  
Flavonoids in their structure have phenolic rings substituted either with alcoholic, carboxylic 
acid or aldehydic groups which can be further deglycosylated in the case of arbutin or 
salidroside (El-Seedi et al., 2012).  
Individual differences within each group arise from the variation in number and arrangement 
of the hydroxyl groups and their extent of alkylation and/or glycosylation. Flavonoids are found 
in plants mainly as -glycosides. Mostly, the processing procedures used in food industries do 
not result in cleavage of the glycosidic linkage, and hence flavonoids in foods largely exist as 
glycosides. The amount of glycosylation, position and nature depend on the plant species 
(Nemeth et al., 2003).The biggest group of polyphenols is characterised by flavonoids. The 
basic structure involves a 15-carbon basic skeleton (flavan) which, is oriented by two aromatic 
rings (ring A and ring B) linked by a 3-carbon bridge forming a closed heterocyclic ring (ring 
C) with the aromatic ring A (figure 1.4).  
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Figure 1.4: Chemical structures of sub-classes of flavonoids (Pandey and Rizvi, 2009). 
Figure 1.4 shows, flavonols (such as quercetin) have a 3-hydroxy pyran-4-one group on the C 
ring. Flavanones (naringenin) possess an unsaturated carbon-carbon bond in the C ring. 
Flavanols (catechins) lack both a 3-hydroxyl group and the 4-one structure in the C ring. 
Flavones (luteolin) lack a hydroxyl group in the 3-position on the C ring. Anthocyanins 
(cyanidin) are characterised by the presence of an oxonium ion on the C ring and in isoflavones 
(for example genistein), the B ring is attached to the C ring in the 3-position, rather than the 2-
position as is the case with the other flavonoids (Pandey and Rizvi, 2009). 
Quercetin flavonoid is found as glycosylated forms, mainly as β-glycosides. The nature of 
glycosylation has considerable impacts on the efficiency of quercetin absorption. The dominant 
type of glycoside differs between foods. For instance, apples contain mostly galactosides, 
rhamnosides and arabinosides, whereas onions contain mainly glucosides (Arts et al., 2004). 
In all onion cultivars, quercetin derivatives of glycosylase moieties are mainly glucose, which 
is attached to the 4́,3 and/or 7-positions of the aglycones (Slimestad et al., 2007). Whereas in 
apple mainly occurs in O-linkage to glucose and galactose at position 3 of the flavan backbone 
(Manach et al., 2004). 
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Figure 1.5: Structure of the poly-hydroxylated flavonoid quercetin representing glycosylated derivatives that are 
found in plants such as onion. A= Quercetin 4́-glucoside, B= Quercetin 3-glucoside, C= Quercetin 3-rutinoside 
and D= Quercetin 3,4́-diglucoside (Nemeth et al., 2003). 
These phenolic compounds have aromatic rings in common which contain one or more 
hydroxyl substituents (figure 1.5). Mostly, they are combined with sugar glucoside and are 
positioned in cell vacuole (figure 1.5). Intervention studies have shown that the primary site 
for the absorption of several flavonoid glucosides is the small intestine. Since quercetin 
glucosides were found to be more bioavailable than quercetin aglycones, they might also 
absorb earlier in the small intestine and result in a greater plasma peak concentration (Nemeth 
et al., 2003). 
 
Figure 1.6: Structure of Phloridzin and its aglycone Phloretin (Jugdé et al., 2008). 
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The phenolic compound phloridzin (phloretin 2´-O-glucoside) belongs to the dihydrochalcone 
flavonoid sub-class and consists of two aromatic rings joined by an alkyl ester (Gosch et al., 
2010) (figure 1.6). 
Moreover, another group of polyphenolic compounds that are derived from cinnamic acid 
derivatives are the stilbenes. They are found in plants as cis- or trans- isomers with trans-
configuration as the most abundant type; they occur in monomeric form as well as dimeric, 
trimeric and polymeric stilbenes, called viniferins (Cassidy et al., 2000). They are widespread 
in red wine from species named Vitis Vinifera L (Riviere et al., 2012). The resveratrol is the 
most known form of stilbene group (Maier-Salamon et al., 2013). 
1.3.2. Dietary sources 
Polyphenols are present in fruits, vegetables, tea, coffee, cereals, red wine and herbs (Kwon et 
al., 2007, Tsao, 2010). The most widely found flavonol in diet is quercetin and its glycosylated 
derivatives, present in onions, apple, berries and tea (Williamson and Manach, 2005). Onions 
have the highest content of quercetin glucosides, it ranges between 28.4 to 48.6 mg/100g, while 
the amount in apples range between 2.1 to 7.2 mg/100g fresh weight (Lee and Mitchell, 2012). 
Yellow onions contain 270-1187 mg of flavonols per kilogram of fresh weight, while red 
onions contain 415-1917 mg of flavonols per kilogram of fresh weight (Slimestad et al., 2007).  
The concentration of phloridzin and phloretin is mainly dependent on the variety of apples and 
initially found in the apple peel and at lower levels in the pulp. For instance, the concentration 
of phloridzin and phloretin in the peel of the apple variety Reineta ranges between 83-418 and 
53-100 mg per 100 gram of fresh weight, respectively, whereas the amount of phloridzin in the 
pulp is between 16 and 20 mg per 100 gram of fresh sample (Escarpa and Gonzalez, 1998). 
The amount of chlorogenic acid in apple varies between 30 and 60 mg/kg in fresh weight and 
208 mg/l in apple juice. Moreover, according to a study, Portuguese red wine contained 50.8 
mg/l of trans-piceid which is the 3-β-glucoside of resveratrol (Ribeiro de Lima et al., 1999).  
Table 1.1, demonstrates the widely distributed fruits and vegetables containing quercetin 
aglycone, quercetin 4́-glucoside and quercetin 3,4́-diglucosides. 
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  Flavonols(Mean)             
(mg/100g) 
Source Quercetin 
Quercetin 4́-
glucoside 
Quercetin 3,4́-
diglucoside 
Apple 0.13 0.64 ND 
Blueberry 4 0.50 ND 
Grape 3.54 2.17 ND 
Red Onion 1.31 38.80 77.08 
Yellow Onion 0.28 21.55 26.58 
Shallot 2 74.62 35.60 
Kale 7.71 ND ND 
Black Tea 3.64 1.31 ND 
Table 1.1: Dietary sources of flavonols in fruits, vegetables and tea (Slimestad et al., 2007, Phenol-explorer, 
2016). ND: Not Detected 
1.3.3. Flavonoid intake  
As the main dietary sources of flavonoids in the western world are fruits, vegetables, red wine 
and tea (Johannot and Somerset, 2006), their content varies and it is highly dependent on 
cultivar, skin to volume ratio of the fruit and other factors (Nyman and Kumpulainen, 2001). 
According to nutritional data, consumption of flavonoids is mostly dependent on measuring 
the flavonols and flavones. However, there is a high possibility for the underestimation of rate 
of intake results derived from diverse flavonoid species in the diet (Aherne and O'Brien, 2002). 
The estimated daily consumption of polyphenols with a diet rich in vegetables and fruit is 
approximately 2 g (Ovaskainen et al., 2008). For individuals with a low intake of fruits and 
vegetables, the other polyphenols sources such as coffee, tea and red wine are considered as 
their main source (Tagliazucchi et al., 2012). It has been estimated that the non-flavonoid 
intake in diets account for one third of total phenolic consumption, whereas flavonoids 
accounts for two thirds (Scalbert and Williamson, 2000). 
There have been many studies estimating varied intake levels of flavonoids in several countries. 
In these studies, they used a variety of methods for flavonoid quantification such as food 
frequency questionnaires and food balance sheets, which may provide different results (Mullie 
et al., 2008). Table 1.2, represents the summary of studies conducted in different parts of the 
world, investigating flavonoid intake from various food sources. 
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Country Population 
Flavonoid Average 
Intake (mg/day) 
Main sources collected by 24-Hour 
Recall, Food Balance Sheet &FFQ 
References 
Australia 
Male & 
Female 
454 Onions, Apples, wine, & black tea 
(Johannot and 
Somerset, 2006) 
Denmark 
Male 
Female 
1786 
1626 
Coffee, tea, fruits 
(Zamora-Ros et 
al., 2016) 
Greece 
Male 
Female 
744 
584 
Coffee, tea, fruits 
(Zamora-Ros et 
al., 2016) 
Ireland 
Male & 
Female 
177 Wine, onion, tea 
(Beking and 
Vieira, 2011) 
Italy 
Male & 
Female 
137 
Tea, red wine, grapes, onion garlic & 
citrus fruits 
(Tavani et al., 
2006) 
Spain 
Male  
Female 
313 
Apples, Red wine, unspecified fruits & 
oranges 
(Zamora-Ros et 
al., 2010) 
UK Female 808 
Tea, coffee, vegetables (onion, 
broccoli) 
(Yahya et al., 
2016) 
USA 
Male & 
female 
190 
Tea, Wine 
Citrus fruit 
(Song and Chun, 
2008, Chun et al., 
2007) 
USA 
Male& 
Female 
200.1 Tea, berries & wine (Kim et al., 2016) 
Table 1.2: Summary of reports investigating consumption of dietary flavonoids. 
Notably, very few flavonoid types are included for quantification, 5-10 most common 
flavonoids are included in intake estimates; these include flavonols quercetin and quercetin 
glycosides, kaempferol and myricetin and flavone, such as luteolin and apigenin, while there 
more than 5000 flavonoids that are concurrently distributed within the human diet (Ovaskainen 
et al., 2008).  
1.4. Intestinal Metabolism of Flavonoids 
It is believed that dietary polyphenols are metabolised by colonic bacteria. Indeed, the 
microbial mechanism is essential for their absorption. Therefore, intestinal bacteria modulate 
polyphenols by various mechanisms, such as hydrolysis and decarboxylation (Boyer et al., 
2005). The crucial step in the metabolism of flavonoids involves deglycosylation of glycosidic 
forms. Lactase-phlorizin hydrolase (LPH) and 1-β-glucosidase are two enzymes at the brush 
borders of the intestines that have been shown to deglycosylate flavonoids within the gut lumen 
(Day et al., 1998).  
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The metabolism of flavonoids has been broadly investigated both in vivo and in vitro. The 
uptake of flavonoids through intestinal epithelium has been illustrated by previous studies 
(Manach et al., 1998, Aziz et al., 1998). However, there is still uncertainty on whether there is 
preferential transport of aglycone or glycosidic forms. In a study conducted by Hollman et al. 
(1995), they found that flavonoid glucosides rate of absorption was dependent on the nature of 
sugar moiety. For instance, quercetin rutinoside had just 20% of the quercetin glucoside 
bioavailability (Hollman et al., 1995). Notably, conjugation to a monosaccharide (i.e. glucose) 
indicates the role of active glucose transporters in the movement or cotransport of flavonoid 
glycosides (Johnston et al., 2005a). However, aglycones are able to be absorbed by facilitative 
diffusion, but conjugation to disaccharides will need further metabolism, such as 
deglycosylation and glucuronidation, prior to complete absorption. Consequently, because of 
occurrence of several steps in preabsorptive metabolism, the bioavailability of conjugated 
forms of flavonoids may be hindered (Spencer, 2003, Johnston et al., 2005a). 
Hydrolysis of glucoside moiety represents the initial step on intestinal metabolism of the 
glucosylated forms. Quercetin aglycones passively diffuse throughout the apical membrane 
and are then glucuronidated. It is suggested that quercetin glucosides are first hydrolysed by 
the lactase site of lactase phloridzin hydrolase (LPH) prior to diffusion across the apical 
membrane (Schwanck et al., 2011). Thus, quercetin glucosides are transported into the cells by 
the SGLT-1 transporters and then hydrolysed by the cytosolic β-glucosidase (Boyer et al., 
2005). 
 
Figure 1.7: Mechanism of flavonoid glucosides metabolism in mammalian small intestine (Day et al., 2000b). 
Lumen 
Basal Membrane 
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Domain III and IV of LPH are demonstrated as transmembrane protein with release of aglycone 
and glucosides (F: Flavonoid, glc: glucose), (Day et al., 2000b). Figure 1.7 shows the SGLT-1 
glucose transporter will carry the glucose released from the LPH action to the small intestine. 
And quercetin glucosides interaction with SGLT-1 results in glucose transport inhibition (Day 
et al., 2000b). 
Phenolic glucosides are relatively hydrophilic and do not diffuse passively throughout the 
biological membrane. It is demonstrated that phenolic glucosides remain intact in the colon 
until they become deglycosylated in the presence of enzymes such as LPH (Nemeth et al., 
2003).  
It has been suggested that glycosides or aglycones transport will occur via different pathways, 
like active or passive mechanisms. Indeed, the hydrophobic status of flavonoid aglycones helps 
them to be transported passively through diffusion or facilitated diffusion across cell 
membranes (Walle, 2004). On the other hand, for flavonoid glucosides which are more polar, 
an active transport is required. Followed by the sodium-dependent glucose cotransporter 
(SGLT-1) and bilitranslocase, which is a plasma membrane protein, has been identified in the 
transport of flavonoid glucosides (Walgren et al., 2000). In addition to this, flavonoid 
aglycones are made readily available in enzymatic action in the intestine. Therefore, the 
impacts of glycosylation on flavonoid aglycone absorption may be negligible (Day et al., 
2000a).  
The tissues in the jejunum of intestine have been observed to have the greatest transport 
efficiencies for flavonoids (Matuschek et al., 2006). Flavonoids that have not been absorbed 
nor metabolised by the luminal enzymes, such as LPH in the small intestine, undergo bacterial 
degradation in the colon (Talavera et al., 2004). In fact, colonic bacteria metabolise flavonoid 
glucosides to aglycones and phenolic acids are easily reabsorbed (Hollman et al., 1995). The 
last step in the metabolism of flavonoids is the excretory pathway. When in polar forms, 
flavonoids are excreted in urine or secreted in bile. Flavonoids secreted in bile will go through 
further intestinal metabolism (Prior and Wu, 2008).  
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Figure 1.8: Metabolism of flavonoids inside enterocyte, from various sources (Lotito et al., 2011, Walle, 2004). 
Figure 1.8 illustrates 1) Flavonoids enter the cells unaltered or go through deglycosylation by 
bacterial or endogenous enzymes. 2) The metabolised flavonoids are then moved to efflux. 3) 
Metabolism is dependent on hydroxylation, sulfonylation or glucuronidation. 4) Flavonoids 
reach the circulation by paracellular diffusion or are released from basolateral membrane 5) 
and can also be released back into the lumen through an apical transporter (Andlauer and Furst, 
2003, Planas et al., 2012). It is previously found that almost 75% of flavonoids in the lumen 
will be absorbed, more than 50% of the initial dose will be metabolised and rereleased back 
into intestinal lumen and up to 20% will be sulfonated and glucuronidated and released into 
the circulation (Lotito et al., 2011, Walle, 2004). 
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Moreover, the secretion of the intestinal hormones glucose-dependent insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) in response to the active absorption of 
nutrients might also be modified by flavonoid phloridzin. These hormones have a significant 
effect on the metabolism of glucose by stimulating insulin secretion (Johnston et al., 2005a). 
Deglycosylation is one of the major steps in the transfer of flavonoids from the intestinal lumen 
into the circulation, as designated by the activity of endogenous β-glucosidases in vitro studies. 
The place of deglycosylation and transport across the intestinal enterocytes depends on the 
nature of the flavonoid aglycone moiety and nature and position of the attached sugar. For 
example, the contradictory pharmacokinetics of quercetin-3-glucoside and quercetin-3-
rhamnoglucoside reveal the importance of structural dissimilarities on the site of absorption. 
Quercetin 3-glucoside is mainly deglycosylated in the small intestine, while intestinal β-
glucosidases appear inactive against quercetin-3-rhamnoglucoside (Day et al., 2000b). 
Moreover, parent compounds may also be absorbed unaltered, and the metabolism at cellular 
level was associated with hydroxylation, conjugation and methylation. Consequently, these 
reactions could result in the efflux of flavonoids back into the lumen or released into the 
circulation (Spencer, 2003). A study by Williamson and Manach, (2005) demonstrated that 
flavonoids are metabolised during absorption and appeared as glucuronide, sulfate and methyl 
conjugates, which are the most common metabolites in the human plasma. Methylation 
improves the solubility of lipids and majority of flavonoids in plasma, also conjugation with 
sulfate or glucuronic acid greatly develops hydrophilicity. It should be noted that the 
conjugated forms of flavonoids (quercetin glucosides) possess different physiochemical 
properties compared to the aglycone forms (quercetin) (Williamson and Manach, 2005). 
A study conducted by (Wen and Walle, 2006) investigated the effect of structure on the 
bioactivity of dietary flavonoids in comparison with methylated and unmethylated flavonoids 
using Caco-2 cell line and human liver S9 fraction. They showed that both Caco-2 cells and S9 
fraction of liver possess promising results on the oral bioavailability of dietary polyphenols. 
The methylated version was more bioavailable for absorption at intestinal tissues and metabolic 
activity (Wen and Walle, 2006). 
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1.5. Health Benefits of Flavonoids and their role on Glycaemic Control 
There have been many studies on protective effects and health promoting importance of 
flavonoids on glycaemic control, cancer cell proliferation, cardiovascular complications and 
neurodegenerative decline (Mursu et al., 2008, Renis et al., 2008). This section will cover the 
research conducted on the effects of flavonoids in vitro and in vivo in relation to glycaemic 
control. 
It is noteworthy to investigate the plant extracts in addition to individual polyphenolic 
compounds that can potentially decrease postprandial increase in blood glucose level by 
inhibition of intestinal monosaccharide transporters with focus on SGLT-1 and GLUT-2. These 
include quercetin glucosides, which have been shown to inhibit the active transport of glucose 
from the luminal side of the brush border into the small intestine via the sodium-dependent 
glucose transporter SGLT-1. By contrast, it is suggested that quercetin aglycone does not 
inhibit SGLT-1 (Cermak et al., 2004, Johnston et al., 2005b). Moreover, phloridzin has been 
established as a known inhibitor of glucose in the sodium-dependent SGLT-1 transporter 
(Johnston et al., 2005a). Phloridzin results in glycosuria through inhibition of the renal 
reabsorption of glucose (Kobori et al., 2012). Moreover, previous research has shown the 
antihyperglycaemic effects of some polyphenolic plant-based foods can be related additionally 
to α-amylase and α-glucosidase inhibitory activity (Adisakwattana et al., 2012). 
In order to overcome complications derived from high levels of glucose and high expression 
of SGLT-1 transporter in diabetes, the intestinal glucose absorption could be supressed by 
inhibitors of SGLT-1. This could decrease the uptake of glucose and prevent postprandial 
portal glycaemic rates, and hence may be supportive in improvement of the metabolic condition 
in type 2 diabetes. There is recent in vitro evidence that polyphenols (flavonoids) are the most 
important group of phytochemicals, which can alter the pattern of intestinal glucose uptake 
through their interactions with certain glucose transporters (Gray, 2010). For instance, 
inhibition of sodium dependent SGLT-1 transporter in which glucose is co-transported with 
sodium ion or by inhibition of GLUT-2 sodium independent glucose transporter (Gray, 2010). 
Notably, the flavonoid- quercetin glucoside ability to block SGLT-1 is reduced when the 
glucoside moiety is cleaved off during lactase hydrolysis (Kottra and Daniel, 2007). Therefore, 
it is still unknown if deglycosylation of quercetin glucosides in lactose tolerant individuals is 
higher than lactose intolerant individuals, and thus are less able to decrease the uptake of 
glucose from the intestine.  
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 1.5.1. In vitro studies 
Inhibition of glucose transporters by the interaction of quercetin and quercetin glucosides such 
as quercetin 3-glucoside, quercetin 4́-glucosides and quercetin 3,4́-diglucoside with SGLT-1 
and GLUT-2 has been investigated in several in vitro studies (Ader et al., 2001, Cermak et al., 
2004, Kwon et al., 2007, Johnston et al., 2005a). An in vitro study on Caco-2 cells have 
examined the effect of quercetin and its derivatives: quercetin 4́-glucoside and quercetin 3,4́-
diglucosides. They demonstrated that transport is associated with the position and nature of 
glucosidic moiety and hypothesised that a glucose moiety in the 3-position could promote 
absorption and vice versa with respect to glycosylation at the 4́-position (Walgren et al., 1998). 
The effect of quercetin on carbohydrate homeostasis has been measured by in vitro studies, 
through inhibition of α-glucosidase activity, inhibition of glucose absorption from the gut, beta 
cells protection in cell culture and abolishing damage from free radicals in the pancreas (Tadera 
et al., 2006).Though inhibition of glucose transporters by the onion extract has been studied in 
few studies, they also showed the onion extract and flavonoids from onion inhibit the SGLT-1 
transporter (Schulze et al., 2015). Moreover, absorption of glucose by Caco-2 cells was 
significantly inhibited by aqueous extract of Kuding tea and purple sweet potato stem under 
both sodium-dependent and sodium-independent conditions suggesting the effects of SGLT-1 
and GLUT-2 transporters (Wang et al., 2008). The flavonoid quercetin has been also found as 
inhibitors of GLUT-2 overexpression and prevents absorption of mediated glucose and fructose 
in GLUT-2 transport (Kwon et al., 2007).  
1.5.2. In vivo animal studies  
According to a study conducted on a rat model of obesity based on high-fat feeding, they 
showed that a purified anthocyanins addition to their diet decreased the body fat and fasting 
glucose levels compared to high-fat fed controls (Prior and Wu, 2008). Moreover, three other 
studies demonstrated that anthocyanins induced expression of adiponectin, which involved 
inhibition of adipocyte differentiation and an increase in energy expenditure, therefore leading 
to reduction in weight gain (Bauche et al., 2007, Tsuda et al., 2006, Hsu et al., 2009). In the 
study carried out by Hsu et al. (2009), they demonstrated in mice intake a high-fat diet and 
supplemented with o-coumaric acid and rutin containing phenolic compounds, that levels of 
serum lipids were reduced, followed by inulin and leptin concentrations (Hsu et al., 2009). 
In other animal models, orally administered phloridzin has been found to decrease the 
absorption of glucose in rodents (Kobori et al., 2012). Moreover, mice models with cancer had 
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up to a 50% increase in their life span when treated with quercetin glucosides (Lamson and and 
Brignall, 2000). Additionally, the administration of quercetin and its derivatives to Zucker 
diabetic rats considerably reduced postprandial hyperglycaemia. Quercetin, quercetin-3-
gucoside and rutin have shown inhibitory activities on α-glucosidase from the rat intestine 
(Song et al., 2005). Thus, quercetin and quercetin glucosides could characterise a therapeutic 
method for diminishing absorption of sugar in type 2 diabetes and metabolic syndrome 
(Mooradian and Thurman, 1999).  
Quercetin has been recognised as an extremely safe compound to be consumed; carcinogenic 
research in rats have presented that it has no evident side effects, even when consumed in large 
quantities (2000 mg in per Kg of body weight) (Tadera et al., 2006).  
1.5.3. Human studies  
A prospective study in type 2 diabetic case-control pairs in the Nurses’ Health Study I and II 
(NHS and NHSII), investigating urinary excretion of eight polyphenol metabolites, found that 
flavanones (naringenin and hesperetin) and flavonols (quercetin and isorhamnetin), as well as 
phenolic acid and caffeic acid, were associated with a 39%-48% lower type 2 diabetes risk 
during early follow-up (median of 4.6 years since urine sample collection) (Sun et al., 2015). 
Apple consumption of ≥ 1 apple/day showed a 28% lower type 2 diabetes risk compared with 
no apple consumption (RR: 0.72; 95% CI 0.56–0.92; p = 0.006) (Song et al., 2005). In another 
study, they found that higher intakes of anthocyanins were significantly associated with a lower 
risk of type 2 diabetes (HR 0.85; 95% CI 0.80–0.91; p < 0.001) (Wedick et al., 2012). 
Apples(HR 0.77; ≥ 5 servings/week vs. < 0.001) and blueberries (HR 0.77; ≥ 2 servings/week 
vs. < 0.001) were inversely associated with type 2 diabetes (Wedick et al., 2012), but total 
flavonoid intake or other flavonoid subclasses were not associated with a lower risk of type 2 
diabetes. 
Coffee intake which contain flavonoids, such as quercetin, quercetin glucosides and phloridzin, 
demonstrated that they were helpful in decreasing the prevalence of type 2 diabetes and obesity, 
The RR of type 2 diabetes was 0.65 (95% CI, 0.54-0.78) for the highest (≥6 or ≥7 cups per day) 
and 0.72 (95% CI, 0.62-0.83) for the second highest (4-6 cups per day) category of coffee 
consumption compared with the lowest consumption category (0 or ≤2 cups per day) (Van 
Dam and Hu, 2005). According to the research conducted by (Song et al., 2005), quercetin, 
kaempferol, myricetin, apigenin and luteolin was significantly associated with risk of type 2 
diabetes. Among flavonoid-rich foods, apple and tea consumption were associated with 
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diabetes risk. Women consuming ≥ apple/day showed a significant 28% reduced risk of type 2 
diabetes compared with those who consumed no apples (RR = 0.72, 95% CI: 0.56, 0.92; p = 
0.006). Tea consumption was also inversely associated with diabetes risk but with a borderline 
significant trend (> or =4 cups/d vs. none: RR 0.73, 95% CI: 0.52-1.01; p = 0.06) (Van Dam 
and Hu, 2005). 
According to a research conducted by Taj Eldin, et al. (2010), intake of crude Allium cepa (red 
onion) in type 1 and type 2 diabetic patients significantly decreased the blood glucose levels 
by about 89 mg/dl in relation to insulin (145 mg/dl) in type 1 diabetic subjects and it decreased 
fasting blood glucose concentrations by 40 mg/dl compared to glibenclamide (81 mg/dl) in 
type 2 diabetic patients after 4 hours of intake (Taj Eldin et al., 2010). Moreover, an oral 
administration of a single dose of quercetin simultaneously with starch or maltose solution to 
normal and diabetic rats as we as all participants with type 2 diabetes resulted in a great 
inhibition of postprandial plasma levels (Kim et al., 2011), whereas quercetin in combination 
with glucose did not affect postprandial blood glucose concentrations (Hussain et al., 2012). 
Moreover, human studies conducted by Johnston et al. (2002) illustrated that intake of 25g of 
glucose in commercial apple juice compared with control (water) has significantly delayed the 
absorption of glucose on plasma levels. In fact, apple juice contains polyphenols such as 
chlorogenic acid, phloridzin and quercetin glucosides (Johnston et al., 2002). Clear apple juice 
compared with the control significantly reduced plasma glucose concentrations at 15 and 
30min (p < 0.001 and p < 0.05) respectively (Johnston et al., 2002). 
1.5.4. Onions (phenolic and non-phenolic) compounds effects on glycaemic control 
Onions (Allium cepa) are the second most produced vegetable crop after tomatoes in the world. 
Onions have a high level of phenolics, which act as protective compounds against different 
diseases such as cardiovascular, neurological, cancer and diabetes. Flavonoids are the major 
phenolics in onions (Perez-Gregorio et al., 2010). The strong evidence in support of use of 
onion in our research is the hypoglycaemic activity of Allium cepa (onion) which has been 
found in several clinical trials showing that, the addition of raw onions to the diet for non-
insulin dependent diabetic individuals reduced the dose of antidiabetic medication required to 
control the disease (Taj Eldin et al., 2010). Allium cepa acts as a hypoglycaemic agent by 
mechanisms rather than increasing insulin levels having extra pancreatic effects; acting directly 
on tissues as liver, muscles and small intestine and alter the activities of the regulatory enzymes 
of glycolysis and gluconeogenesis (Taj Eldin et al., 2010). 
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In a recent study which was in accordance with antiglycaemic significance of onion, they 
focused on the polyherbal formulation of five different medicinal plants, mango (6g) guava 
(10g), amla (3g) onion (50g) and garlic (1g) with proven antidiabetic effects were selected for 
treatment of type 2 diabetic patients (Sukalingam et al., 2015). Reduction in hyperglycaemia 
by polyherbal may reduce the risk of developing micro vascular complications and most 
possibly lower the risk of macro vascular complications (Latha et al., 2004). The antidiabetic 
activity of the polyherbal formulation which mainly contained onion used the glucose induced 
hyperglycaemic model. High level of glucose in the blood induced the insulin secretion. This 
secreted insulin can stimulate peripheral glucose intake and control the production of glucose 
through different mechanisms (Obatomi et al., 1994).  
Moreover, it is noteworthy that oral administration of Allium cepa crude hydroalcoholic extract 
in animal models (alloxan-induced diabetic rats) formed a great hypoglycaemic activity and 
favourable good health effects which may be most probably attributed to improvement and/or 
regeneration of pancreatic beta-cells (Taj Eldin et al., 2009). Also, Allium cepa acts as a 
hypoglycaemic agent by mechanisms rather than elevating insulin concentrations having extra 
pancreatic effects; acting directly on tissues such as liver (Shukia et al., 2000, Taj Eldin et al., 
2008).Flavonols and anthocyanins are the most available types of flavonoids in onions. They 
are usually found as glycosylated forms. For instance, quercetin 4́-glucoside and quercetin 3,4́-
diglucoside are commonly ingested flavonoids. In addition to flavonoids, Inulin-type fructans 
(inulin) contain fructose monomers linked by β (1-2) bonds) are present in significant amounts 
in onion, wheat, chicory, banana and garlic root (Liu et al., 2017). Average daily consumption 
has been estimated to be 1 to 4 g in the U.S. and 3 to 11 g in Europe. Chicory inulin and 
oligofructose are officially recognised as natural food ingredients and classified as dietary fibre 
in almost all European countries (Flamm et al., 2010). Inulin can be found in onions (1–5% on 
a fresh weight basis), garlic (4–12%), banana (0.2%), and chicory roots (15–20%). Inulin type 
fructans are consist of 2–60 fructose units linked by a glycosidic linkage often with a terminal 
glucose unit (Liu et al., 2017). These fructans are not hydrolysed by the digestive enzymes in 
the small intestine; they reach the colon unabsorbed and are utilised selectively as a substrate 
for the growth of bifidobacteria (Fedewa and Rao, 2014). Indeed, it is considered as a soluble 
fibre that can be incorporated into various food products (Reimer and Russle, 2008). In the 
food industry, inulin is used as a fat or sugar replacement and soluble dietary fibre (Barclay et 
al., 2010). Table 1.3, demonstrates the content of phenolic compounds and fructans found in 
different types of onions. 
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Phenolic Compounds 
Red Onion, raw 
Mean (mg/100g) 
Yellow Onion, raw 
Mean (mg/100g) 
White Onion, raw 
Mean (mg/100g) 
 Flavonols 
Quercetin 1.31 0.28 0.03 
Quercetin 3-O-glucoside 1.80 0.70 ND 
Quercetin 3-O-rutinoside 0.21 0.68 ND 
Quercetin 3,4-́O- 
Diglucosides 
77.08 26.58 3.12 
Isorhamnetin 1.51 9.31 ND 
Quercetin 7,4-́ O-
diglucoside 
1.80 0.36 ND 
Quercetin 4-́O-glucoside 38.80 21.55 2.25 
Isorhamnetin 4́-O-
glucoside 
6 2.89 ND 
Kaempferol-3-O-glucoside 1 0.80 ND 
 Anthocyanins 
Cyanidin 3-O-glucoside 1.50 1 ND 
Cyanidin 3-O-glucosyl-
glucoside 
6.5 ND ND 
Delphinidin 3-O-glucosyl-
glucoside  
1 ND ND 
 Phenolic acids 
Protocatechuic acid  2 1 ND 
  Non-phenolic  
Fructan  2.1 1.2 1.8 
Table 1.3: Content of polyphenols and fructan in onion varieties, mean (mg/100mg) (Phenol-explorer, 2016). 
In a recent meta-analysis conducted by (Liu et al., 2017), from the 15 trials, in general there 
was no significant difference in the glucose level (CI: 0.18, 0.08; p = 0.44) with no significant 
heterogeneity between the individual study results, following inulin supplementation. However, 
in another study, data reported that inulin-type fructans extracted from chicory roots regulated 
glucose and lipid homeostasis by enhancing colon production of GLP-1. It is reported that 
fructans from any botanical origin initiated the production of GLP-1 from the colon, and it is 
responsible for the amendment of glucose and lipid metabolism (Urias-Silvas et al., 2008).  
In the colon, inulin is degraded by gut microbiota into short-chain fatty acid, such as acetate, 
propionate and butyrate (Kimura et al., 2011). Both propionate and butyrate are metabolised in 
the colon and liver, which mainly affect their functions. They also induce intestinal 
gluconeogenesis and sympathetic activity, which thereby improves glucose homeostasis 
(Mithieux and Gautier-Stein, 2014). Evidence from animal studies has illustrated that inulin or 
oligofructose supplementation improves weight loss and promotes regulation of glucose in 
diabetic models (Cani et al., 2005). The mechanism by which inulin acts on glucose 
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metabolism is still unclear. Several studies have demonstrated increased plasma PYY and 
GLP-1 and upregulation of proglucagon mRNA with inulin-type fructans in rodents (Delzenne 
et al., 2005, Urias-Silvas et al., 2008). GLP-1 has many antidiabetic characteristics, such as 
food intake inhibition, delayed gastric emptying, induction of β-cell proliferation and insulin 
secretion stimulation (Drucker, 2006).  
It is shown in previous studies that a high fibre diet, onion solution significantly reduced plasma 
glucose area under the curve (AUC) during oral glucose tolerance test (OGTT) in obese rats, 
which reflected both an increased GLP-1 AUC and higher fasting insulin (Reimer and Russle, 
2008). Due to the body's limited ability to process fructans, inulin has minimal increasing 
impact on blood glucose levels. It is considered suitable for diabetics and potentially helpful in 
managing blood sugar-related illnesses (Flamm et al., 2010). 
In another study it was shown that the fibrous root of the Welsh onion decreased fasting and 
postprandial hyperglycaemia by inhibiting α-glucosidase in an animal model of diabetes. Thus, 
the fibrous root of the Welsh onion may be helpful in controlling blood glucose (Kang et al., 
2010). 
In a study conducted by (Campos et al., 2003), a normal control (group A), and a non-diabetic 
group (group B), were treated daily with 1 ml onion solution (0.4 g onion/rat). Groups C and 
D were made diabetic by an intraperitoneal injection of streptozotocin (STZ) (60 mg/kg body 
weight) in citrate buffer (pH 6.3). These animals (groups C and D) were the STZ diabetic 
control and STZ diabetic rats with onion intake, respectively. Onion increased the fasting 
serum high-density lipoprotein levels, and demonstrated alleviation of hyperglycaemia in STZ 
diabetic rats. The hypoglycaemic and hypolipidaemic actions of onion were associated with 
antioxidant activity, since onion decreased superoxide dismutase activities while no increased 
lipid hydroperoxide and lipoperoxide concentrations were observed in diabetic rats treated 
with onion (Campos et al., 2003). 
According to a study on acute effect of onion on blood glucose levels of diabetic patients, when 
the glucose and onion were administered, the plasma glucose levels were found to be decreased 
when compared to those levels after giving glucose only: (225.60 ± 27.25 mg/dl vs 214.40 ± 
33.39 mg/dl at 30 min; p = 0.099), (282.55 ± 31.67 mg/dl vs 229.40 ± 37.61 mg/dl at 60 min; 
p = 0.0001), (270.20 ± 22.48 mg/dl vs 194.45 ± 37.26 mg/dl at 90 min; p = 0.0001) and (248.75 
± 20.13 mg/dl vs 161.65 ± 30.50 mg/dl at 120 min; p = 0.0001), respectively. This study 
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showed that onion has an acute effect of lowering the plasma glucose levels which could be 
useful in the management of patients with diabetes mellitus (Myint et al., 2009). 
1.6. Lactose Intolerance 
The term lactose intolerance determines the inability to hydrolyse dietary lactose and derives 
from adult or congenital lactase deficiency. Two-third of the world’s population have lactose 
intolerance condition (Lomer et al., 2007). NDDK (The National Institute of Diabetes and 
Digestive and Kidney Disorders) estimated that up to 90% of Asian Americans and 75% of all 
adult Native Americans and African Americans and of North Europeans are lactose intolerant 
(Devesh and Kayastha, 2012). Lactose is available in the mammalian milk and it is hydrolysed 
by the enzyme lactase-phloridzin hydrolase (LPH), which is mostly known as lactase. Lactase 
is a type of β-galactosidase that mediates the hydrolysis of lactose to glucose and galactose in 
the small intestine (Lomer et al., 2007). 
Common symptoms of lactose intolerance include: abdominal bloating, abdominal pain, gas 
and diarrhoea. These symptoms range from mild to severe according to the amount of lactose 
the person intakes or the amount an individual can tolerate (Lomer et al., 2007). Thus, 
decreasing the amount of lactose in milk could possibly reduce gastrointestinal symptoms in 
lactose intolerant subjects. There are also other several possible ways to overcome this problem, 
either by adding lactase enzyme in dairy products that hydrolyse lactose available in food or 
using complementary prebiotics microorganisms (Lomer et al., 2007).  
It is found in a human study (Meloni et al., 2001), that patients with diabetes type 1 and 2 have 
elevated lactase activity; consequently, those with a high intake of lactose-based foods (dairy 
products) would be exposed to lager amounts of monosaccharides galactose and glucose, and 
this may lead to a greater blood glucose concentration. High prevalence of lactase persistence 
has been found in the diabetic patients from Sardinia (Italy), where the prevalence of lactase 
deficiency is very high (Meloni et al., 2001). This supports the idea that high intestinal lactase 
activity in diabetic subjects contributes to the high level of blood glucose, while less intestinal 
lactase activity could be associated with healthy subjects who are lactose intolerant. 
According to a recent study conducted by Ji et al. (2014), lactose intolerant subjects had 
decreased risk of lung and breast cancer in a population-based study in Sweden, which is 
suggested to be linked to their specific dietary pattern, low consumption of lactose-containing 
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food (Ji et al., 2014). Milk can contain high amounts of saturated fat, and some growth factors, 
such as insulin like growth factor-I (IGF-I), and these dietary components have been suggested 
to be linked with the development of various cancer types (Ji et al., 2014). Moreover, 
consumption of milk in individuals with lactase persistence has been associated with an 
increased risk of cataract. Therefore, it has been suggested that hypolactasia would protect an 
individual against cataract. Another disease, which is suggested as being linked with the ability 
to digest lactose, is ovarian cancer, the background to this study is suggested as toxin to oocyte 
(Vesa et al., 2000). Nolan et al. (2010) also found that lactase persistence as evident by presence 
of the T allele of rs4988235 was associated with the risk of Crohn’s disease in the Caucasian 
population of New Zealand (Nolan et al., 2010). 
1.6.1. Role of LPH in relation to flavonoid metabolism  
LPH is mainly responsible for metabolism of lactose from milk during infant years. This 
enzyme is genetically regulated with lower levels in adolescents and most adults in the world 
are lactose intolerant (Tribolo et al., 2007). Different types of -galactosidase are found in the 
small intestine. These include glucocerebrosidase, lactase phloridzin hydrolase (LPH), broad-
specificity cytosolic -glucosidase and pyridoxine glucoside (Day et al., 2000b). All of these 
enzymes, apart from LPH, act intracellularly and would need transport of intact flavonoid 
aglycones if they were to act as an important factor in the metabolism of these compounds. 
Whereas LPH is found in the brush border of the small intestine and is able to act on dietary 
glucosides prior to the absorption (Tribolo et al., 2007). Thus, LPH enzyme acts as a crucial 
factor for the hydrolysis of flavonoid glucosides, which consequently alters blood glucose level 
in the small intestine.  
Notably, in addition to the role of lactase in the metabolism of lactose, it is also associated in 
the intestinal metabolism of several phenolic compounds. Therefore, those individuals who do 
not express lactase may act differently in the metabolism of some phenolics present in plant-
based foods, such as onions or apples, compared to those who continue to express lactase. 
Therefore, it is possible that this may influence particular diseases risks such as type 2 diabetes 
on which these phenolic phytochemicals are associated (Shrier et al., 2008). Table 1.4, 
demonstrates the effect of LPH (lactase) enzyme purified from different sources on three most 
widely found quercetin glucosides in onion as substrates. 
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3 most widely found 
Quercetin-glucosides in 
Onion 
Quercetin-3́-
glucoside 
Quercetin-4́-
glucoside 
Quercetin 3,4́-
diglucoside 
L
a
ct
a
se
 S
o
u
rc
e 
 
Lactase present in 
rat small intestine 
cell free-extract 
Deglycosylation 
(Ader et al., 2001) 
Deglycosylation 
(Ader et al., 2001) 
Not examined 
Lactase present in 
Rat liver cell free-
extract 
No- 
Deglycosylation 
(Day et al., 2003) 
No- 
Deglycosylation 
(Day et al., 2003) 
Not examined 
Lactase purified 
from sheep small 
intestine 
Deglycosylation  
(Nemeth et al., 
2003) 
Deglycosylation 
(Nemeth et al., 
2003) 
Deglycosylation 
(Nemeth et al., 
2003) 
Lactase in small 
intestine and liver of 
(patients 
undergoing 
gastrointestinal 
Surgery) 
No-  
Deglycosylation 
(Day et al., 2000c) 
 
Deglycosylation 
(Day et al., 2000c) 
No- 
Deglycosylation 
(Day et al., 
2000c) 
 
Lactase from the 
Fungus Penicilium 
Decumbent 
Deglycosylation 
(Mamma et al., 
2004) 
Not examined Not examined 
Lactase purified 
from pig liver 
No- 
Deglycosylation 
(Lambert et al., 
1999) 
 
Deglycosylation 
(Lambert et al., 
1999) 
No- 
Deglycosylation 
(Lambert et al., 
1999) 
Table 1.4: Effect of LPH (Lactase) from different sources on Quercetin Glucosides. 
 
Since lactase (LPH) can cleave several phenolic glucosides, it is possible that people with 
lactase insufficiency also have a reduced ability to hydrolyse phenolic glucosides in the gut 
(Nemeth et al., 2003). Hence, there is the possibility that lactose intolerant subjects retain more 
intact phenolic glycosides in the gut, and that this is associated with a greater inhibition of 
glucose uptake than occurs in lactase persistent individuals. 
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Figure 1.9: Role of lactase (LPH) in the metabolism of phenolic glucosides. 
The above figure is a brief summary of our hypothesis, demonstrating the possible role of 
lactase in the metabolism of phenolic glucosides such as quercetin glucosides in onion. 
The evidence from epidemiological studies on the health benefits of polyphenol rich foods are 
helpful; however, only controlled human studies confirm the positive results obtained through 
in vitro assays and animal models. It is believed that controlled human studies are required to 
achieve conclusive results in respect to the role of polyphenols on maintaining blood glucose 
levels. Thus, a pilot clinical study was planned to be conducted in the later stages of the current 
research project. 
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1.7. Hypothesis and aims of this thesis 
We hypothesised that dietary onion flavonoids are capable of reducing intestinal glucose 
transport. To address this, we investigated the effects of dietary flavonoids in purified forms 
and flavonoid-rich onion extract on intestinal epithelial Caco-2 cells, followed by pre-treatment 
of flavonoids with β-galactosidase enzyme from Aspergillus oryzae. In support of in vitro study, 
an in vivo study was conducted, and we hypothesised that quercetin glucosides may be less 
effective at blocking glucose uptake in lactose-tolerant people, because they can hydrolyse 
quercetin glucosides to the aglycone with lactase compared to lactose-intolerant people. 
 
 To model human gut condition for glucose transport by conducting in vitro Caco-2 cell 
models to assess the role of two main glucose transporters, i.e. SGLT-1 (sodium-
dependent) and GLUT-2 (sodium-independent) on glucose uptake. 
 
 To evaluate the effect of onion flavonoids (mainly quercetin 4́-glucoside and quercetin 3,4́-
diglucoside) and onion extract on glucose uptake in human intestinal epithelial Caco-2 cells 
through bidirectional transport model, illustrating both apical uptake and basolateral release. 
 
 To model the role of human intestinal LPH by incubating Caco-2 cells with purified β-
galactosidases  
 
 To compare inhibition of sodium-dependent and sodium-independent glucose uptake in 
Caco-2 cells by flavonoid glucosides and onion extract before and after β-galactosidase 
treatment. 
 
 A human study to compare inhibition of the glycaemic response to glucose by a dietary 
source of quercetin glucosides (onion solution) in lactose tolerant adults (n=12) and lactose 
intolerant adults (n=12). 
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2. CHAPTER TWO - IN VITRO STUDIES 
2.1. Introduction 
2.1.1. Caco-2 cell line as a model of intestinal barrier  
The human intestinal Caco-2 cell line has been widely used as a model of the intestinal barrier. 
The parent cell line, originally derived from a human colon carcinoma, forms monolayers of 
cell through spontaneous cellular differentiation, leading to expression of several 
morphological and functional characteristics of mature enterocyte (Sambuy et al., 2005). The 
conditions related to culture is suggested to affect these characteristics, partly because of the 
intrinsic heterogeneity of parental cell line, resulting in selection of sub-populations of cells 
becoming prominent in the culture. Caco-2 cells differentiate spontaneously in culture 
without supplementation of differentiating factors and, usually, standard protocols 
recommend to subculture cell when culture reaches at least 80% of confluence (Natoli et al., 
2011).  
The Caco-2 cell line can be used for the assessment of absorption of drugs via the intestinal 
membrane enterocytes (Artursson and Karlsson, 1991, Rubas et al., 1996). It was developed 
through research by Jorgen Fogh (1975) at Sloan-Kettering Institute for Cancer Research 
(Fogh and Trempe, 1975). The Caco-2 cells have the intrinsic ability to initiate spontaneous 
differentiation on reaching confluence in the presence of normal culture conditions (Rubas 
et al., 1996). At confluence, there is progressive development of brush border. The surface 
occupied by each cell gradually reduces from 5 to 21 days, post-confluence and intimate 
intercellular junctions are developed. During the same period, the length and density of 
microvilli increase.  
Most cells develop complete brush borders with tall and regular microvilli when the full 
structural polarisation is achieved after 30 days (Artursson et al., 2001). The complete 
polarised Caco-2 cells resemble human small intestinal mucosa cells expressing brush 
borders, tight junctions and efflux and uptake transporters at both apical and basolateral 
compartments. The Caco-2 cell line represent a biochemical barrier in the small intestine due 
to expression of membrane efflux proteins (P-gp, MRP 1–3), CYP450 isoenzymes and phase 
II conjugating enzymes such as sulfotransferase, UDP-glucuronyltransferase, glutathione S-
transferase (Awortwe et al., 2014).  
53 
 
For differentiation of human intestinal Caco-2 cell models, it is suggested to seed them on 
culture inserts made with polycarbonate filters, and allowing spontaneous differentiation to 
process for 2-3 weeks in culture medium in both the apical and basolateral compartments 
(symmetric protocol) (Ferruzza et al., 2012). Concurrently, in vivo, the basolateral side of 
enterocyte is in direct contact with fluids found in the intestine, whereas the apical side is in 
association with rapid change of intestinal fluid, which is highly affected by rate of food 
digestion (Ferruzza et al., 2012). 
In the current study, Caco-2 cell line was used as it has been greatly employed as a model of 
intestinal barrier in literature, it provides a quick and inexpensive screening model, standard 
Caco-2 model lack morphological and physiological features of complete intestinal tissues. 
For example, Caco-2 cells show differences with complete intestinal tissue with regard to 
mucus production, passive diffusion, carrier-mediated uptake and excretion, paracellular 
transport via tight junctions and intestinal metabolism (Rozehnal et al., 2012). 
 In fact, Caco-2 cell model is the most suitable choice to investigate sugar transport inhibition 
due to several morphological and functional characteristics of the mature enterocyte can be 
expressed by Caco-2 (Angelis and Turco, 2011). The Caco-2 cell line is the most extensively 
characterised cell-based model for the assessment of absorption of quercetin and its 
glycosides via the intestinal membrane enterocytes (Boyer et al., 2005, Johnston et al., 
2005b). Several quercetin glucosides inhibit glucose uptake into brush border membrane 
vesicles of porcine jejunum and also are capable of interacting with sodium-dependent 
glucose transporters in the mucosal epithelium, as a consequence, this may even be the route 
by which these flavonol glucosides are absorbed by the small intestine in vivo (Cermak et al., 
2004).  
The intestinal absorption of compounds across the intestinal epithelium depends on their 
chemical characteristics, and compounds can be substrates for numerous transporter proteins 
and metabolising enzymes in the currently used model Caco-2 cell. Although, there is some 
literature available on the gene expression of drug transporter genes in Caco-2 cells and 
human intestine (Hilgendorf et al., 2007, Englund et al., 2006), mRNA expression levels of 
transporter proteins are shown not to correlate well with protein abundance levels (Ohtsuki 
et al., 2012). 
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However, there are possible limitations associated with the use of Caco-2 cell line, since it is 
not applicable to mimic all the biological activity of the human intestine (Sambuy et al., 
2005). Also, problems of reproducibility occur in use of this cell line, due to variability in 
different laboratories as well as different culture conditions, like the type of animal serum 
used, the passage number, the source of clones (Natoli et al., 2012). 
2.1.2. β-galactosidase as a model of human intestinal LPH 
Lactase (LPH), a part of the β-galactosidase family of enzymes, catalyses the hydrolysis of 
lactose to glucose and galactose, it is found in plants, microorganism and animals and is 
widely used in the food industry due to its hydrolytic activity on lactose and 
galactooligosaccharides production (Ansari and Husain, 2012). The active site of the enzyme 
has one sulfhydryl and one imidazole group, and the reaction corresponds to a SN2-like 
displacement mechanism (Meera et al., 2013). Factors that can influence enzyme activity 
include substrate concentrations, pH and temperature. 
It is indicated that LPH plays an important role in the metabolism of glycosylated 
phytochemicals, and that the expression and activity of this enzyme in the small intestine can 
modify the profile of metabolites appearing in the circulation (Wilkinson et al., 2003). 
Hydrolysis of LPH is the first step in the uptake of daidzein glucosides as rats’ small 
intestines exhibit a broad substrate specificity for quercetin glucosides, daidzein glucosides 
as well as kaempferol and luteolin glucosides (Wilkinson et al., 2003). In this study, we 
investigated the deglycosylation of individual quercetin glucosides and onion containing 
quercetin glucosides as substrates by -galactosidase from Aspergillus oryzae (isolated 
enzyme) to model the condition in human intestine in the presence of LPH, and evaluated 
the concentration of quercetin aglycone after deglycosylation of quercetin glucosides by β-
galactosidase. 
 β-galactosidase from Aspergillus oryzae has several advantages in comparison with other 
microbial sources. It is extensively accepted as the source of enzyme used for food and has 
been recorded as GRAS (generally regarded as safe) status (Godfrey and Reichelt, 1983). 
Since this natural isolate produced very low levels of β-galactosidase, attempts were made 
to increase the productivity by optimising following parameters pH, and temperature 
(Nizamuddin et al., 2008). Several possible bacterial species, which are currently used by the 
dairy industries, produce β-galactosidase enzyme and are derived from Lactobacillus and 
Bifidobacterium. Moreover, the yeast Kluyveromyces lactis and fungi Aspergillus oryzae are 
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considered as the main commercial source of lactase due to their dairy environmental habitat. 
However, β-galactosidase Kluyveromyces lactis has low thermo-stability, which is a major 
disadvantage (Dagbagli and Goksungur, 2008). 
2.1.3. Aims 
 To assess the inhibitory effects of polyphenols on Caco-2 cells under sodium-
dependent and sodium-independent conditions.  
 To evaluate the effects of β-galactosidases on inhibitory role of phenolic glucosides 
on glucose uptake.  
2.2 Materials  
2.2.1. Materials used in vitro studies  
Chemicals/Samples & Purity 
Grade 
Product code  Supplier 
Caco2-cell lines 86010202 
Life and Medical 
Sciences division, 
University of 
Hertfordshire, UK 
D-[6-3H] Glucose  NET100C  
 
Perkin Elmer (Boston, 
USA) 
Liquid Scintillation Counting 
Cocktail (≥99.5% HPLC grade) 
4000ml 
SC/9205/21 Fisher Scientific, UK 
Cell culture medium and plastic 
ware  
CLS290, C6231 
Sigma Aldrich (UK) 
and Merck Millipore 
(UK) 
Foetal Bovine Serum (FBS) 
500ml 
F2442  Sigma Aldrich, UK 
Trypsin-EDTA solution 10x  
20ml 
T4174 Sigma Aldrich, UK 
HEPES (≥99.5% HPLC grade) 
25g 
H3375 Sigma Aldrich, UK 
Phloridzin (99% HPLC grade) 
100mg 
274313  Sigma Aldrich, UK 
Quercetin (≥95% HPLC grade) 
10g 
Q4951 Sigma Aldrich, UK 
Quercetin 3-β-D-glucoside (≥90% 
HPLC grade) 10mg 
17793 Sigma Aldrich, UK 
Quercetin-3,4́-O-diglucoside 
(≥98.5% HPLC grade) 5mg 
1023 Extrasynthese, France 
Quercetin-4́-O-glucoside (≥95% 
HPLC grade) 10mg 
1201 Extrasynthese, France 
56 
 
Industrial Methylated Spirits 
(IMS) (99% HPLC grade) 2500ml 
MESP-1485-22 ReAgent, UK 
Methanol (99.8% HPLC grade) 
2000ml 
322415 Sigma Aldrich, UK 
2-Nitrophenyl--
galactopyranoside ONPG (≥98% 
HPLC grade) 500mg 
N1127 Sigma Aldrich, UK 
Ortho-Nitrophenyl ONP (98% 
HPLC grade) 5g 
N19702 Sigma Aldrich, UK 
-galactosidase from Aspergillus 
oryzae (≥8.0 units/mg) 
G5160 Sigma Aldrich, UK 
Inulin from chicory (10g) 12255 Sigma Aldrich, UK 
Trypan blue solution (0.4%) 20ml T8154 Sigma Aldrich, UK 
DMSO (≥99.5% HPLC grade) 
100ml 
D4540 Sigma Aldrich, UK 
Non-essential amino acid solution 
(100x) 100ml 
M7145 Sigma Aldrich, UK 
DMEM media 500ml D5796 Sigma Aldrich, UK 
Tetrahydrofuran (≥99.9% HPLC 
grade) 100ml 
401757 Sigma Aldrich, UK 
Trifluoroacetic acid (≥99% HPLC 
grade) 100ml 
T1647 Sigma Aldrich, UK 
PBS tablets (1x) BR0014G 
ThermoFisher 
Scientific, UK 
Penicillin-Streptomycin (100x) 
100ml 
15140122 
ThermoFisher, UK 
Scientific 
Red onion (500g)  921002 Asda, Hatfield, UK 
Table 2.1: Material used in cell culture and HPLC labs 
2.2.2. Consumables and equipment used in Caco-2 Cell-culture  
Consumables/Equipment Product details Supplier 
Air Cabinet Airtech Class2  Howorth, Bolton, UK 
Glass pipettes (10ml) CLS4487 Sigma Aldrich, UK 
Pipette tips (10µl, 100µl, 1000µl, 
5000µl) 
CLS4809 Sigma Aldrich, UK 
Eppendorf ( 1ml, 1.5ml, 2ml) BR780546 Sigma Aldrich, UK 
Freezing vials, 2m sterile V9380 Sigma Aldrich, UK 
Centrifuge 5810R Eppendorf, Cambridge 
CO2 Incubator MCO-36A Sanyo 
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Cover slips 631-1566  VWR, PA 
Haemocytometer CM175-20 Sigma Aldrich, UK 
Disposable filters (0.2µM) Z259942 Sigma Aldrich, UK 
Falcon tubes (15-50 ml) 210261 Grenier Bio One 
Flasks (T-25/T75) 690/658175 Grenier Bio One 
Waterbath TSGP10 ThermoFisher Scientific 
Upright light microscope TS100 Nikon 
Scintillation counter LS6500  Beckman-Coulter 
Sterile 24- transwell inserts  TKT-526-010M  Fisher Scientific 
Sterile 24-well plates CLS3527  Sigma Aldrich, UK 
Spectrophotometer  DU530 Beckman model, CA 
UV quartz cuvette Z276693  Sigma Aldrich, UK 
Hand Blender DDF644 Moulinex, UK 
Table 2.2: Equipment and consumables used in cell culture lab 
2.2.3 Composition of HEPES-buffered salt solution (HBSS) used in glucose uptake studies 
Reagent 
Concentration (mM) 
Sodium Dependent 
Concentration (mM) Sodium-
Independent 
Sodium chloride 140 5 
Potassium chloride 2.5 140 
Sodium phosphate 1 0 
Potassium phosphate 0 1 
Calcium chloride 1 1 
Magnesium chloride 0.5 0.5 
HEPES 10 10 
BSA 0.2% (w/v) 0.2% (w/v) 
Table 2.3: Concentration of reagents used for HBSS sodium-dependent and sodium-independent (Wang et al., 
2008). 
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2.3. Methods (Cell Culture Studies) 
2.3.1. Cell culture medium and seeding 
Stock cultures of Caco-2 cells were maintained in T75 plastic flasks and cultured in 95% air 
and 5% CO2 atmosphere in Dulbecco’s modified Eagle’s minimal essential medium 
(DMEM), supplemented with 20% FBS, 1% penicillin/streptomycin, 1% non-essential 
amino acids and 1% L-glutamine. All experiments were carried out on cells between passage 
numbers 40 to 80 from the initial cell line stock with passage number. For experiments, cells 
were seeded at density of 10,000 cells/cm2 into 24 well plates and grown for 5-20 days. The 
expression of sugar transporter SGLT-1 increases from 12-20 days (Johnston et al., 2005a); 
therefore, we chose 14 days as the most appropriate time duration for the growth of cells 
prior to the glucose uptake assays. 
2.3.2. Aseptic Techniques 
Disposable gloves were worn at all times. Separate lab coats were used in the cell culture 
laboratory. Fume hood and suction were cleaned thoroughly with 70% IMS to minimise 
contamination of the cells. 
2.3.3. Cell passaging 
For the detachment of cells from the walls once cells were adherent, trypsinisation of cells 
were required. For this, cells were washed twice with 5 ml phosphate buffered saline (5mM 
PBS) which maintain pH and osmotic balance of the cells. Following this, cells were then 
treated with 2 ml of 1% trypsin for 40 seconds with vigorous taping on the sides of the flask 
to detach cells from the walls. Floating cells were seen under the microscope at 10X 
magnification, and at this point, 8 ml of complete culture medium were added to the flask. 
Afterwards, 2 ml of floated cells was transferred to new T-75 flasks and 13 ml of fresh 
medium was added to make a final volume of 15 ml. Cells were then checked every couple 
of days for their confluency and their medium was changed, thus kept in the cell culture 
incubator gassed with 5% CO2 at 37°C. Stock cells were subcultured once a week at a 1:10 
ratio; media for all cells was changed too. Cells were seeded at a density of 10,000 cells/cm2 
in growth media and left to differentiate for 10 days after reaching confluence. 
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2.3.4. Counting cells with Trypan Blue 
Trypan Blue is one of the several stains suggested for counting of viable cells; staining 
enables the visualisation of cell morphology (Boyer et al., 2005).This method is based on the 
principle that viable cells do not take up certain dyes, whereas non-viable cells do. The 
procedure for cell counting is shown below: 
1. Resuspend the cell pellet and mix to have a homogenous suspension; therefore, mix 50µl 
of the cell suspension with 50µl of 4% (v/v) Trypan Blue solution, and allow to stand for 
5-15 minutes. 
2. Transfer the cell suspension: Trypan Blue mixture to a haemocytometer and leave under 
a microscope (10x objective) with use of coverslip. 
3. Each square of the haemocytometer shows total volume of 0.1 mm3. Since 1 cm3 is 
equivalent to approximately 1 ml, the following cell concentration per ml (and total 
number of cells) is measured by using the following calculations 
4. Cell concentration (cells/ml) = total number of cells in 1 x 0.1mm3 square x (1 x 104) x 
2. 
5. Total number of cells = total number of cells (viable and non-viable) x original volume 
of cell suspension. 
6. Cell viability % = total viable cells (unstained) / total cells (stained and unstained) x 100. 
2.3.5. Freezing the Caco-2 cells (Cryopreservation) 
After passaging the cell line, followed by centrifugation of cells within DMEM media, we 
resuspended the cell pellet in 1ml 10% DMSO and 90% complete DMEM medium, and then 
transferred the cell suspension to a sterile cryovial, labelled with cell type, passage number, 
date and name. This was followed by transfer of cryovials to a polystyrene box where it was 
stored at -80ºC for 2-3 days. Thereafter, the cryovial were moved into the liquid nitrogen tank 
at -196ºC and the details were added to the cell culture lab log book for future use. 
2.3.6. Preparation of Flavonoids and Inulin  
Quercetin and quercetin glucosides are soluble in dimethyl sulfoxide (DMSO) and are stable 
in this form when stored at 4C, immediately prior to the reaction: an aliquot was diluted in 
1% (v/v) methanol at pH 6 to give a final DMSO concentration of 0.1% (v/v) in the reaction 
mixture. Thus, 20µM, 50µM and 100M of the Phloridzin, Quercetin, Quercetin 3--
glucoside, Quercetin 4́-glucoside and Quercetin 3,4́-diglucoside were prepared for the 
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enzyme assay and analysis by HPLC. 5% (w/v) Inulin from chicory was also dissolved in 
0.1% DMSO. 
2.3.7. Onion sample preparation 
Red onions were washed with tap water to remove dirt and dried thoroughly with absorbent 
paper. The outer layer was then removed and onion was cut into small pieces for extraction; 
20 g was weighed and 80 ml of 80% v/v methanol was added, immediately after the solution 
was grounded with an electric blender to a homogeneous reddish puree. Thus, the solution 
was filtered twice by using suction filtration and then filter paper (P8 Fisher Scientific), then 
0.22 µm syringe filter (Sigma-Aldrich Z290807). Thereafter, 25% w/v red onion extract 
filtrate was collected in Eppendorf tubes and placed into storage at -20Cº until analysis.  
2.3.8. Glucose Uptake Assay 
Glucose uptake assay were performed with 3 D-[3H]-glucose to demonstrate the effects of 
flavonoid and onion extract on glucose uptake in the presence and absence of sodium which 
allowed differentiation between effects of sodium-dependent (mediated by SGLT-1) and 
sodium-independent (mediated by GLUT-2) pathways. 
Caco-2 cells in the 24-well plates were treated with serum free medium (1 ml each well) and 
were kept in the incubator 24 hours before uptake studies. After 24 hours, serum free media 
was aspirated and HBSS with sodium (NaCl &Na2HPO4) and without sodium (KCL 
&K2HPO4) were used to run the experiments. Caco-2 cells were first treated with HBSS, 
containing both sodium and sodium free, for 15 minutes followed by the test compounds 
20M, 50M and 100M flavonoids (phloridzin, quercetin glucosides and quercetin 
aglycone). 1mM glucose was added to each solution as well as 3H-glucose. The concentration 
of radioactive glucose in either the test or the control compound was 12.5 kBq per ml 
according to the known glucose uptake assay method used in a study conducted by (Johnston 
et al., 2005a). The addition of 1 mL of HBSS solution containing glucose, tested compounds 
and 3H-glucose initiated the uptake both in the presence and absence of sodium. The effect 
of phloridzin (positive control), quercetin and quercetin derivatives and onion extract on 
glucose uptake were measured over 2 minutes. For time-dependent experiments, cells were 
incubated at various time points with test compounds in sodium dependent and sodium free 
solutions. Followed by removal of radioactive glucose first, ice-cold PBS was added twice 
to wash the cells. After washing of the cells, PBS was aspirated and 1 ml 200 mM NaOH 
was added at each well and then kept overnight prior to scintillation counting. The solution 
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from wells were removed and placed in scintillation vials. In the last step, 4 ml of scintillation 
fluid in scintillation vials were added and mixed properly. Vials were taken to the scintillation 
counter for counting and the uptake values shown by radiolabelled glucose. The counting 
time for activity measurement was 2 minutes for all the vials (Johnston et al., 2005a). 
 
 
Figure 2.1: Glucose uptake assay conducted on a 24-well plate. 
 
 
Figure 2.2: Picture taken from the 24-well plate containing DMEM medium, consequently removed and 
HBSS sodium-dependent and independent containing test compounds with 3H-glucose were added. 
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2.3.9. Method for detection of radioactivity (3H-glucose)-Liquid Scintillation Counting 
A scintillation counter is the most widely used method for detection of radioactivity, and 
therefore we used it in this research project for measurement of radiation from β-emitting 
nuclides like tritium 3H (a low energy β-emitter). Radioactive samples for counting were 
prepared by combining with a liquid scintillation cocktail. An ionising particle is produced 
by the decay of radionuclide. Part of the kinetic energy of this ionising particle is transferred 
to the ‘scintillator’, which converts this energy into light photons, and these light photons are 
detected by the liquid scintillation system. These photons are directed towards either of two 
photomultiplier tubes (PMTs). Thus, DPM (disintegrations per minute) values were shown 
by tritiated glucose after the uptake study (Wang et al., 2008). Units of radioactivity involves 
1 Becquerel (Bq) = 1 disintegration per second (dps) or 60 disintegrations per minutes (dpm) 
and 1 Curie (Ci) = 3.7 x 1010 disintegrations per second or 2.2 X 1012 disintegrations per 
minute. NaOH from all the wells were mixed with 4 mL of scintillation fluid in translucent 
vials and mixed uniformly for each vial before running on the liquid scintillation counter 
6500. 
 
Figure 2.3: Picture taken from liquid scintillation counter including data storage system, monitor and printer 
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2.3.10. Wipe testing for the use of 3H glucose (Regular monitoring before and after each 
experiment) 
Wipe testing was required for detection of possible radioactive contamination in all the areas 
where liquid isotopes were used. First, the end of the cotton bud was moistened with 70% 
IMS. Then, the areas which were used regularly (100 cm2) and equipment such as Gilson 
pipettes, stock container of 3H glucose and background (unused area) as control were wiped. 
Then, the bud was placed into a scintillation vial and scissors were used to cut off the unused 
end. Then, 4mL scintillation fluid was added to each vial containing wipes, it was ensured 
that the cap was fully in place and then shaken well. The activity was calculated as CPM 
values (counts per minute) in the liquid scintillation counter. 
2.3.11. Bidirectional transport assay (Caco-2 cell models) 
Millicell inserts for (24-well plates) or Transwell-24 insert permeable plates with a treated 
polycarbonate membrane and 0.4 µm pore size were used, which provided an excellent 
substrate for Caco-2 cell attachment, growth and differentiation. An open culture reservoir 
plate was used to reduce liquid handling during cell feeding, and a medium insert was 
transferred to a standard Corning® 24 well microplate for running experiments. This allowed 
easy access to both the apical and basolateral sides of cells. The volume of medium added to 
per plate well and transwell inserts were 0.6ml and 0.1ml respectively (Transwell®, 2010). 
Caco-2 cells were placed in serum-free media for 24 hours prior to uptake studies and were 
incubated for 15 minutes at room temperature in HBSS (with sodium and without sodium) 
prior to experiments. Uptake was initiated by the addition of 1% methanol as control in the 
presence or absence of the test substrate (100 µM quercetin 4́-glucoside and 100 µM 
quercetin 3,4́-diglucoside) pretreated with 3H-glucose at the apical for apical to basolateral 
transport side of monolayer, (Transport from inserts to wells) (Awortwe et al., 2014). The 
reaction was terminated after 2 minutes by aspiration of the uptake buffer followed by the 
addition of ice-cold PBS. Cells were washed twice in ice-cold PBS and solubilised overnight 
in 200 mM NaOH prior to scintillation counting (Johnston et al., 2005a). 
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Figure 2.4: Transwell insert system shows the compartmentalisation of apical and basal sides of glucose 
transporters 
In Figure 2.4 above, number (1) indicates the transwell insert system by the 
compartmentalisation of two main glucose transporters (both apical uptake and basolateral 
release); number (2) inserts allow cells to become highly confluent and polarise on a 
semipermeable membrane, where both apical and basolateral sides of cells are exposed to 
media; (3) shows the media on the apical side is in contact with the apical surface of the 
Caco-2 monolayers and models the intestinal lumen conditions; this is followed by number 
(4), which depicts the semipermeable membrane that allows a physical barrier for cells to 
grow on, as well as separating the apical media from the basolateral media, therefore resulting 
in quantification of apical to basolateral transport in contact with the basolateral side of the 
Caco-2 cells; and finally, (5) shows the basolateral chamber carries media in contact with the 
basal side of Caco-2 and mimics the conditions in circulation.  
 
Figure 2.5: Picture taken from a 24-well plate with transwell inserts. 
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2.3.12. Statistical analysis (cell culture studies)  
Values are presented as mean  SEM. For each analysis, at least three independent 
experiments with nine replicates (control and treated wells) were carried out. Comparisons 
of only two mean values were performed by Student's t-test or one-way ANOVA. If more 
than two means were statistically evaluated, a two-way ANOVA with subsequent multiple 
comparisons, according to Bonferroni, was performed. In order to correct for multiple 
comparisons, the level of significance (x-value) was reduced to p < 0.001. However, the 
mean difference was statistically significant at the 5% level. In all experiments, a probability 
of p < 0.05 (*) was significant, p < 0.01 (**) and p < 0.001 (***) were determined as 
statistically highly significant and p > 0.05 was not statistically significant (ns) (GraphPad 
Prism 6.01, Version Date: 19/10/2012, GraphPad Software, San Diego, USA). 
2.3.13 Dialysis Procedure 
Dialysis involves removal of a very small molecular weight solutes from a solution. It 
contains “dialysis tubing” which was used and has a semi-permeable membrane, made of 
cellulose acetate. Dialysis tubing was cut into desired length. Then, the dialysis tubing was 
rinsed inside and outside with distilled water, as there was glycerol inside. Dialysis tubing 
was immersed into 1L of 2% sodium biocarbonate/1Mm EDTA in 2L glass beaker. Then, a 
knot was tied at one end of the tubing, checked for leakage and then samples were loaded 
into the tubing using a pasteur pipette, and added 50% Ethanol/1Mm EDTA and submerge 
completely. Then, a stirrer bar was placed at the bottom of the beaker and the beaker was 
placed on a magnetic stirring plate in cold room. After dialysis proceeded to two hours, the 
buffer was replaced with a fresh dialysis buffer. Subsequently, the dialysis buffer was 
removed after 8 and 24 hours respectively from the beaker.  
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2.4 Methods (β-Galactosidase Assay) 
2.4.1. Properties and activity of β-galactosidase (LPH)  
The properties, specificity and structure of β-galactosidase significantly differ on the 
microbial source of the enzyme, e.g. different molecular weight, amino-acids chain length, 
position of the active site, pH- and thermal-optimum and stability (Table 2.4). The choice of 
suitable β-galactosidase source depends on reaction conditions of lactose hydrolysis. For 
example, dairy yeasts with a pH optimum 6.5–7.0 are habitually used for the hydrolysis of 
lactose in milk or sweet whey. On the other hand, the fungal β-galactosidases with optimum 
pH 3.0–5.0 are more suitable for acidic whey hydrolysis. The activity of different β-
galactosidases also depends on the presence of ions. The fungal β-galactosidase Aspergillus 
oryzae is active without ions as cofactors, but the yeast β-galactosidase isolated from 
Kluyveromyces lactis requires ions, such as Mn2+, Na+. Interestingly, Ca2+ and heavy 
metals inhibit the enzyme activity of all β-galactosidases (Mlichova and Rosenberg, 2006).  
 
Microorganism 
Production 
of enzyme 
pH-
optimum 
Temperature 
ºC-optimum 
References 
Fungi 
Aspergillus niger 
 
Aspergillus 
oryzae 
Extracellular 
3.0-4.0 
 
 
4.5-5.0 
55-60 
 
 
50-55 
(Greenberg and Mahoney, 
1981) 
(Boon et al., 2000, Tanaka 
et al., 1975, Tanriseven 
and Dogan, 2002) 
Yeasts 
Kluyveromyces 
Lactis 
 
Kluyveromyces 
fragilis 
Intracellular 
6.5-7.0 
 
 
 
6.6 
30-35 
 
 
 
30-35 
(Boon et al., 2000, Roy 
and Gupta, 2003, Jurado et 
al., 2004) 
(Jurado et al., 2004, Boon 
et al., 2000) 
Bacteria 
Escherichia 
coli 
 
Bacillus 
circulans 
Intracellular 
7.2 
 
 
 
6 
40 
 
 
 
65 
(Greenberg and Mahoney, 
1981, Giacomini et al., 
2001) 
(Boon et al., 2000) 
Table 2.4: Properties of microbial β-galactosidases 
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2.4.2. β-galactosidase Assay 
The hydrolysing activity of β- galactosidase was determined by measuring the release of o-
nitrophenol (ONP) from o-nitrophenyl β-D-galactopyranoside (ONPG) at 450 nm. One unit 
of enzyme -galactosidase from fungi Aspergillus oryzae will hydrolyse 1 mole of o-
Nitrophenyl -D-Galactoside to o-Nitrophenol and D-galactose per minute at pH 4.5-5 at 37 
C (Kaur et al., 2007). For thermal stability, enzymes were incubated at the temperature range 
of 24C-60C for 20 minutes and optimum pH was studied by the same method in the pH 
range of 3.0-7.0. Physicochemical properties (pH and temperature) can play an important 
role on rate of products formation through β-galactosidase hydrolysis (Meera et al., 2013). 
 
       
 
ONPG, which is the substrate, was hydrolysed by β-galactosidase into galactose and ortho-
nitrophenol (ONP). Thus, yellow colour appeared, indicating the enzyme activity by means 
of using a colorimetric assay (at 450nm wavelength).  
The reaction was carried out with continuous shaking in an assay volume of 2.0 ml containing 
1 ml of 100 mM PBS buffer, pH 4.5, 0.1 ml 𝛽-galactosidase (2 U), and 0.9 ml of reaction 
mixture (5.6 ml 0.1 M PO4 pH 5.5 + 1.4 ml of 20 mM ONPG). The reaction was stopped 
after 20 minutes by adding 1 ml potassium carbonate solution (4% K2CO3) and o- nitrophenol 
(ONP) formation was measured spectrophotometrically at 450 nm (Ansari and Husain, 
2012). The activity of β-galactosidase was determined at different temperatures (24, 37, 45 
and 60 ºC at pH 4.5 using ONPG as the substrate. The reaction mixture contained 20 mM 
phosphate buffer at pH (5.5) and 1.6 mM ONPG (Mlichova and Rosenberg, 2006). One unit 
of β-galactosidase activity (EU) was determined as the amount of enzyme hydrolysing one 
micromole of the ONPG to o-nitrophenol and D-galactose per minute under different 
conditions as stated above (Jin et al., 2015). The effective pH for the activity of β-
galactosidase from Aspergillus oryzae is 4.5-6.0 and the optimum temperature is up to 55 C 
(Ansari and Husain, 2012).  
 
-galactosidase 
ONP + Galactose ONPG 
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Test Tube PBS (ml) Rxn Mix (ml) Enzyme (l) Final Volume (ml) 
1 (Blank) 1 1 0 2 
2 0.975 1 25 2 
3 0.95 1 50 2 
4 0.90 1 100 2 
5 0.80 1 200 2 
6 0.70 1 300 2 
Table 2.5: Test tubes containing enzyme and substrates for -galactosidase enzyme assay 
 
Figure 2.6: Picture taken from 6 test tubes representing β-galactosidase assay after a noticeable yellow colour 
developed 
Results were presented as means ± standard deviations (SD) for three replicates for each 
sample. The buffers used were glycine-HCl (pH 3.0), sodium acetate (pH 4.0, 4.5, and 5.0), 
and sodium phosphate (6.0-7.0). The standard calibration curve of ONP versus OD 
absorbance (450nm) was demonstrated in order to calculate the concentration of formed ONP 
(µmol/ml/min) products by hydrolysis of ONPG with β-galactosidase from Aspergillus 
oryzae. 
2.4.3. Enzyme hydrolysis 
One millilitre of purified quercetin 3,4́-diglucoside or methanol extract of onions was dried 
under vacuum at 45 ºC. One millilitre of β-galactosidase from Aspergillus oryzae solution (2 
mg/ml) was added and the solution was kept at 45 ºC for 2 hours to achieve complete 
hydrolysis. The hydrolysate was suspended in 1 ml 80% methanol, and analysed by the 
analytical HPLC system. Completion of hydrolysis was confirmed by disappearance of 
quercetin glucosides peaks in the chromatogram.  
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2.5 Methods (HPLC) 
2.5.1. Identification and quantification of flavonoid in onions 
High performance liquid chromatography (HPLC) is used widely and is a powerful technique 
in separation and analysis of various natural compounds such as flavonoids (aglycones and 
glycosides). Its advantages include simplicity, sensitivity, specificity, high resolution, speed, 
precision, good reproducibility, recovery, accuracy and sample preservation (Amorim et al., 
2014). This technique also allows simultaneous separation and quantification of flavonoids. 
To obtain adequate resolution, a wide range of stationary and mobile phase combinations 
have been used for the separation of flavonoids in a mixture. Silica gel columns are used in 
normal phases for appropriate separation of nonpolar or weakly polar flavonoid aglycones. 
Usually no gradient is employed and different classes of flavonoids in plants are separated 
by using reversed phase HPLC (RP-HPLC) (Lombard et al., 2002). The common HPLC 
instrument includes C18 column, a solvent delivery system, sample injection, detector and 
recorder. The column is selected based on the class of flavonoids to be separated and the 
characteristics of the stationary phase that is capable of receiving satisfactory retention, peak 
shapes and selectivity. Guard columns are used to extend the life time and to protect the 
analytical column from sample impurities (Amorim et al., 2014). 
HPLC was used to identify and quantify the quercetin aglycone and main quercetin 
glucosides in onions, and this technique was then used to study the effects of -galactosidase 
enzyme on the hydrolysis of quercetin glucosides to free quercetin aglycone. HPLC (Model 
200, Perkin Elmer) at wavelength = 370 nm was used. HPLC includes pumps, which pass 
pressurised liquid and a sample mixture through a column, leading to the separation of 
sample components. Solvents A (water-tetrahydrofuran-trifluoroacetic acid 98:2:0.1 v/v) and 
B (acetonitrile) were run at a flow rate of 1 ml/min, using a gradient of 17% B (2 min), 
increasing to 25% B (5 min), 35% B (8 min), 50% B (5 min) and then to 100% B (5 min). A 
column clean-up stage maintained B at 100% (5 min) followed by a re-equilibration 17% B 
(15 min). Diode array detection monitored the eluent at 370 nm for 25 minutes (Lombard et 
al., 2006). The appropriate flavonoid glycoside for each enzyme analysis was used as an 
external standard.  
The product in each of the reactions will be confirmed by co-elution of peak with standard 
compounds and by matching UV spectra (Day et al., 2000c). Identification of quercetin 
glucosides in onion will be determined by comparing the relative position of the peaks in 
70 
 
onion extract with standards. Moreover, 0.1% is the maximum concentration of DMSO, 
which was used as the solvent for each of these flavonoids for enzyme assay and HPLC 
analysis. 
 
Figure 2.7: Demonstration of RP-HPLC system. 
2.5.2. Identification and quantification of flavonoids 
Identical standard curves of flavonoids quercetin 3́-glucoside, quercetin 4́-glucoside and 
quercetin 3,4́-diglucoside, were made for quercetin quantification by HPLC methods. 
Absorbance values and peak areas (RP-HPLC) for each level of the standard curve were 
recorded every 25 minutes for calibration purposes. Quercetin dihydrate was also used as 
standards for identification of other flavonol compounds (quercetin glucosides) during HPLC 
analysis.  
Concentrations of quercetin conjugates in red onion extract were calculated by linear 
regression onto the standard curve of known samples. The relationship of peak area versus 
concentration for HPLC analyses were used to express results. The standard curve of 
quercetin and quercetin 4́-glucoside, quercetin 3,4́-diglucoside in 80% methanol, ranged 
between 0 and 50 µg/ml. Data analysis was performed in Excel using general linear model 
and correlation procedure. 
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For quantification of quercetin 4́-glucoside and quercetin 3,4́-diglucoside, paired series of 
quercetin glucosides in methanol and 1 millilitre of Aspergillus oryzae β-galactosidase 
solution (2 mg/ml) was added for enzyme hydrolysis. A total of 25% w/v onion extract in 
80% methanol and onion solution boiled in water for 15 minutes were used, which showed 
differences in the levels of individual quercetin and quercetin glucosides in the onion extract 
during enzyme hydrolysis monitored over time. One millilitre of onion extract was mixed 
with 1 ml of β-galactosidase solution and incubated at pH 4.5 and 45 ºC for 20, 40 and 60 
minutes. After the incubation, samples were placed on ice to stop the enzyme activity (Yoo 
et al., 2010).  
2.5.3. Statistical analysis (Flavonoids quantification-HPLC) 
Results are presented as means ± standard deviations (SD) for three replicates for each 
sample. In chromatographic assays, each replicate solution was injected two or three times, 
and the averaged peak areas were used to calculate analyte concentrations. Differences 
between mean values were assessed by Student’s t-test with a significance level of p < 0.05. 
The calibration curve was constructed by plotting the measurements of mean absorbance 
versus the concentration of the standard solutions. The results were analysed by linear 
regression and the correlation coefficient (R2) was calculated (GraphPad Prism 6.01 from 
GraphPad Software, San Diego USA). One-way ANOVA was calculated to compare the 
replicates of the calibration curve. All statistical calculations were performed using GraphPad 
Prism 6.01, V2.01, Version Date: 19/10/2012, GraphPad Software, San Diego USA). 
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2.6. Results 
2.6.1. Caco-2 cells morphology  
 
Figure 2.8: 20-50% Non-confluent Caco-2 cells (10x and 20x magnification) 
 
Figure 2.9: 80-90% confluent Caco-2 cells (30x and 40x magnification) 
Trypsinisation (passage) of the Caco-2 cells were required for detachment of the Caco-2 cells. 
For this, cells were washed twice with 5 ml phosphate buffered saline (PBS) which 
maintained pH and osmotic balance of the cells. Following this, cells were then treated with 
2 ml of 1% trypsin for 40 seconds with vigorous taping on the sides of the flask to detach 
cells from the walls. 
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Floating cells were seen under the microscope at 10X magnification, and at this point, 8 ml 
of complete culture medium were added to the flask. Afterwards, 2 ml of floated cells was 
transferred to new T-75 flasks and 13 ml of fresh medium was added to make a final volume 
of 15 ml.  
Cells were divided into 3 to 4 T-75 flasks and then checked every couple of days for their 
confluency; and their DMEM medium was changed, and thus kept in the cell culture 
incubator gassed with 5% CO2 at 37 °C. According to figure 2.8, Caco-2 cells were less than 
50% confluent, whereas figure 2.9 presents up to 90% confluency which was essential for 
cell passage stage. The growth of these cells involved formation of monolayers, which 
showed a cylindrical polarised morphology, with microvilli on the apical membrane, tight 
junction between adjacent cells and express small intestinal hydrolase enzyme activities on 
the apical membrane. 
2.6.2. Glucose Uptake Assay 
2.6.2.1. The Effect of DMSO and Methanol on Caco-2 cells- Dose Response Experiments 
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Figure 2.10: Effect of DMSO at different concentrations on Caco-2 cells glucose uptake under sodium-
dependent condition within 2 minutes, results are expressed as mean ± SEM, n=3 with p > 0.05 
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Figure 2.11: Effect of DMSO at different concentrations on Caco-2 cells glucose uptake under sodium-
independent condition within 2 minutes, results are expressed as mean ± SEM, n=3 with p > 0.05 
Both figures illustrate that 0.1% concentration of DMSO caused no effect on glucose uptake 
levels (p > 0.05) under sodium-dependent and sodium-independent conditions, thus 0.1% is 
the maximum concentration of DMSO to be used as the solvent for flavonoids.  
Cytotoxicity of methanol was assessed on the Caco-2 cells by using different concentrations 
of methanol. 1% has been found as the maximum concentration mostly used in previous 
studies (Salucci et al., 2002). 
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Figure 2.12: Effect of methanol at different concentrations on Caco-2 cells glucose uptake under sodium-
dependent condition within 2 minutes, results are expressed as mean ± SEM, n=3 with p > 0.05 
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Figure 2.13: Effect of methanol at different concentrations on glucose uptake under sodium-independent 
condition within 2 minutes, results are expressed as mean ± SEM, n=3 with p > 0.05 
Figure 2.12 and 2.13: compare different concentrations 0.5%, 1% and 2% of methanol to 
control in the presence and absence of sodium conditions respectively. According to 
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statistical t-test, it is shown that methanol at 1% concentration had p = 0.55 (p > 0.05), 
confirmed no statistical difference on the uptake of glucose at 1% concentration compared 
to the control. Therefore, 1% methanol caused no cellular toxicity and it was chosen as the 
top concentration of methanol in our experiments. Following this, 20M, 50M and 100M 
phloridzin, quercetin 3-glucoside, quercetin 4́-glucoside and quercetin 3,4́-diglucoside were 
dissolved in DMSO, the final concentration of DMSO in treatment media was 0.1 w/v%. 
In vitro studies were conducted to compare the inhibition of sodium-dependent and 
independent glucose uptake in Caco-2 cells by flavonoids in onion which are mainly 
phloridzin, quercetin 4́-glucoside and quercetin 3,4́-diglucoside (Day et al., 2000b). These 
experiments were conducted at different µM concentrations of flavonoids (aglycone and 
glycosides) and 25% w/v red onion extract, to measure the optimum glucose uptake in the 
presence and absence of sodium conditions. 
2.6.2.2. Phloridzin as a positive control  
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Figure 2.14: Glucose uptake in Caco-2 cells in the presence of phloridzin under sodium-dependent condition 
with n=3 ± SEM, *** p < 0.001, ** p < 0.01 and * p < 0.05 
Figure 2.14 illustrates the significant inhibitory influence of phloridzin as a positive control 
on Caco-2 cellular glucose uptake under sodium dependent condition. There was a higher 
glucose inhibition as the concentration of phloridzin increased, showing up to 80% inhibition 
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of glucose at 100µM at significance level of p < 0.0001 (p = 0.0004) and 65% and 50% were 
determined at 50µM and 20 µM with p < 0.05 (p = 0.01) and p < 0.05 (p = 0.045) respectively. 
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Figure 2.15: Glucose uptake in Caco-2 cells in the presence of phloridzin under sodium-independent 
condition with n=3 ± SEM, p > 0.05 
Figure 2.15 shows under sodium-independent conditions, there was not a significant 
reduction in cellular glucose uptake when Caco-2 cells were treated with phloridzin. Even at 
the highest concentrations, 100µM only 30% inhibition was found at a statistical significant 
level of p > 0.05 (p = 0.17). Subsequently, lower levels, 50µM and 20µM, demonstrated 20% 
and 15% glucose inhibition with p > 0.05 respectively. 
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2.6.2.3. Effects of Flavonoids (glycosides and aglycone) on Caco-2 cells glucose uptake 
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Figure 2.16: Glucose uptake in Caco-2 cells in the presence of quercetin 4́-glucoside under sodium-dependent 
condition with n=3 ± SEM, *** p < 0.001, * p < 0.05 and ns (not significant) = p > 0.05 
Figure 2.16 illustrates that 100M quercetin 4́-glucoside significantly reduced the uptake of 
glucose compared to control by 75% at significance level of (p < 0.001) with p = 0.0007 
under sodium-dependent condition. This result demonstrated the concentration-dependent 
inhibitory effect of quercetin 4́-glucoside on Caco-2 cells glucose uptake with 65% and 42% 
reduction at 50M and 20M respectively. The glucose inhibition at 50M was statistically 
significant with p = 0.037 (p < 0.05), while no statistical significance was found at 20 µM 
with p = 0.3 (p > 0.5).  
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Figure 2.17: Glucose uptake in Caco-2 cells in the presence of quercetin 4́-glucoside under sodium-
independent condition with n=3 ± SEM, p > 0.05 
Figure 2.17 indicates that under sodium-independent condition, quercetin 4́-glucoside did not 
significantly inhibit the glucose uptake in Caco-2 cells, only 30% reduction was found at the 
presence of 100 M quercetin 4́-glucoside with p = 0.065 (p > 0.05).  
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Figure 2.18: Glucose uptake in Caco-2 cells in the presence of quercetin 3,4́-diglucoside under sodium-
dependent condition with n=3 ± SEM, * p < 0.05 and p > 0.05 
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Figure 2.18 shows quercetin 3,4́-diglucoside at 50 µM and 100µM significantly reduced the 
glucose uptake by 64% and 75% at significance level of P < 0.05 (p = 0.04) and p ≤ 0.01 (p 
= 0.01) respectively under sodium-dependent condition. Our finding suggests that quercetin 
3,4-́diglucoside, similar to quercetin 4́-glucoside, compete with the glucose present at the 
SGLT-1 transporters at the apical membrane, and thus inhibits the uptake of glucose at 
sodium-dependent condition. 
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Figure 2.19: Glucose uptake in Caco-2 cells in the presence of quercetin 3,4́-diglucoside under sodium-
independent condition with n=3 ± SEM, p > 0.05 
Figure 2.19 shows under sodium-independent condition quercetin 3,4́-diglucoside caused 
only 5%-10% reduction in cellular glucose uptake (p > 0.05). It is suggested that SGLT-1 
will be inactive in the sodium-independent conditions and the uptake of glucose is carried 
out by the GLUT-2 facilitative component.  
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Figure 2.20: Glucose uptake in Caco-2 cells in the presence of quercetin 3-glucoside under sodium-dependent 
condition with n=3 ± SEM, * p < 0.05 and p > 0.05 
Figure 2.20 illustrates that 100M of the compound is resulting in significant inhibition 
(52%) compared to 50M (21%) and 20M (13%) in the sodium dependent condition at 
significance level of p < 0.05, p = 0.034. Therefore, under the sodium-dependent condition, 
100M concentration of quercetin 3-glucoside caused the highest inhibition concentration 
compared to 50M and 20M; therefore, the higher the concentration, the more inhibition 
was determined.  
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Figure 2.21: Glucose uptake in Caco-2 cells in the presence of quercetin 3-glucoside under sodium-
independent condition with n=3 ± SEM, p < 0.05 
Figure 2.21, illustrates a slight inhibitory effect in the sodium independent condition. At 
sodium free condition, the highest glucose inhibition was 20% at 100µM, which was not 
statistically significant with p > 0.05.  
83 
 
Q u e rc e t in  C o n c e n tra t io n  ( M )
3
H
 G
lu
c
o
s
e
 u
p
ta
k
e
 (
D
P
M
/m
l)
0 2 0 4 0 6 0 8 0 1 0 0 1 2 0
0
5 0 0 0
1 0 0 0 0
1 5 0 0 0
2 0 0 0 0
n s
n s
n s
 
Figure 2.22: Glucose uptake in Caco-2 cells in the presence of quercetin under sodium-dependent condition 
with n=3 ± SEM, p > 0.05 
Figure 2.22 shows quercetin aglycone caused no statistically significant inhibition on the 
cellular glucose uptake under sodium-dependent condition with p > 0.05 (p = 0.1) at 100µM 
concentration. This result suggests that quercetin can possibly compete with glucose 
molecules at the GLUT-2 transporter; therefore, under sodium-dependent conditions, 
quercetin had no effect of the accumulation of glucose by Caco-2 cells compared to control. 
Thus, SGLT-1 was inactive and glucose was mediated solely by GLUT-2 facilitative 
component.  
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Figure 2.23: Glucose uptake in Caco-2 cells in the presence of quercetin under sodium-independent condition 
with n=3 ± SEM, ** p < 0.01 and p > 0.05 
Figure 2.23 demonstrates a significant inhibitory effect of quercetin on glucose uptake in the 
sodium free condition at 100 µM with 58% reduction compared to control, with p < 0.01 (p 
= 0.008). Therefore, sodium-dependent glucose absorption appears to be rather specific to 
quercetin mono and diglucosides such as quercetin 4́-glucoside, quercetin 3,4́-diglucoside 
and quercetin 3-glucoside (figures 2.16, 2.18 and 2.20).  
Since quercetin 4́-glucoside and quercetin 3,4́-diglucosides and quercetin 3-glucoside are the 
main flavonoids in onions, we were interested to conduct further experiments with the same 
conditions to demonstrate the effect of onion and these quercetin glucosides on Caco-2 cells 
glucose uptake.  
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Figure 2.24: Glucose uptake in Caco-2 cells in the presence of 100 µM quercetin, 100 µM quercetin 3-
glucoside and 25% (w/v) red onion extract under sodium-dependent and sodium-independent conditions with 
n=3 ± SEM, ** p < 0.01 and * p < 0.05, from two-way ANOVA multiple comparisons. 
Figure 2.24 illustrates in the sodium dependent condition, there was a significant reduction 
of glucose levels in the presence of quercetin 3-glucoside and onion, with up to 42% and 
55% inhibitory effect respectively. Therefore, this data illustrates that both may act as 
inhibitors of glucose in SGLT-1 and GLUT-2 transporters. However, in the absence of 
sodium, quercetin 3-glucoside did not significantly inhibit the glucose uptake compared to 
control 27% at significance levels with p = 0.12 (figure 2.24). 100 M quercetin 
demonstrated a significant inhibitory effect in the sodium free condition with 56% reduction 
compared to control, and p = 0.02 (p < 0.05).  
From our result, it is evident that quercetin 3-glucoside is most likely to cause inhibition of 
glucose uptake in the presence of sodium, while quercetin blocks glucose uptake in the 
absence of sodium which is most likely through GLUT-2. Our results suggest that inhibition 
of SGLT-1 by onion extract is mainly caused by quercetin glucosides, while GLUT-2 
inhibition by onion extract could be caused by quercetin aglycone (Boyer, et al. 2005). 
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2.6.2.4. Effect of quercetin glucosides on glucose uptake at both Apical and Basolateral 
membrane  
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Figure 2.25: Glucose inhibition in Caco-2 cells in the presence of 100µM quercetin 4́-glucoside and 100µM 
quercetin 3,4́-diglucoside under sodium-dependent condition at apical side with n=3 ± SEM, * p < 0.05 and 
** p < 0.01 
Figure 2.25 shows under sodium dependent condition, there was a significant reduction in 
the cellular glucose apical uptake treated with 100µM quercetin 3,4́-diglucoside and 100µM 
quercetin 4́-glucoside, 70% and 60% with p < 0.01 and p < 0.05 respectively. The significant 
decrease in glucose levels by quercetin glucosides are possibly due to the competitive 
inhibition of sodium-dependent glucose transport across the intestinal brush-border 
membrane, which was subsequently mediated by sodium-dependent glucose transporter 
SGLT-1. 
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Figure 2.26: Glucose inhibition in Caco-2 cells in the presence of 100µM quercetin 4́-glucoside and 100µM 
quercetin 3,4'-diglucoside under sodium-dependent condition at the basolateral side with n=3 ± SEM, * p < 
0.05 and p > 0.05 
Figure 2.26 illustrates under sodium dependent condition at the basal side, both quercetin 
3,4-́diglucoside and quercetin 4́-glucoside showed a slight inhibitory effect on glucose 
transport; it was not statistically significant p > 0.05. Our result is in support of previous 
findings where quercetin glucosides were sodium-dependent; therefore, they played through 
SGLT-1 transporters available at the apical membrane of Caco-2 models (Johnston et al., 
2002). Thus, our finding characterises that Caco-2 cells in transwell inserts represent the 
apical membrane of enterocytes where glucose is transported by SGLT-1 transporters.  
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Figure 2.27: Glucose inhibition in Caco-2 cells in the presence of 100 µM quercetin 4́-glucoside and quercetin 
3,4́-diglucoside under sodium-independent condition at apical side with n=3 ± SEM, p > 0.05 
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Figure 2.27 shows under sodium independent conditions, none of the quercetin glucosides 
reduced the transport of glucose at cellular levels with p > 0.05. This is in accordance with 
findings from (Lombard et al., 2002), where quercetin 4́-glucoside and quercetin 3,4́-
diglucoside did not decrease glucose levels in Caco-2 cells, as they mostly function at 
sodium-dependent condition through SGLT-1 glucose transports.   
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Figure 2.28: Glucose inhibition in Caco-2 cells in the presence of 100 µM quercetin 4’-glucoside and 
quercetin 3,4́-diglucoside under sodium-independent condition at the basolateral side with n=3 ± SEM, * p < 
0.05 and p > 0.0 5 
Reduction of glucose uptake at the basolateral membrane of enterocytes, which in the current 
Caco-2 model was presented by the transport of glucose from the upper to lower side of 
transwell inserts (wells), may be related to inhibition of GLUT-2 by quercetin produced from 
the hydrolysis of quercetin glucoside by α-glucosidase. It is important to note that quercetin 
has been shown to inhibit GLUT-2, and transport of glucose from the gut to the blood stream 
requires not only luminal glucose uptake into enterocytes via SGLT-1, but also release from 
the basal membrane of enterocytes into the blood stream via GLUT-2 (Zheng et al., 2011). 
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2.6.2.5. Effect of Inulin and onion extract on Caco-2 cells glucose uptake 
In addition to flavonoids, there is another important compound, such as Inulin, which belongs 
to a class of compounds known as Fructans. This compound is widely found in onions 
(Mcclearly and Murphy, 2000). Inulin is a soluble fibre, some soluble fibres may help lower 
blood glucose levels (Kaur and Gupta, 2002). 
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Figure 2.29: Glucose uptake in Caco-2 cells in the presence of 25% w/v onion extract and 5% w/v, inulin 
under sodium-dependent condition with n=3 ± SEM, * p < 0.05 and p > 0.05 
Figure 2.29 shows 5% w/v inulin did not result in a significant inhibition of glucose uptake 
compared with control, 15% reduction was found at sodium dependent condition with p > 
0.05 (p = 0.6). However, again the onion extract significantly reduced glucose uptake with 
47% inhibition p < 0.05 (p = 0.01). Our result indicates that the inhibitory effect of onion on 
lowering glucose levels could mainly be due to the presence of flavonoids. It is believed that 
more than 95% of the flavonoids in onion is quercetin, and its derivatives, 1-5% inulin 
(Perez-Gregorio et al., 2010). Therefore, inulin is suggested to have a lower anti-glycaemic 
effect in our Caco-2 cells models. 
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Figure 2.30: Glucose uptake in Caco-2 cells in the presence of quercetin 4́-glucoside, quercetin 3,4-́
diglucoside and 5% w/v inulin under sodium-dependent conditions with n=3 ± SEM, * p < 0.05, ** p < 0.01 
and p > 0.05 
Quercetin 3,4́-diglucoside shows 70% reduction at Caco-2 glucose concentrations, followed 
by 50% reduction through quercetin 4́-glucoside with P = 0.01 and p = 0.03 p < 0.05 
respectively. Whereas, no statistically significant inhibition was caused by inulin p > 0.05. 
Under a sodium-dependent condition, both quercetin 4́-glucoside and 3,4́-diglucoside caused 
a drastic reduction on glucose absorption, through the SGLT-1 transporter (figure 2.30). 
Our result is in accordance with findings from most of the previous studies and our earlier 
findings; therefore, quercetin monoglucosides and quercetin diglucosides were found as the 
main inhibitors of glucose uptake through sodium-dependent conditions on the apical side 
(Figures 2.16, 2.18 and 2.20). 
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Figure 2.31: Glucose uptake in Caco-2 cells in the presence of 100 µM quercetin 4́-glucoside, 100 µM 
quercetin 3,4́-diglucoside and 5% w/v inulin under sodium-independent condition with n=3 ± SEM, * p < 
0.05 and p > 0.05 
Comparing the effect of quercetin 4́-glucoside, quercetin 3,4́-diglucoside and inulin with 
control on Caco-2 cells glucose uptake, Inulin showed a non-significant glucose uptake 
inhibition 22% and 10% at both sodium dependent and independent conditions with p > 0.05 
(Figure 2.30 & 2.31). Also, none of the quercetin glucosides reduce the glucose uptake at a 
significant level in the absence of sodium condition, since they found to be mostly active at 
sodium-dependent conditions (figure 2.30). Therefore, our result proposes that inhibition in 
glucose uptake by onion extract is mainly by flavonoids quercetin 4́-glucoside and quercetin 
3,4-́diglucoside, not by inulin. It is important to note that in our research we used inulin from 
chicory (not onion); therefore, our result is not defining a consistent effect of inulin (from 
chicory not onion) on Caco-2 cells glucose uptake under the same conditions compared with 
onion extract and its flavonoid glycosides. 
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2.7. Validation of HPLC -Limit of Detection 
A validation study was carried out to demonstrate the applicability of this analytical approach. 
Therefore, limit of detection (LOD) of several samples were detected. LOD of an individual 
analytical procedure is the lowest amount of analyte in a sample which can be detected but 
not necessarily quantified (Tuszynska, 2014). Based on signal-to-noise approach, 
determination of signal-to-noise ratio was performed by comparing measured signal from 
quercetin 4́-glucoside and quercetin 3,4́-diglucoside with 1ng/ml and 2ng/ml concentrations 
of analyte with those of blank samples and by establishing the minimum concentration at 
which the analyte can be reliably detected. A signal-to-noise-ratio between 3 or 2:1 is 
considered acceptable for estimating detection limit (Chen et al., 2012). The test samples 
with signal-to-noise-ratio rates are shown as below. 
 
Figure 2.32: Limit of detection (LOD) of 1ng/ml of quercetin 4́-glucoside in 80% v/v methanol (RT= 11.23 
min) 
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Figure 2.33: Limit of detection (LOD) of 2ng/ml of quercetin-4́ glucoside in 80% v/v methanol (RT= 11.34 
min) 
 
Figure 2.34: Limit of detection (LOD) of 1ng/ml of quercetin 3,4́-diglucoside in 80% v/v methanol (RT=3.75 
min) 
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Figure 2.35: Limit of detection (LOD) of 2 ng/ml of quercetin 3,4́-diglucoside in 80% v/v methanol (RT= 4 
min) 
According to figure 2.32-2.35, no other significant peaks with a signal-to-noise of three or 
more were observed at specific retention times of quercetin 4́-glucoside and quercetin 3,4'-
diglucoside. LOD was detected at 1ng/ml and 2 ng/ml of quercetin 4́-glucoside with UV-
chromatogram at RT= 11.23 and 11.34 min, which showed 2.6 and 2.9 times more signal 
than the noise at RT= 10.78 and 10.88 min respectively. Moreover, 3,4́-diglucoside at 1ng/ml 
and 2ng/ml with UV-chromatogram at RT=3.75 and 4 min, demonstrated 3.8 and 1.9 times 
more signal than the noise at 3.05 to 3.15 min. 
According to a signal-to-noise approach, detection of signal-to-noise ratio was evaluated 
through comparison of measured signal from quercetin 4́-glucoside and quercetin 3,4́-
diglucoside with 1ng/ml and 2ng/ml concentrations with those of blank samples. Both 
quercetin 4́-glucoside and quercetin 3,4́-diglucoside showed a signal-to-noise-ratio between 
2 to 3, which indicated 1ng/ml or 2ng/ml are accepted as their limits of detection (Chen et 
al., 2012). 
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2.8. Identification of flavonoids in onion by RP-HPLC-DAD  
HPLC-DAD was used to identify components by the comparison of their spectrum. The 
spectrum was recorded from 200-600nm; therefore, flavonoids were identified by maximum 
UV absorption wavelength. In the current research based on the spectral analysis from RP-
HPLC DAD, the UV spectrum of red onion extract was compared with each control standard 
(Quercetin and Quercetin glucosides) from 200nm-600nm; therefore, the main four 
flavonoids present in the onion were identified as follows quercetin 4́-glucoside, quercetin 
3,4-́diglucoside, quercetin 3-glucoside and quercetin (Figures 2.36-2.43). 
 
Figure 2.36: UV-scan of onion extract, peak at 3.83min appears at Wavelength: 218nm 283nm and 347nm. 
Based on the UV spectrum and by comparison with the standards, four flavonoids were 
identified as follows: quercetin, quercetin 3-glucoside, quercetin 4́-glucoside and quercetin 
3,4-́diglucoside in the red onion extract (25% w/v), which supported our previous findings. 
Peaks were assigned to quercetin and quercetin glucosides when monitoring the 
chromatographic runs at 370nm.  
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Figure 2.37: UV-scan of quercetin 3,4́-diglucoside peak at 3.77min appears at wavelength: 219nm, 263nm and 
348nm. 
Samples Red Onion Extract Quercetin 3,4-́Diglucoside 
Retention Time- RT (min) 3.8 3.8 
UV Scans 
(wavelengths nm) 
218, 283, 347 219, 263, 348 
Table 2.6: RT (min) and UV scans (nm) of red onion extract and quercetin 3,4́-diglucoside  
The similar UV-scans from quercetin 3,4́-diglucoside to onion extract at RT=3.8min, 
confirmed the presence of this compound in the onion extract. 
 
Figure 2.38: UV-scan of onion peak at 7.31min appears at wavelength= 213, 257 and 355nm. 
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Figure 2.39: UV-scan of quercetin 3-glucoside peak at 7.27min appears at wavelength= 220, 260 and 355nm. 
Samples Red Onion Extract Quercetin 3-Glucoside 
Retention Time-RT (min) 7.3 7.3 
UV Scans (Wavelengths 
nm) 
(wavelengths nm) 
213,257, 355 220, 260, 355 
Table 2.7: RT (min) and UV scans (nm) of red onion extract and quercetin 3-glucoside 
UV-scans from quercetin 3-glucoside is similar to the onion extract at RT= 7.3 min, which 
determined the presence of this compound in the onion extract. 
 
Figure 2.40: UV-scan of onion peak at 10.31min appears at wavelength= 221, 253 and 265nm. 
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Figure 2.41: UV-scan of quercetin 4́-glucoside peak at 10.34min appears at wavelength= 218, 263 and 265nm. 
Samples Red Onion Extract Quercetin 4-́Glucoside 
Retention Time-RT (min) 10.3 10.3 
UV Scans 
 (wavelengths nm) 
221, 253, 265 218, 253, 265 
Table 2.8: RT (min) and UV scans (nm) of red onion extract and quercetin 4́-glucoside 
UV-scans from quercetin 4-glucoside is in accordance to the onion extract at RT=10.3min 
which showed this compound is found in the onion extract. 
 
Figure 2.42: UV-scan of onion extract peak at 15.2 min appears at wavelength= 217, 255 and 379nm 
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Figure 2.43: UV-Scan of quercetin peak at 15.5 min appears at wavelength= 217, 255 and 370nm. 
Samples Red Onion Extract Quercetin 
Retention Time - RT (min) 15.2 15.5 
UV Scans  
(wavelengths nm) 
217, 255, 379 217, 255, 370 
Table 2.9: RT (min) and UV scans (nm) of red onion extract and quercetin 
The similar UV-scans from quercetin to the onion extract at RT=15 min also confirmed our 
previous findings, thus it was found in the onion extract. Based on the current spectral 
analysis, the four flavonols present in the onion were identified as follows: quercetin 3,4́-
diglucoside, quercetin 4́-glucoside, quercetin 3-glucoside and quercetin. 
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2.8.1. Standard curves of quercetin and quercetin glucosides 
 
Figure 2.44: Quercetin standard curve (10-50 g/ml) 
 
Figure 2.45:Quercetin 4́-glucoside standard curve (10-50 g/ml) 
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Figure 2.46: Quercetin 3,4-́diglucoside standard curve (10-50 g/ml) 
2.9. Effect of Quercetin 3,4́-diglucoside, Quercetin 4́-glucoside, onion 
extract and dialysed onion extract on Caco-2 cells glucose uptake 
 
Figure 2.47: 25% w/v onion extract, absorbance against time (RT= 4.021 and 11.201 min) 
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According to figure 2.47, 25% onion extract indicates two large peaks occurring at RT 4.021 
and 11.201min, which are identified as quercetin 3,4́-diglucoside and quercetin 4́-glucoside 
respectively by relative position of these peaks compared to standards (3,4́-diglucoside and 
4́-glucoside.  
 
Figure 2.48: Dialysed 25% w/v onion extract after 8 hours, absorbance against time (RT= 4.063 and 11.259 
min) 
 
Figure 2.49: Dialysed 25% w/v onion extract after 24 hours, absorbance against time (RT= 4.027, 11.167 
min) 
103 
 
 
 
Figure 2.50: The effect of dialysis on the concentration of quercetin glucosides in 25%w/v onion extract (n=3 
± SEM) through standard curve of both quercetin glucosides (Figures 2.45 & 2.46) 
Figure 2.50 shows that after 8 hours of dialysis, the concentration of both quercetin 3,4́-
diglucoside and quercetin 4́-glucoside significantly reduced from 40.1 g/ml and 30.4g/ml 
to 6.5µg/ml and 4.4g/ml respectively (p < 0.01). Moreover, after 24 hours of dialysis, 
quercetin 3,4́-diglucoside and quercetin 4́-glucoside concentrations significantly decreased 
to 1.7 µg/ml and 1.1 µg/ml respectively with p < 0.001. This could be due to the low 
molecular weight of quercetin glucosides which results in their loss in the 25% w/v onion 
extract after dialysis. Also, dialysis buffer was assessed to check if quercetin glucosides were 
still present; therefore, the presence of both quercetin 4́-glucoside and quercetin 3,4́-
diglucoside with RT= 11.167 and 4.027 min were obtained which were in accordance with 
their standards.  
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Figure 2.51: Glucose uptake in Caco-2 cells in the presence of 100µM quercetin 3,4́-diglucoside, 100µM 
quercetin 4́-glucoside, 25% w/v non-dialysed onion and dialysed onion under sodium-dependent condition 
with n=3 ± SEM, *** p < 0.001,** p < 0.01 and * p < 0.05 and p > 0.05 
Figure 2.51 illustrates a significant reduction in cellular glucose uptake in the wells treated 
with quercetin 3,4́-diglucoside and quercetin 4́-glucoside by 65% at a statistical significant 
level of p < 0.001; followed by inhibitory influence of non-dialysed onion by 51% with p < 
0.01 (p = 0.007), whereas after 8 hours of dialysis of onion, the inhibitory effect significantly 
reduced to 29% with p > 0.5 (p = 0.2). 
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Figure 2.52: Glucose uptake in Caco-2 cells in the presence of 100 µM quercetin 3,4́-diglucoside, 100 µM 
quercetin 4́-glucoside, 25% w/v non-dialysed onion and dialysed onion under sodium-independent condition 
with n=3 ± SEM, ** p < 0.01 and p > 0.05 
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Figure 2.52 demonstrates that there was a significant reduction in cellular glucose uptake in 
the wells treated with 100µM quercetin 4́-glucoside by 60% at a statistical significant level 
of p < 0.01 (p = 0.0008). Followed by lower inhibitory influence of 25% w/v non-dialysed 
onion, 100 µM quercetin 3,4́-diglucoside and dialysed onion by 42%, 32% and 10% with p 
> 0.05 respectively.  
Dialysed onion did not have a significant inhibitory effect in glucose uptake at both sodium 
dependent and sodium free conditions respectively (figure 2.51 & 2.52). This could be due to 
the low molecular weight of quercetin glucosides, which leads to their loss after dialysis of 
onion extract. Our finding suggests that some of the inhibitory activity in onion is dialysable.  
2.10. Modelling of lactase with β-galactosidase 
 
Figure 2.53 Standard curve of ONP (mol/ml) vs. absorbance, n=3 ± SD 
The substrate used in the -galactosidase assay from Aspergillus oryzae is Ortho-Nitrophenyl 
-galactoside, which upon hydrolysis of -galactosidic bond, yields galactose and 
nitrophenol, a yellow compound (absorption maximum = 450nm). Figure 2.53, illustrates the 
linear relationship between the rate of OD A450 and ONP product formed (µmol/ml/min), and 
therefore was used to demonstrate the rate of conversion of 1µmol substrate (ONPG) into 
product in one minute. The rate at which product can be formed is limited by the 
concentration of substrate, pH and temperature (Mlichova and Rosenberg, 2006). 
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Figure 2.54: pH dependent β-galactosidase activity (Aspergillus oryzae), n=3 ± SD 
Figure 2.54 illustrates that at 37 C, the effect of pH was measured by the rate of product 
formed within the range of pH 3:0-7:0. The maximum (ONP) mol/ml/min product was 
formed at pH 4.5. Therefore 4.5 is the optimum pH for β-galactosidase from Aspergillus 
oryzae activity. -galactosidase enzyme activity drastically decreased after pH 4.5-5.0. 
Notably, pH-dependent enzyme activity is proportional to the increase in absorbance of A450 
during a timed incubation due to ONPG. Therefore, the maximum concentration of product 
formed was determined through ONP (µmol/ml) standard curve (figure 2.53). 
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Figure 2.55: Temperature dependent β-galactosidase activity (Aspergillus oryzae), n= 3± SD 
Figure 2.55 illustrates the optimum temperature at (45 C). To assess the optimum 
temperature for enzyme activity, lactase was incubated at the temperature range of 24 ºC, 37 
ºC, 45 ºC and 60 ºC at pH 4.5 for 20 minutes. Maximum activity of enzyme was obtained at 
45C; therefore, high temperature reduced the rate of product ONP (µmol/m) formation 
(figure 2.53). 
 
Figure 2.56: Time dependent -galactosidase activity (Aspergillus oryzae) from 0 to 120 min, n=3± SD 
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Figure 2.56 demonstrates as the time increased from 0 to 60 minutes, due to enzyme 
hydrolysis, more substrates were converted to products ONP (µmol/ml). It shows the 
maximum activity of -galactosidase enzyme occurring at (60 minutes), 60 minutes is the 
time point where enzyme activity reduced/stopped, thus less product ONP is produced after 
β-galactosidase incubation. However, at longer incubation time, such as after 60 minutes 
there was not a big increase on the product formation, and the linear range went off from the 
graph. The rate of formation of product now depends on the activity of the enzyme itself, and 
increasing β-galactosidase incubation time did not affect the rate of the reaction to any 
significant effect after 60 minutes.  
Following the current β-galactosidase assay, quercetin glucosides and onion extract/onion 
solution as the substrates were incubated with β-galactosidase for 20, 40 and 60 minutes to 
evaluate the concentration of free quercetin (products) after hydrolysis by β-galactosidase 
from Aspergillus oryzae.  
 
Figure 2.57: Quercetin in 80% v/v methanol , peak area against retention time (RT= 2.036, 16.239 min) 
In figure 2.57 quercetin illustrates one large peak at RT 16.239 min, which is in accordance 
with the peak in the onion extract occurring at RT 16.373 min (figure 2.60). 
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Figure 2.58: Quercetin 4́-glucoside in 80% v/v methanol, absorbance against time (RT= 11.121 min) 
 
Figure 2.59: Quercetin 3,4́-diglucoside in 80% v/v methanol, peak area against retention time (RT= 3.968 
min) 
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Figure 2.60: High-performance liquid chromatography of flavonoids in red onion extract. Compounds 
quantified were quercetin 3,4́-diglucoside, quercetin 4́-glucoside and quercetin aglycone. 25% w/v fresh 
onion extract (red) in methanol, absorbance versus time (RT= 2.244, 4.122, 8.56, 11.417, 16.373 min) 
Onion extract indicates two large peaks occurring at RT 4.122 min and 11.417 min, which 
were identified as quercetin 3,4́-diglucoside and quercetin 4́-glucoside respectively by 
relative position of these peaks compared to standards (3,4́-diglucoside and 4́-glucoside with 
RT 3.968 and 11.121 respectively (figures 2.58 and 2.59).  
 
Figure 2.61: Quercetin 4́-glucoside in 80% methanol incubated with β-galactosidase enzyme from Aspergillus 
oryzae, for 60 minutes, absorbance against time (RT= 10.896 and 16.647 min) 
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Figure 2.62: Concentration of quercetin and quercetin 4́-glucoside after incubation of  quercetin 4́-glucoside 
with β-galactosidase from Aspergillus oryzae for 60 minutes with n=3 ±SD 
Figure 2.62 shows the concentration of both quercetin and quercetin 4́-glucoside calculated 
from calibration curves (figures 2.44 & 2.45). Quercetin concentration increased from 2.2 
g/ml to 12.1 g/ml, whereas quercetin 4́-glucoside reduced from 31.2 g/ml to 17.1 g/ml 
after 60 minutes pre-treatment with β-galactosidase from Aspergillus oryzae. 
 
Figure 2.63: Quercetin 3,4́-diglucoside in 80% v/v methanol incubated with β-galactosidase from Aspergillus 
oryzae for 20 min (RT= 3.172, 16.373 min) 
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Figure 2.64: Quercetin 3,4́-diglucoside in 80% v/v methanol incubated with β-galactosidase from Aspergillus 
oryzae for 40 min (RT= 3.984, 16.479 min) 
 
Figure 2.65: Quercetin 3,4́-diglucoside in 80% v/v methanol incubated with β-galactosidase from Aspergillus 
oryzae for 60 min (RT= 3.962, 16. 396 min) 
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Figure 2.66: Concentration of quercetin and quercetin 3,4-́diglucoside after quercetin 3,4’-diglucoside were 
treated with β-galactosidase from Aspergillus oryzae for 20, 40 and 60 minutes with (n=3  SD) 
Figure 2.66 demonstrates after 20 minutes’ concentration of quercetin 3,4́-diglucoside 
significantly decreased by 58% after incubation with the β-galactosidase enzyme from 
Aspergillus oryzae at a significant level of p = 0.022 (p < 0.05), whereas the concentration 
of quercetin increased by 15%. There was a steady decrease and increase in quercetin 3,4́-
diglucoside and quercetin respectively after 40 minutes of incubation with the β-
galactosidase. Quercetin 3,4́-diglucoside concentration decreased from 40.1 g/ml to 11.2 
g/ml, suggesting its break down by β-galactosidase which results in quercetin concentration 
from 0.7 to 13.3 g/ml after 60 minutes of incubation. 
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Figure 2.67: Isorhamnetin in 80% v/v methanol, peak area against retention time (RT= 20.027 min) 
It is shown that red onion extract did not show a peak at similar RT=20.027 with 
Isorhamnetin (figure 2.60), therefore Isorhamnetin was not identified in the current onion 
extract. 
 
Figure 2.68: Quercetin 3-glucoside in 80%v/v  methanol, peak area against retention time (RT= 8.585 min) 
Quercetin 3-glucoside at figure 2.68 illustrates a small peak at RT 8.585min, which is in 
accordance with the peak in the onion extract occurring at RT=8.56 min (figure 2.60). 
Therefore, quercetin 3-glucoside also existed in the onion extract, but only consisted 6% of 
total flavonoid AUC in the onion extract. 
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2.10.1. Effect of β-galactosidase from Aspergillus oryzae on flavonoids in red onion extract 
in methanol 
 
Figure 2.69: High-performance liquid chromatography of flavonoids in red onion extract. The compounds 
quantified were quercetin 3,4́-diglucoside, quercetin 4'-monoglucoside and quercetin aglycone. Red onion 
extract (25% w/v) in methanol (80% v/v), absorbance against time (RT= 4.218, 4.554, 11.480, 11.778, 12.077 
min) 
 
Figure 2.70: Onion extract in 80% methanol incubated with β-galactosidase from Aspergillus oryzae for 20 
min, absorbance against time (RT= 4.243, 4.613, 8.415, 11.487, 16.401 min) 
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Figure 2.71: Onion extract in 80% v/v methanol incubated with β-galactosidase from Aspergillus oryzae for 
40 min, absorbance against time (RT= 4.209, 4.594, 8.372, 16.441, 20.008 min) 
 
Figure 2.72: Onion extract in 80% v/v methanol incubated with β-galactosidase from Aspergillus oryzae for 
60 min, absorbance against retention time (RT= 4.217, 4.593, 8.405, 16.479, 20.021 min) 
Figure 2.69 confirms the presence of quercetin 3,4́-diglucoside and quercetin 4́-glucoside in 
onion extract. Figure 2.70, 2.71 and 2.72 illustrate that onion in the presence of -
galactosidase is no longer showing quercetin 4́-glucoside peak as the incubation time with -
galactosidase increased, while free quercetin peak appeared, suggesting the hydrolysis of 
quercetin 4́-glucoside to free quercetin.  
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Figure 2.73: Concentration of Quercetin 3,4́-diglucoside, Quercetin 4-́glucoside and Quercetin aglycone after 
incubation of 25% onion extract with β-galactosidase from Aspergillus oryzae for 20, 40 and 60 min with 
(n=3 ±SD) 
Figure 2.73 illustrates pre-treated red onion extract with -galactosidase for 20, 40 and 60 
min from Aspergillus oryzae, showed 96% decrease in the concentration of quercetin 4́-
glucoside from 42.2 µg/ml to 2.3 µg/ml with p = 0.0004 (p > 0.001). However, quercetin 3,4́-
diglucoside concentration 31 µg/ml remained almost the same in onion after incubation with 
β-galactosidase at various time points. 
Our data is in accordance with previous findings from Schwanck et al. 2011, about 40% of 
quercetin 4́-glucoside. The main component of onion extract was deglycosylated with LPH 
which demonstrated its importance in the metabolism of biologically active compounds 
(Schwanck et al., 2011). 
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2.10.3. Effect of β-galactosidase enzyme from Aspergillus oryzae on onion extract and 
quercetin 3,4́-diglucoside  
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Figure 2.74: 25% w/v onion extract incubated with β-galactosidase (β-gal) from Aspergillus oryzae for 20, 40 
and 60 minutes at sodium-dependent condition with n=3±SEM, *** p < 0.001, ** p < 0.01 and p > 0.05 
Figure 2.74 illustrates onion extract (25% w/v) incubated with β-galactosidase from 
Aspergillus oryzae for various times, Caco-2 cells treated with onion no added β-
galactosidase showed a significant reduction on glucose levels, with 53% inhibition p = 0.001 
(p < 0.001). However, the pre-treated onion solution with the β-galactosidase had a no 
inhibitory effect, illustrating only 15% reduction after 60 minutes of incubation with β-
galactosidase at a significance level of p = 0.8 (p > 0.05) (figure 2.74). This suggests that 
quercetin 4’-glucoside and quercetin 3,4́-diglucoside may be contributing to the inhibition of 
glucose uptake in Caco-2 cells. Notably, the breakdown of quercetin glucosides in onion 
extract to free quercetin by β-galactosidase caused less inhibition at glucose levels on Caco-
2 cell lines in the presence of sodium. Therefore, β-galactosidase pre-treated onion solution 
caused slight inhibition of glucose uptake than un-pretreated onion extract on Caco2-cells. 
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Figure 2.75: Quercetin 3,4́-diglucoside (DIQG 3,4́ at 100 µM) incubated with β-galactosidase (β-gal) from 
Aspergillus oryzae for 5, 10 and 20 minutes at sodium-dependent condition with n=3 ±SEM, ** p < 0.01, * p 
< 0.05 and p > 0.05 
Figure 2.75 elucidates that pre-treated quercetin 3,4́-diglucosides for 60 minutes’ incubation 
with β-galactosidase, caused no statistically significant inhibition p = 0.8 (p > 0.05). Whereas 
at control with quercetin 3,4́-diglucoside and 20 minutes’ incubation with β-galactosidase, 
72% and 65% significant inhibition were found with p = 0.001 and p = 0.02 p < 0.05 
respectively. 
Both figures 2.74 and 2.75 demonstrating that β-galactosidase from Aspergillus oryzae 
greatly reduced the inhibitory effect of onion and quercetin 3,4́-diglucoside after 60 minutes 
of incubation. Consequently, there was not a significant inhibition of glucose uptake on 
Caco-2 cells by both pre-treated onion and quercetin 3,4́-diglucoside with Aspergillus oryzae 
β-galactosidase for 60 minutes, only 15% reduction was found with p > 0.05. Our finding 
indicates that onion inhibited glucose uptake on the Caco-2 cells, and pre-treatment of onion 
extract with Aspergillus oryzae β-galactosidase possibly broke the intact quercetin 3,4́-
diglucoside to free quercetin aglycones in onion, which therefore reduced the ability of onion 
to inhibit glucose uptake.  
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2.11. Discussion 
2.11.1. Inhibitory effect of dietary flavonoids in onion and onion extract on glucose uptake 
via SGLT-1 and GLUT-2 on Caco-2 cells  
Significant data are available which link the effect of dietary flavonoids in plants and herbs 
on lowering uptake of glucose and regulating the metabolism of carbohydrates. These 
phenolic compounds may include mechanisms for development of insulin release and 
improved insulin sensitivity. Therefore, there is a potential for these compounds to act as 
protective agents against development of type 2 diabetes and metabolic syndrome (Song et 
al., 2005). Also, polyphenols could decrease the postprandial increase in blood glucose levels 
through their interaction with glucose transporters and intestinal enzyme that are effective in 
the dietary glucose absorption and release (Williamson, 2013).  
Polyphenols are mostly consumed in plant rich diets, fruits (apple and strawberry), vegetables 
(onion) and green tea. They may exist at high levels in lumen of human gut, and therefore 
could be transported to the intestinal glucose transporters and cause their inhibition by 
competing with glucose levels (Johnston et al., 2005a). Monolayers of a well differentiated 
human intestinal epithelial cell line, Caco-2 cells were used as a model to investigate effects 
of dietary polyphenols-flavonoids in onion and onion extract on transport of glucose levels 
across the intestinal epithelium. 
Phloridzin flavonoid has been established as a known inhibitor of glucose in the sodium-
dependent SGLT-1 transporter (Johnston et al., 2005a). According to figures 2.14, there was 
a statistically greater cellular glucose reduction as phloridzin concentration increased, 80% 
glucose inhibition at 100µM at significance level of p < 0.001 (p = 0.0004), followed by 65% 
and 50% significant glucose inhibition at 50µM and 20 µM with p < 0.05 (p = 0.01) and p < 
0.05 (p = 0.045) respectively under sodium-dependent conditions (figure 2.14). On the other 
hand, according to figure 2.15, in the absence of sodium, there was not a drastic reduction in 
glucose uptake when Caco-2 cells were treated with phloridzin, even at the highest 
concentration 100µM, only 30% glucose reduction was observed with p > 0.05 (P = 0.17). 
Consequently, lower levels, 50µM and 20µM, established 20% and 15% glucose inhibition 
with p > 0.05. This result confirms that our findings were in agreement with previous research 
by (Johnston et al., 2005a). Also, a previous study demonstrated that the phloridzin-sensitive 
SGLT-1 transport, accounted for saturable glucose uptake, the diffusive component, however, 
it is suggested to be mediated via GLUT-2 at an apical localisation (Helliwell et al., 2000). 
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In accordance with that, there has been an in vivo study on mice, where a significant 
inhibition of glucose absorption was obtained after an acute administration of 15 mM 
phloridzin together with a 10% glucose solution to normoglycaemic mice. It is suggested that 
the main reduction of glucose levels occurred through SGLT-1 transporters in the presence 
of phloridzin flavonoids (Takki et al., 1997). 
Phloridzin is also a substrate for the phloridzin domain of LPH. Phloretin, released from the 
hydrolytic step, will compete with other phenolics for both UDP-glucuronosyl transferase 
(UGT) during process of conjugation to apical and basolateral transporters (Day et al., 2003). 
While phloridzin is a competitive inhibitor of SGLT-1 (Mariappan and Singh, 2004), its 
aglycone phloretin inhibits SGLT-1 non-competitively and 800-fold less potent than 
phloridzin (Hirayama et al., 2001).This illustrates the crucial role of glucose moiety at 2́-
position for binding to SGLT-1. It has been suggested that phloridzin binding to SGLT-1 
occurs at both aglycone-binding site as well as the sugar binding site (Sala-Rabanal et al., 
2012). Besides, past research has established that aglycone flavonoids, such as phloretin, can 
target GLUT-2; therefore, the inhibitory effect is expected to be carried out in the sodium-
independent condition (Kwon et al., 2007). Moreover, according to an in vivo study, 
phloridzin has reduced over expression of SGLT-1 mRNA that occurs in diabetes. The 
decreased SGLT-1 mRNA is possibly a response to changes in cellular oxidative balance 
with the increase with an antioxidant capacity with the phloridzin treatments (Li et al., 2004). 
Quercetin and its glucosides are the major flavonoids present in several vegetables, in 
particular fresh onions and fruits (Yahya et al., 2016) . According to figures 2.16, 2.18 and 
2.20 under sodium-dependent conditions, quercetin glycosides resulted in a great Caco-2 
cells glucose inhibition at 100µM with p < 0.01 and p < 0.001. As the concentration of these 
compounds elevated from 20µM to 100µM, further glucose inhibition was found. For 
example, according to figures 2.16 and 2.18, 100M quercetin 4́-glucoside and quercetin 3,4́-
diglucoside significantly reduced the uptake of glucose compared to control by 75% at 
significance level of (p < 0.001) with p = 0.0007 under sodium-dependent condition, 
followed by almost similar but less effective inhibitory role of quercetin 3-glucoside on 
Caco-2 glucose uptake under sodium-dependent conditions, 52% inhibition was observed by 
100µM at significance level of p = 0.012 (figure 2.20). 
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However, under sodium-independent conditions, less than 30% inhibition (p = 0.065) was 
observed by 100µM of quercetin 4́-glucoside (figure 2.17), notably only 10% glucose 
inhibition was determined by quercetin 3,4́-diglucoside p > 0.05 (figure 2.19). Our finding 
was in accordance with a study conducted by Ader et al. (2001), where they found no 
significant inhibitory effect of quercetin 4́-glucoside on glucose uptake of rat-jejunum under 
sodium-independent conditions (Ader et al., 2001). Also, only 20% reduction in glucose 
uptake was found at 100µM of quercetin 3-glucoside in the absence of sodium condition (p 
> 0.05) (figure 2.21). However, there is evidence that quercetin 3-glucoside inhibited SGLT-
1-independent, non-saturable uptake of glucose, this is possibly because of passive diffusion 
or to glucose transport via a sodium-independent glucose transporter. It is rather unlikely that 
quercetin 3-glucoside changed the permeability of the BBM, thus inhibiting glucose 
diffusion (Day et al., 2003). 
Under sodium-independent conditions, it is suggested that GLUT-2 was the main pathway 
of glucose mass absorption across the apical membrane at high luminal glucose 
concentrations (Helliwell et al., 2000). This is through a rapid translocation of GLUT-2 from 
an internal vesicle pool into the apical membrane in response to an activation of protein 
kinase, initiated by SGLT-1 (sodium-dependent) mediated transport across the apical 
membrane (Kellet et al., 2008). The majority of studies that propose transport of polyphenolic 
glucoside through SGLT-1 were performed in isolated rat intestinal segments as well as 
Caco-2 cell models that express, in addition to SGLT-1 other carriers that could contribute 
to transport of polyphenolic compounds (Day et al., 2000a).  
From the current in vitro results shown in figures 2.16, 2.18 and 2.20, it is evident that 
quercetin glycosides are most likely to cause inhibition of glucose uptake in the presence of 
sodium conditions. In several studies such as Day et al. (2003), Walgren et al. (2000) and 
Cermak et al. (2004), they also showed that quercetin glucosides such as quercetin 3-
glucoside and quercetin 4́-glucoside caused inhibition of glucose uptake in Caco2- cell line 
through sodium-dependent SGLT-1 transporter. This result can be explained by the weak 
inhibition of GLUT-2 expressed on the apical membrane of Caco-2 cells under sodium 
dependent conditions. Moreover, it is demonstrated that quercetin 4́-glucoside is effluxed 
from Caco-2 monolayers through apically expressed multidrug resistance-associated-protein, 
MRP2 (Walgren et al., 2000). Thus, quercetin 4́-glucoside absorption in intestinal apical 
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membranes appears to be controlled by the balance between SGLT-1 uptake and MRP2 
efflux (Walgren et al., 2000). 
In a study conducted by (Kwon et al., 2007), they demonstrated that flavonoid glucosides 
such as quercetin 4́-glucoside and quercetin 3-glucoside were not transported by SGLT-1. 
They failed to detect high transport of either glycosylated or non-glycosylated flavonoids; 
however, they detected several compounds that potentially reduced electrogenic SGLT-1-
mediated α-MDG uptake. Moreover, in another study conducted by Murota et al. (2000), 
they observed no transport of quercetin glucosides, such as quercetin 4́-glucoside and 
quercetin 3,4́-diglucoside across the apical membrane of Caco-2 cells (Murota et al., 2000). 
It should be noted that most of the studies that suggested the transport of flavonoid glucosides 
through SGLT-1 were conducted in isolated rat intestinal segments along with cell culture 
models (Caco-2 cells) which also express other carriers such as GLUT-2 and multi-drug 
resistance-associated protein 2 (MRP2) could help in the transport and bioavailability of 
polyphenolic compounds in onion. 
According to figure 2.22, in the presence of quercetin aglycone, there was no statistically 
significant inhibition on the cellular glucose uptake under sodium-dependent conditions at 
100µM concentration with p > 0.05 (p = 0.1); quercetin is an aglycone, which according to 
previous studies does not inhibit the sodium-dependent SGLT-1 glucose uptake pathway 
(Kwon et al., 2007). However, figure 2.23 demonstrated a significant inhibitory effect of 
quercetin on glucose uptake in the sodium free condition at 100 µM with 58% reduction 
compared to control (p = 0.008) p < 0.01. Quercetin aglycone blocks glucose uptake in the 
absence of sodium which is most likely through GLUT-2 (Kwon et al., 2007). It is suggested 
that this could be because GLUT-2 translocates to the apical membrane of enterocytes when 
exposed to high concentrations of glucose (Zheng et al., 2011). Interestingly, Barranetxe et 
al. (2006) found that the uptake of maltose and galactose, but not glucose, was decreased by 
quercetin through SGLT-1. Also, Kwon et al. (2007) and Johnston et al. (2005) illustrated 
that quercetin was unable to block the uptake of glucose in the sodium dependent condition, 
which is through SGLT-1. Also, in a previous research performed on mouse intestine, there 
was no uptake of glucose through GLUT-2 in the apical membrane, even at high 
concentrations of glucose (Roder et al., 2014). These results were in agreement with findings 
from a study conducted on isolated rat everted gut sleeves that did not show any GLUT-2 in 
the apical membrane (Scow et al., 2011). 
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However, GLUT-2 mediated glucose uptake into Xenopus oocytes injected with cRNA 
encoding human GLUT-2 greatly reduced in the presence of onion extract containing 
quercetin and quercetin glycosides (Kottra and Daniel, 2007). Our result is in agreement with 
findings from a previous study Zheng et al. (2011), where quercetin aglycone caused 
significant GLUT-2 inhibition (figure 2.22). In the absence of sodium, quercetin 4́ -glucoside 
and quercetin 3,4́-diglucoside did not compete with glucose transport through GLUT-2 
sodium-independent; therefore, no inhibition was found (figures 2.17 & 2.19) (Zheng et al., 
2011).  
Under sodium-independent conditions, lower glucose levels were transported by the Caco-2 
cells in most of our cell culture models. This may suggest that when quercetin and its 
derivatives, coupled with two sodium molecules under sodium dependent conditions, there 
was possibly a lower transport ability for glucose levels from the apical to the basolateral 
side. It is suggested that inhibition of Caco-2 cells apical uptake was of mixed type, with 
GLUT-2 inhibited non-competitively and SGLT-1 inhibited competitively, whereas 
basolateral release of glucose inhibited in a non-competitive manner, indicated an effect on 
GLUT-2 only (Manzano and Williamson, 2010). 
The high content and great inhibition of blood glucose levels by quercetin 4́-glucoside and 
quercetin 3,4́-diglucoside in onion solution would have suggested for their effect on SGLT-
1 and GLUT-2 transporters in the subject’s small intestine. Both quercetin glucosides could 
have hydrolysed by LPH in the small intestine, which is far less active in inhibition of SGLT-
1 but highly active in GLUT-2 inhibition. This also holds true for phloridzin which can 
quickly cleaved to phloretin and glucose by LPH with phloretin much less effective in SGLT-
1 inhibition. 
In the current in vitro study, Caco-2 cell monolayer has been used because they mimic 
intestinal absorptive epithelium. However, due to their cancerous origin, they may have some 
limitations; for instance, several proteins are significantly different from that found in healthy 
animal models and human tissue (Nemeth et al., 2003).  
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2.11.2. Glucose transport via Apical and Basolateral compartments (Transwell inserts)  
According to figure 2.25, in the presence of sodium conditions, there was a significant 
inhibition in Caco-2 cells glucose uptake on transwell inserts treated with 100µM quercetin 
3,4-́diglucoside and 100µM quercetin 4́-glucoside, 70% and 60% with p < 0.01 and p < 0.05 
respectively. The great inhibitory effects on glucose levels by quercetin glucosides are 
possibly caused by competitive inhibition of sodium-dependent glucose transport across the 
intestinal brush-border membrane by transporter SGLT-1 and MRP2. On the other hand, 
according to figure 2.26, under sodium dependent condition at the basal side (wells), both 
quercetin 3,4́-diglucoside and quercetin 4́-glucoside indicated a slight inhibitory effect on 
glucose uptake, it was not statistically significant p > 0.05. Our result are in support of 
previous findings where quercetin glucosides were sodium-dependent; therefore, they played 
through SGLT-1 transporters available at the apical membrane of Caco-2 models (Johnston 
et al., 2002). There is also a possibility of reduced abundance of GLUT-2 protein in response 
with quercetin 4́-glucoside and quercetin 3,4́-diglucoside. This could be the result of either 
protein degradation and/or reduced translation. The reduction in translation would arise from 
the decrease in GLUT-2 mRNA expression (Salucci et al., 2002). 
However, stating that there is less inhibitory effect on glucose levels through GLUT-2, it is 
possible that degradation may be site-specific. In other words, GLUT-2 that is not localised 
for apical uptake is subjected to degradation. Rather, the basolaterally GLUT-2 would have 
been targeted. Otherwise, another glucose uptake transport may have been involved, or the 
apical presence of GLUT-2 is not the rate-limiting factor for intestinal glucose uptake. 
Therefore, more in vitro research is required to demonstrate the degradation and migration 
of GLUT-2 in Caco-2 cells.  
According to figure 2.27, under sodium independent conditions, quercetin 4́-glucoside and 
quercetin 3,4́-diglucoside did not decrease the uptake of glucose at cellular levels with p > 
0.05. Our data are in agreement with findings from (Lombard et al., 2002), where quercetin 
4́-glucoside and quercetin 3,4́-diglucoside in the absence of sodium condition caused no 
glucose inhibition on Caco-2 cells, as they are mainly active at sodium-dependent condition 
through SGLT-1 glucose transporters. Reduction of glucose levels at the basolateral 
membrane of enterocytes, which in the current Caco-2 model was illustrated by the transport 
of glucose from the upper to lower side of transwell inserts (wells), could be associated with 
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inhibition of GLUT-2 by quercetin aglycone from the breakdown of quercetin glucoside 
through glucosidase activity (figure 2.28). 
Notably, flavonoids have been identified to retain insulin-like properties (Andersom et al., 
2004), and insulin is known to have impacts on the presence of GLUT-2 at apical membranes 
(Tobin et al., 2008). Subsequently, SGLT-1 is known to traffic between intracellular pools 
and the apical membrane (Khoursandi et al., 2004) and it is likely that polyphenols in onion 
extract effect the distribution of transporter protein without changing the overal levels of 
SGLT-1 proteins. However, the roles of other flavonoid importers, and their impacts on the 
release of glucose on basolateral membrane, followed by the effects of GLUT-2 in flavonoid 
efflux, need more investigation.  
The source of Caco-2 cells and inter-laboratory discrepancies in protocol design contribute 
to differences in paracellular permeability of compounds in the monolayer. For instance, 
previous studies have shown that the source of Caco-2 cells could deliver 20-fold differences 
in TransEpithelial Electrical Resistance (TEER) because of various culture conditions and 
composition of cell subpopulation (Jonker et al., 2000). TEER could be used as indicators 
for determination of monolayer integrity and how much cells were confluent (Srinivasan et 
al., 2015). Change in TEER across confluent Caco-2 monolayers over time could 
demonstrate the level of confluency. 
2.11.3. Effect of Inulin (fructan) on Caco-2 cells glucose uptake  
In addition to quercetin and quercetin derivatives, inulin is a soluble fibre, which is widely 
found in onions. Soluble fibres may help lower blood cholesterol and glucose levels, because 
normal digestion does not break inulin down into monosaccharides, or elevate blood sugar 
levels and may, therefore, be helpful in the management of diabetes. Inulin also stimulates 
the growth of bacteria in the gut. Inulin passes through the stomach and duodenum 
undigested and is highly available to the gut bacterial flora (Reimer and Russle, 2008).  
According to figures 2.29 and 2.30, on Caco-2 cells treated with 5% w/v inulin from chicory, 
there was no statistically significant inhibition of glucose uptake compared with control; 15% 
and 13% reduction were found at sodium dependent conditions with (p = 0.6 and p = 0.65) 
respectively. However, according to figure 2.30, the onion extract significantly decreased 
glucose absorption compared to control with 47% inhibition p < 0.05 (p = 0.01). Our data 
demonstrated the inhibitory effect of onion extract on lowering glucose levels could possibly 
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be due to the high presence of flavonoids. It is believed that more than 95% of the flavonoids 
in onion is quercetin and its derivatives and only 1-5% inulin (Perez-Gregorio et al., 2010). 
Hence, inulin is proposed to have a lower antiglycaemic effect in the current Caco-2 cell 
models. It should be noted that in this in vitro study, the source of inulin was chicory not 
onion; therefore, it initiated possibility for inconsistency in our data.  
Figure 2.30 showed that under sodium-dependent condition both quercetin 4́-glucoside and 
quercetin 3,4́-diglucoside significantly reduced Caco-2 glucose levels (p < 0.01), through 
SGLT-1 transporter. Comparing the effect of quercetin 4́-glucoside, quercetin 3,4́-
diglucoside and inulin with control on Caco-2 cells glucose uptake, inulin illustrated a non-
significant inhibition on radiolabelled glucose levels by 22% and 10% at both sodium 
dependent and independent conditions with p > 0.05 (figures 2.30 and 2.31). Also, figure 
2.31 showed none of the quercetin glucosides reduce the glucose uptake at a significant level 
in the absence of sodium condition, since they are found to be mostly active at SGLT-1 
sodium-dependent transporters.  
2.11.4. Overall flavonoids (phenolic compounds) effects on Caco-2 cells glucose uptake 
In addition to quercetin glucosides and phloridzin in onions, some phenolic acids like p-
coumaric acid and ferulic acid were found to inhibit the glucose uptake in Caco-2 cells 
(Manzano and Williamson, 2010). However in another study, they showed no effect of 
phenolic acids including chlorogenic acid, ferulic acid and caffeic acid on the levels of 
glucose uptake in Caco-2 cells under sodium-dependent (SGLT-1) and sodium-independent 
(GLUT-2) conditions (Johnston et al., 2005a). Interestingly, other research on rat intestinal 
membrane vesicles showed that 1mM chlorogenic acid inhibited the absorption of glucose 
up to 80%, while ferulic acid and caffeic acid with similar concentrations decreased the 
glucose uptake by only 38% and 35% respectively (Welsch et al., 1989). Therefore, the 
inhibitory effects of chlorogenic acids, ferulic acid and caffeic acid on glucose levels were 
inconsistent. However, their effect could interfere with the inhibitory effects of flavonoids in 
onions, and be considered as cofactors on overal glucose inhibition levels. 
In the current in vivo study, quercetin illustrated the strongest inhibition of radiolabelled 
glucose uptake in Caco-2 cells through sodium-independent condition whereas, quercetin 4́-
glucoside, quercetin 3,4́-diglucoside and quercetin 3-glucoside revealed strong inhibition at 
sodium-dependent condition. These findings propose the inhibition of glucose transport 
under sodium-independent condition by onion extracts were mostly due to quercetin and 
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phloretin and sodium-dependent glucose inhibition was caused mainly by quercetin 
glycosides and phloridzin.  
We investigated the functional effects of flavonoids and onion extract on Caco-2 cells in 
order to characterise the competitive or interactive effects of flavonoids, i.e. co-incubation of 
flavonoids and radiolabelled glucose. The treatment with onion extract and quercetin 
glucosides reduced glucose uptake mediated through sodium-dependent SGLT-1 and 
sodium-independent GLUT-2 transporters. The acute inhibitory effects of phloridzin as well 
as quercetin glucosides and quercetin aglycone confirmed the function of both glucose 
transporters in the Caco-2 cell line as phloridzin and quercetin are specific inhibitors of 
SGLT-1 and GLUT-2 glucose uptake, respectively. It seems that flavonoids must be present 
to inhibit the uptake of glucose, as we have obtained in current in vitro experiments.  
2.11.5. Effect of dialysis on flavonoids content in onion extract 
Dialysis procedure was also conducted on onion extracts, in order to illustrate the effect of 
dialysis procedure on the presence of quercetin glucosides in the onion. Therefore, figure 
2.50, illustrated the change in the concentrations of quercetin 3,4́-diglucosides and quercetin 
4́-glucoside after 8 hours of dialysis, and the concentration of both compounds significantly 
reduced from 40.1g/ml and 30.4g/ml to 6.5µg/ml and 4.4g/ml respectively (p < 0.01) 
(figure 2.48). Followed by greater loss of their concentrations after 24 hours of dialysis, 
quercetin 3,4́-diglucoside and quercetin 4́-glucoside concentrations drastically decreased to 
1.7µg/ml and 1.1µg/ml respectively with p < 0.001 (figure 2.49). This could be due to the 
low molecular weight of quercetin glucosides, which result in their loss in the onion extract 
after dialysis. 
2.11.6. Effect of dialysed onion extract on Caco-2 cells glucose uptake 
Figure 2.51 demonstrated a statistically significant inhibition in Caco-2 cells glucose uptake 
under sodium dependent condition in the wells treated with 100 µM quercetin 3,4-
diglucoside and 100 µM quercetin 4́-glucoside by 65%, p < 0.001. This was followed by an 
inhibitory influence of 25% w/v non-dialysed onion extract by 51% with p = 0.007, though 
after dialysis of onion extract, the inhibitory effect considerably decreased to 29% with p = 
0.2. 
 
129 
 
 Figure 2.52 demonstrated under sodium-independent conditions, a great inhibition of 
glucose levels in Caco-2 cells were observed in the wells treated with 100µM quercetin 4́-
glucoside by 60% at a statistical significant level of p < 0.01 (p = 0.0008). This was followed 
by lower inhibitory influence of 25% w/v non-dialysed onion, 100 µM quercetin 3,4́-
diglucoside and 25% w/v dialysed onion by 42%, 32% and 10% with P > 0.05 respectively. 
In onion extract, the enzymatic activity of quercetin 4́-glucosidase and quercetin 4-
glucosyltransferase could increase during dialysis, therefore resulted in deglycosylation of 
quercetin glucosides into quercetin aglycone. Also, a less inhibitory effect was found as 
sodium-dependent conditions through SGLT-1 (Griffiths et al., 2002). Whereas, the slight 
reduction on glucose uptake levels could possibly be due to the hydrolysis of quercetin 
glucosides to free quercetin during dialysis procedure; therefore, GLUT-2 transporters were 
inhibited on the basal side. 
After dialysis of the onion for 8 hours and changing the buffer every 2-3 hours, the dialysed 
onion resulted in about 40% loss of quercetin glucosides (figure 2.50). This could be due to 
low molecular weight of quercetin glucoside, which led to their loss. However, dialysed 
onion still caused 35% glucose inhibition on Caco2-cells. This could be due to their high 
concentration of sulfur compounds, such as allyl propyl disulfide and fructans (Griffiths et 
al., 2002).  
2.11.7. Modelling of lactase (LPH) with β-galactosidase and its effects on hydrolysis of 
flavonoid glucosides in onions 
β-galactosidase was used as its optimum pH and temperature to model human intestinal LPH. 
It is highly distributed in several biological systems; for instance, microorganism, plants and 
animal tissues. In our study, we have used β-galactosidase from Aspergillus oryzae (fungi) 
as compared to plant or animal sources of enzyme, and produce enzyme at higher yields, thus 
resulting in a decrease price of β-galactosidase (Santos et al., 1998). In this study, β-
galactosidase from Aspergillus oryzae was used to model the lactase and its effect on the 
hydrolysis of flavonoid glucosides in onion extract. During absorption, quercetin glucosides 
are hydrolysed by cytosolic β-glucosidase to quercetin aglycone. It has been suggested that 
the main factor for the absorption of quercetin glucoside starts with hydrolysis by lactase 
(LPH) enzyme (Boyer et al., 2005).Therefore, deglycosylation and availability of lactase 
enzyme are also important factors for the absorption and transfer of flavonoids from the 
intestinal lumen into the circulation (Day et al., 2003). In order to model the hydrolysis of 
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flavonoids with intestinal lactase, β-galactosidase from Aspergillus oryzae was used. The 
role of -galactosidase from Aspergillus oryzae in the deglycosylation of onion and quercetin 
3,4-́diglucoside has been previously shown (Takahama and Hirota, 2000). Deglycosylation 
of quercetin glucosides at the brush border membrane places the resulting aglycone in a prime 
position for diffusion across the brush border. The deglycosylation of the quercetin glucoside 
would lead to a greater concentration of aglycone at the apical enterocyte membrane and 
eventually elevate the absorption rates (Boyer et al., 2005).  
Properties, specificity and structure of β-galactosidase is dependent on the length of amino-
acid chains, various molecular weight, active site position, pH and thermal optimum and 
stability (Zhou and Chen, 2001). These enzymes have two major properties: the removal of 
lactose from milk and dairy products for lactose-intolerant people and production of 
galactosylated products (Neri et al., 2008). β-galactosidases function in broad pH range: 
enzymes from fungi Aspergillus oryzae are active between pH 2.5-5.4 (Jacob et al., 2002). 
Based on our results, the β-galactosidase from Aspergillus oryzae displayed its optimum 
activity at pH 4.5 with little activity outside pH 3.0 and pH 7.0 (figure 2.54). 
 It may be noted that different pH optimum is the result of the presence of several enzymes 
in crude preparation or by the presence of several substrates on which the enzyme can act. 
The effect of temperature on β-galactosidase from Aspergillus oryzae illustrated maximum 
enzyme activity at temperature 45C (figure 2.55). A similar result has also been established 
in a study conducted by (Ansari and Husain, 2012), in which β-galactosidase from 
Aspergillus oryzae were useful in milk hydrolysis at temperature 45°C. 
According to figure 2.56, ONPG as the substrate was hydrolysed to β-galactose and ONP 
through activity of β-galactosidase; therefore, from 0 to 60 minutes the formation rate of 
ONP µmol/ml product increased. Whereas, at longer incubation times, such as after 60 
minutes, there was no increase on the product formation (figure 2.56). Therefore, β-
galactosidase has the highest activity at 60 minutes, while as the time increased after 60 
minutes its activity was stopped, hence resulting in lower ONP (µmol/ml) formation.  
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2.11.8. Identification and quantification of flavonoids in onion extract before and after 
incubation with β-galactosidase from Aspergillus oryzae  
For the quantitative determination of individual flavonoid glycosides in onion extract, the 
glycosides were hydrolysed by -galactosidase from Aspergillus oryzae, and thus aglycones 
were identified and quantified by using the HPLC-DAD approach. Therefore, on the basis of 
the results obtained with standards, the concentration of quercetin glycosides and free 
quercetin were determined.  
HPLC technique was conducted for identification and separation of flavonoids such as 
quercetin and quercetin glucosides in onion extract and to model the effect of LPH on 
phenolic glucosides by assessing the activity of -galactosidase from Aspergillus oryzae on 
the hydrolysis of these phenolic glycosides in onion extract. Figure 2.60, onion extract 
indicated two large peaks occurring at RT 4.122 and 11.417min, which are identified as 
quercetin 3,4́-diglucoside and quercetin 4́-glucoside respectively by relative position of these 
peaks compared to standards (3,4-diglucoside and 4́-glucoside) in figures 2.58 and 2.59. 
Quercetin aglycone illustrated one peak at RT = 16.239min (figure 2.57), which was in 
accordance with the peak in the onion extract occurred at RT = 16.373 min (figure 2.60).  
The incubation of quercetin 4́-glucoside with -galactosidase Aspergillus oryzae for 60 
minutes illustrated a UV peak at RT = 16.647 (figure 2.61), which occurred at a similar 
position to standard quercetin with RT = 16.239min (figure 2.57). Concentration of both 
quercetin and quercetin 4́-glucoside were calculated by using their standard curves (figures 
2.44 and 2.45). Quercetin concentration increased from 2.2g/ml to 12.1g/ml, whereas 
quercetin 4́-glucoside reduced from 31.2g/ml to 17.1g/ml after 60 minutes pre-treatment 
with Aspergillus oryzae β-galactosidase (figure 2.62). Our findings were in accordance with 
findings from the study conducted by Nemeth et al. (2003).  
Moreover, quercetin 3,4́-diglucoside was incubated with β-galactosidase from Aspergillus 
oryzae, for 20, 40 and 60 minutes. The standard quercetin 3,4́-diglucoside showed a peak at 
RT = 3.969min (figure 2.59), after 20 minutes with β-galactosidase incubation, two UV peaks 
appeared at RT 3.172 and 16.373min (figure 2.63), followed by appearance of bigger peaks 
occurring after 40 and 60 minutes at RT 16.479min and 16.396min respectively (figures 2.64 
and 2.65), which were in accordance with quercetin standard peak with RT = 16.239 (figure 
2.57). 
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 Figure 2.63 showed hydrolysis of quercetin 3,4́-diglucoside with β-galactosidase for 20 
minutes of incubation significantly reduced the concentration of quercetin 3,4́-diglucoside 
by 58% at significance level of p = 0.022 (p < 0.05), while quercetin aglycone levels 
increased by 15%. There was a steady reduction and increase in quercetin 3,4́-diglucoside 
and quercetin respectively after 40 minutes of incubation with β-galactosidase (figure 2.64). 
Quercetin 3,4́-diglucoside concentration decreased from 40.1g/ml to 11.2g/ml (figure 
2.65) indicated its break down by β-galactosidase which caused an increase in quercetin 
concentration from 0.7 to 13.3g/ml after 60 minutes of incubation (figure 2.66).  
Figure 2.67, Isorhamnetin showed a peak at RT = 20.027 which was not in a similar position 
compared to onion extract peaks (figure 2.60). Thus, this compound was not found in this 
particular onion type in the current research. UV peaks from quercetin 3-glucoside appeared 
at RT = 8.585 (figure 2.68) which was in a similar position compared to the chromatogram 
of onion extract at RT = 8.612 (figure 2.60); notably, quercetin 3-glucoside was counted for 
only 6% of total flavonoids AUC in the onion extract.  
Figure 2.69 showed the main flavonoids in onion such as quercetin 3,4́-diglucoside and 
quercetin 4́-glucoside in 25% w/v red onion extract. Figures 2.70, 2.71 and 2.72 demonstrated 
that onion extract in the presence of -galactosidase no longer possessed quercetin 4́-
glucoside peak as the incubation time with -galactosidase increased, while free quercetin 
peak occurred at RT = 16.479. Figure 2.73 illustrated the change in concentration of these 
quercetin glucoside in an onion extract after incubation with β-galactosidase. Hence, pre-
treated red onion extract (25% w/v) with -galactosidase for 20, 40 and 60 minutes from 
Aspergillus oryzae presented a statistically significant 96% reduction in the concentration of 
quercetin 4́-glucoside from 42.2µg/ml to 2.3µg/ml with p = 0.0004 (p > 0.001). Whereas, 
quercetin 3,4́-diglucoside concentration 31µg/ml stayed with almost no change in onion after 
incubation with β-galactosidase from 0 to 60 minutes (figure 2.73). 
Our data supports the idea that -galactosidase causes deglycosylation of quercetin 
glucosides (quercetin 4́-glucoside) which suggests that quercetin glucoside can no longer 
stay intact in the presence of -galactosidase; thus, free quercetin will be released. Nemeth 
et al. (2003) have already published the substrate specificity of purified sheep LPH for the 
above quercetin glucosides, which is in line with our present findings that quercetin 4́-
glucoside and onion are suitable substrates for β-galactosidase hydrolysis. Also, our data is 
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in agreement with previous research from Schwanck et al. (2011), as about 40% of quercetin 
4́-glucoside was hydrolysed with LPH which showed its importance in the metabolism of 
biologically active compounds (Schwanck et al., 2011). 
Figures 2.74 and 2.75 illustrated that on Caco-2 cells under sodium dependent condition, 
both onion extract and quercetin 3,4-́diglucoside were hydrolysed by β-galactosidase enzyme, 
suggesting the release of free aglycone, thus lower inhibition was found in glucose uptake in 
Caco-2 cell models. β-galactosidase from Aspergillus oryzae, prominently decreased the 
inhibitory effect of 25% w/v onion extract and 100µM quercetin 3,4́-diglucoside after 60 
minutes of incubation. Therefore, there was not a significant inhibition of glucose uptake on 
Caco-2 cells under sodium dependent conditions by both pre-treated onion extract and 
quercetin 3,4́-diglucoside with Aspergillus oryzae β-galactosidase for 60 minutes, only 15% 
and 17% reduction were observed with p > 0.05 (figure 2.74 & 2.75). Our result suggests 
that onion extract inhibited Caco-2 cell glucose uptake as pre-treatment of onion extract with 
Aspergillus oryzae β-galactosidase possibly deglycosylated the intact quercetin 3,4́-
diglucoside to free quercetin aglycones, and consequently diminished the ability of onion on 
inhibition of glucose levels, although such deglycosylation has been previously shown 
(Takahama and Hirota, 2000).  
We demonstrated that the principal quercetin compounds in onion are the -glycosides 
quercetin 3,4́-diglucoside and quercetin 4́-glucoside. We found that β-galactosidase 
(Aspergillus oryzae) increased the levels of quercetin aglycone, with concomitant reductions 
in quercetin 3,4́-diglucoside and mainly quercetin 4́-glucoside, and thus confirmed that 
Aspergillus oryzae β-galactosidase may regioselectively deglycosylate the 4́-O- linked 
glycosyl moiety of quercetin 3,4́-diglucoside and quercetin 4́-glucoside of onion (Chung et 
al., 2011). Furthermore, the loss of quercetin 3,4́-diglucoside and quercetin 4́-glucoside after 
60 minutes could also be due to the conversion of quercetin 3,4́-diglucoside into quercetin 4́-
glucoside by the activity of quercetin 3-O-β-glucosidase, and to the conversion of quercetin 
4́-glucoside in quercetin by the activity of quercetin 4́-O-β-glucosidase (Perez-Gregorio et 
al., 2010). 
The β-galactosidase-pretreated onion solution showed lower levels of quercetin glucosides 
than un-pretreated onion solution. This also supports our previous findings where intact 
quercetin 4́-glucoside and quercetin 3,4́-diglucoside in onion may be contributing to a 
decrease in glucose levels of Caco-2 cells. Notably, according to our results, the content of 
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total flavonoids is higher in fresh red onion extract compared to the red onion solution boiled 
for 15 minutes. The loss of quercetin and quercetin derivatives after boiling condition could 
be due to the high temperature or filtration procedure. 
2.11.9. LPH effects on hydrolysis of flavonoids on glucose uptake in intestine  
In vitro studies with purified LPH from sheep intestine demonstrated that several flavonoid 
glucosides were substrates for LPH enzyme (Day et al., 2000c). In a study conducted by Art 
et al., 2004, they showed that during perfusion of the small intestine of rat with quercetin-3-
glucoside, inhibition of LPH caused up to 67% decrease in hydrolysis of quercetin-3-
glucoside. Studies with isolated human LPH demonstrated high deglycosylation of 
phloridzin. Moreover, both quercetin 4́-glucoside and quercetin 3-glucoside were observed 
as LPH substrates, but determined lower affinities than phloridzin (Nemeth et al., 2003). 
Therefore, LPH may have substrate specificity for hydrolysis of different quercetin 
glucosides, which leads to their varying bioavailability (Arts et al., 2004).  
According to two other studies on rat intestine tissues conducted by Sesink et al. (2003) and 
Day et al. (2003), there was a reduction in the deglycosylation of quercetin 3-glucoside and 
quercetin 4́-glucoside when treated with LPH inhibitor N-butyldeoxygalactonojirimycin 
(NB-DJG). Therefore, this overlapped with slight appearance of quercetin on intestinal 
serosal side, indicating the role of LPH on quercetin 3-glucoside and quercetin 4́-glucoside 
at intestinal levels (Day et al., 2003, Sesink et al., 2003). It was suggested that NB-DJG LPH 
inhibitor decreased the hydrolysis of quercetin 4́-glucoside, and therefore transport of 
quercetin aglycone was reduced in intestinal tissues, meaning SGLT-1 played a minor role 
in intestinal uptake of quercetin glucoside in vivo.  
It is noteworthy that LPH can also cause deglycosylation of daidzein-7-O-glucoside in the 
rat small intestine (Wilkinson et al., 2003). In addition to the effect of LPH, cytosolic β-
glucosidase (CBG) was also found to be effective in deglycosylation of flavonoid glucosides; 
the deglycosylation of trans-piceid in the presence of purified rat small intestine with both 
LPH and CBG resulted in the release of trans-resveratrol from trans-piceid (Wilkinson et al., 
2003). Although several other apical transporters (MCT1, PEPT1, SMCT) of intestinal 
epithelial cells are likely to be involved in the absorption of these polyphenolic compounds 
from onions, by which they cross the intestinal brush border membrane (Wilkinson et al., 
2003).  
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2.11.10. Possible factors affecting the bioavailability and absorption of flavonoids  
There are several important factors which could affect the bioavailability and rate of 
absorption of quercetin glucosides by intestine. Indeed, quercetin is present as conjugates 
with the flavonoid aglycone linked to variable sugar moieties by β-glyosidic bond, dietary 
flavonoids are attached to sugar residues which affect the mechanism of absorption by 
altering their physicochemical properties and ability to enter cells, or to interact with 
transporters and cellular lipoproteins (Day et al., 2003). Moreover, deglycosylation and 
availability of lactase enzyme (LPH) are also important factors for the absorption and transfer 
of flavonoids from the intestinal lumen into circulation (Day et al., 2003). The 
deglycosylation of the quercetin glucoside would lead to a greater concentration of aglycone 
at the apical enterocyte membrane and eventually elevate the absorption rates (Boyer et al., 
2005). Moreover, it is important to consider the conjugation reactions, such as sulfation or 
glucuronidation, which result in modification of quercetin and quercetin glucosides in liver 
and intestinal cells (Day et al., 2000c). 
Caco-2 cells, due to their cancerous origin, may have some limitations; for instance, several 
proteins are significantly different from that found in healthy animal models and human 
tissue (Nemeth et al., 2003). In terms of bioavailability of flavonoids, it is suggested that 
quercetin glucosides are more bioavailable in humans than the quercetin aglycone (Boyer et 
al., 2005). Quercetin glucoside is more stable than quercetin and is consequently more likely 
to stay intact in the gut. For instance, quercetin-glucoside bioavailability in Caco-2 cells 
increased up to 2-fold, while there was no change in the absorption of quercetin (Boyer et al., 
2005). Also, Hollman et al (1995) showed that 52% of the quercetin glucosides from onions 
was absorbed, whereas only 24% of free quercetin was absorbed in human intestinal model. 
It would therefore appear that the quercetin glucosides are better absorbed than the free 
aglycone (Salucci et al., 2002). 
2.11.11. Effect of hydroxylation and localisation of flavonoids on intestinal metabolism 
Onion extract is also rich in anthocyanins such as cyanidin, petunidin and delphinidin (Park, 
1999). These anthocyanins are all hydroxylated at the C-5 and C-7 positions. Hydroxylation 
at these positions has been previously discussed as a structural feature that elevates inhibitory 
effects of flavonoids on Caco-2 cells glucose absorption (Park, 1999). The research 
conducted by Park (1999) is of high importance as he evaluated 10 different flavonoid species, 
the structural classes of which covered flavones, flavonols, flavanones, isoflavones, 
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anthocyanidins and catechins. He also investigated various hydroxylation patterns, 
orientation of the B-ring, availability of a ketone group, presence of double bonds on the 6-
member rings and moiety effect on inhibitory effects of these compounds. 
 Notably, Park (1999) found that hydroxylation at specific positions was effective for glucose 
inhibition; for instance, hydroxylation at C-5 and C-7 are necessary, while at C-3 and C-3’, 
it had no effect. Moreover, positioning of the B-ring is crucial, as flavonoids have a greater 
inhibitory property than isoflavonoids that contain the B-ring conjugated at C-3 rather than 
C-2. Also, presence of a double bond among C-2 and C-3 raised the inhibitory capacity (Park, 
1999). Other studies have shown that glucose moieties will bind to the similar transporter 
binding site as hexoses; therefore, competitively delaying the transport of monosaccharide 
through steric interference preventing transport of glucose alone (Johnston et al., 2005a). 
Alternatively, both glycoside and aglycone flavonoids may bind to a separate binding site, 
affecting both transporter function and membrane integrity (Nakayama et al., 2000). 
However, regardless of the possibility of non-specific polyphenol interactions with any 
membrane or any glucose binding site, in support of our current findings, this inhibition has 
been previously shown in Caco-2 and Xenopus oocytes, the effect seems to be glucose 
transporter specific (Kwon et al., 2007, Salucci et al., 2002). 
As GLUT-2 translocates in accordance to its substrate; therefore, it is crucial to detect its 
localisation at the suitable area to be inhibited (Helliwell et al., 2000). In our research, we 
have shown the inhibition of GLUT-2 under sodium-independent condition through function 
of GLUT-2 on basolateral compartment. Other studies have also illustrated appearance of 
GLUT-2 on the basolateral membrane (Kwon et al., 2007). Here we have demonstrated on 
Caco-2 cell models that, mimicking human gastrointestinal enterocyte, flavonoids could 
inhibit both glucose-transporters: i.e. apical uptake from the lumen and glucose into blood 
circulation through basolateral membrane. This is important because metabolism of 
flavonoid will involve the apical reflux of flavonoids as well as biliary excretion into 
intestinal lumen (Lotito et al., 2011). Thus, the presence of flavonoids or their reabsorption 
before arrival of dietary glucose into lumen of intestine could lead to a great inhibition of 
glucose transport at intracellular levels.  
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Moreover, it is suggested that membrane proteins can interact with lipid bilayers on the C-
13 terminal loop of SGLT-1, therefore that interactions of quercetin glycosides with 
phospholipids prevent proper conformational changes of membrane proteins essential for 
substrate binding, thus leads to glucose transport inhibition (Raja and Kinne, 2005).  
In the current in vitro study, the effects of polyphenols on glucose transport across the 
intestine were demonstrated by using intact cellular models, Caco-2 cells. Here, two 
parameters were measured, the amount of glucose that appeared inside the cells, as a result 
of apical uptake, and the amount that appears in the basolateral side, indicated the amount 
that passed through the apical and basolateral sides. According to our findings, quercetin 4́-
+glucoside and quercetin 3,4́-diglucoside, quercetin 3-glucoside and phloridzin and onion 
extract all inhibited this transfer from the apical to the basolateral side, mainly by inhibition 
of glucose transport under sodium-dependent conditions with less inhibition under sodium-
independent conditions. In support of our findings, one study showed that strawberry and 
apple extracts also inhibited this apical to basolateral transfer (Manzano and Williamson, 
2010). 
2.11.12.Other mechanisms for the biological effects of polyphenol consumption 
The metabolism of polyphenols is expected to be a key factor determining whether a normal 
diet can deliver effective concentrations of polyphenols to target tissues. The bioavailability 
of different polyphenols is highly variable, containing diverse and complex physiological 
processes. There are between subject variations, which are partially explained by 
heterogeneity in enzymatic activity and gut flora in human beings (de Bock, et al. 2012). 
It is found that concentration of polyphenol metabolite in humans after normal dietary 
exposure is mostly below 1 µmol/L. In vitro studies use media mostly in excess of 1 µmol/L 
for sustained period of time (Manach et al., 2004). Blood concentrations may provide 
information on polyphenol absorption but they do not necessarily correspond to target tissue 
levels. Therefore, measuring polyphenol levels in plasma may not accurately evaluate 
exposure (Hanhineva et al., 2010). Once absorbed, polyphenols undergo rapid reconjugation 
and excretion through similar pathways as pharmaceutical drugs. Whereas, pharmaceutical 
drugs manage to saturate these pathways, polyphenols in normal dietary levels do not. The 
rate of reconjugation of polyphenols is associated with genetic polymorphism for example 
catechol-O-methyltransferase and environmental factors such as smoking (Lotito et al., 
2011). Nevertheless, the net effect of diverse bioavailability, failure to saturate metabolic 
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pathways, and rapid clearance determines why plasma levels of polyphenols in most human 
studies do not reach the required levels as per in vitro and animal studies (Scalbert and 
Williamson, 2000). However, the intestinal absorption can be high, measurement of the 
parent polyphenol in blood rarely exceeds 1% of the raw product (Scalbert and Williamson, 
2000). The half-life values of antioxidant and anti-inflammatory polyphenol properties 
obtained in vitro are 5 to 100 µmol/L, a target hardly found in human studies. For instance, 
eating five apples let to no detectable antioxidant effects, even though just 1% polyphenol 
bioavailability would likely necessary to yield the observe in vitro effects (Lotito et al., 
2011). In order to mimic an in vitro environment, several intakes per day of polyphenol-rich 
diet would be required to ingest the amount and mix of polyphenols necessary to apply the 
observed beneficial effects on glucose homeostasis.  
2.11.12.1. Calorie restricted diet 
In mammals calorie restriction (CR) repeatedly delay disease onset, thereby prolonging 
healthspan. As diet consumption also seems to influence health, like preventing CVD and 
type 2 diabetes. Interestingly, polyphenols intake and calorie restriction seem to have similar 
effects on metabolism in humans, and supplementation with polyphenols induce may 
decrease negative effects from a high fat diet in mice (Pallauf et al., 2013). Thus, polyphenols 
are also referred to as CR mimetics. An important mechanism by which polyphenols induce 
CR-like signaling pathways suggested to function through sirtuin activation. Sirtuins are 
NAD-dependent deacetylases that were shown to be involved in the metabolism in different 
organisms (Pallauf et al., 2013). More evidence exists in support of the polyphenols role in 
gene regulation through gamma coactivator 1-alpha (PGC-1α) and transcription factors such 
as a nuclear factor-erythroid 2 (Nrf2), all of which are also implicated in CR-mediated effects 
(Shai, et al. 2008). 
Mediterranean diet, which involves restricted-calorie diet and meals rich in vegetables with 
high amounts of secondary plant bioactives such as polyphenols, appears to be a safe strategy 
to benefit from potentially healthspan-improving CR mimetics (Amiot et al., 2016). 
According to a study, mice with diets rich in olive oil phenolics had reduced oxidative 
damage markers such as lipid peroxides, and improved expression of Nrf2-dependentt gene 
encoding antioxidant proteins (Pallauf et al., 2013). Resveratrol in red wine and quercetin in 
onion highly consumed in Mediterranean diet could both induce Sirtuin, results in 
endothelium protection and inhibition of inflammation via NFkB downregulation (Shai, et 
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al. 2008). 
2.11.12.2. Epigenetics 
Epigenetics is the study of heritable changes in gene expression caused by mechansims other 
than changes in the underlying DNA sequence. During epigenetic changes, the nucleotide 
sequence of a gene does not change, however other alterations occur in the DNA, like DNA 
methylation or histone acetylation that affect gene expression (Korzus, 2010). Changes in 
the pattern of DNA methylation has been associated with a range of activities in prevention 
and alleviation of various diseases such as cancer, type 2 diabetes and nueroinflammation 
(Ayissi et al., 2014). It has been suggested that many polyphenols exert some of their 
beneficial effects through chromatin remodeling and epigenetic modifications. Initial 
evidence indicates that dietary polyphenols change epigenetic state and accordingly might 
reverse abnormal gene expression (Rahman and Chung, 2010). These compounds are able to 
alter DNA methylation and histone modifications, leading to gene activation or silencing. 
Many polyphenols, such as resveratrol and catechins are reported to modulate nuclear factor 
kappa B (NF kappaB) expression and chromatin remodeling through modulation of histone 
deacethylase (HDAC) and DNA methyl transferase (DNMI) activities (Ayissi et al., 2014). 
2.11.13. Common Pitfalls in Caco-2 Assays 
Some of the current in vitro results were unexpected due to possible limitations associated 
with cell culture studies. Therefore, it is important to note how accurately cell culture 
techniques are performed. For instance, improper distribution of cells in the wells and inserts 
or low viability rate of Caco-2 cells in the wells, could cause inconsistency in the 
radiolabelled glucose uptake levels. Moreover, the high likelihood of contamination or over-
growth of cells within 5-20 days need to be considered. Also, inaccurate use of Gilson 
pipettes may determine a great possibility on incorrect volume of the sample solutions to be 
taken, and lead to discrepancy of our findings. 
At cellular level, it has been shown that there is a significant difference in mRNA expression 
levels of efflux transporters in Caco-2 cell monolayer compared to small and large intestines 
in humans. The variations in transporter proteins expression in Caco-2 cell monolayer create 
false negative results that may not associate with human or animal studies (Awortwe et al., 
2014).Moreover, the expression of CYP3A4-intestinal Cytochrome plays a vital role in the 
metabolism of flavonoids and herbs. An ideal cell-based model for intestinal permeability 
studies should mimic the human gastrointestinal enterocytes by expressing metabolic 
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enzymes together with the lipid bilayer combined with transporters and tight junctions to 
give a consistent representation of the interaction between CYP3A4 and (P-glycoprotein) P-
gp. However, there is a low expression of CYP3A4 on Caco-2 cell monolayer which fails to 
simulate in vivo intestinal environment, and is considered the core flavonoid-metabolising 
enzyme in the human epithelial cells (Rege et al., 2002).  
Several factors that affect the permeability of flavonoid compounds on Caco-2 monolayers 
include: the amount of flavonoid compounds that appeared in the receiver (wells) 
compartment, the initial concentration in the donor section (inserts), and the surface area of 
the physical barrier (for example, lipid bilayers and cell monolayer) affect the permeability. 
It is also possible that these polyphenolic compounds non-specifically bind to plastic devices 
(transwell plates), changing the concentration in the donor and receiver compartments during 
incubation period and therefore leading to underestimation of permeability estimates and 
false negatives. Non-specific binding can also occur during transfer of cultured sample 
together with the quercetin glucosides or onion into another container.  
Another important factor could be the lack of adequate solubility; interestingly, the 
permeability evaluation of test compounds in Caco-2 is underestimated due to poor aqueous 
solubility. In our study, organic co-solvent such as DMSO was added to the tests samples at 
a concentration less than1% v/v. Above this concentration, the cell tight junction is 
compromised and reduces the monolayer viability (Bogman et al., 2003).  
Intestinal pH variations from the upper small intestine to the distal large intestine define the 
nature of compounds absorbed at a specific region. For instance, weak acidic compounds 
remain unchanged in the upper small intestine because of high pH. Thus, passive transcellular 
transport becomes the main absorption route into the circulation (Rege et al., 2001). Caco-2 
studies are incapable of simulating the changes of intestinal pH system since it is performed 
at constant pH conditions (apical pH of 6.5 and basolateral pH of 7.4). Any changes in pH of 
Caco-2 cell protocols may influence its cytoarchitecture and underestimate the permeability 
characteristics (Awortwe et al., 2014).  
Other experimental variability, for example, different laboratories work under diverse 
experimental conditions such as culturing, passage number and culture duration, could 
account for differences in permeability rates. Also, the inter-laboratory variations affect the 
141 
 
expression levels of glucose transporters which depend on the age of the cell culturing, 
culture duration and passage number (Balimane and Chong, 2005).  
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3. CHAPTER THREE - IN VIVO STUDY 
3.1 Introduction 
3.1.1. Clinical Study 
Some dietary polyphenols can modify the apparent GI of foods by reducing glucose 
absorption (Hanhineva et al., 2010a). Onions are a major dietary source of polyphenols, such 
as quercetin glucosides, and the glucosides in an onion meal can be completely hydrolysed 
in the human small intestine to quercetin, as demonstrated in ileostomy patients (Walle et al., 
2000).  
According to a previous study conducted by Walgren, et al. 2000, both quercetin 4́-glucoside 
and quercetin 3,4́-diglucoside in an onion solution were effectively hydrolysed in the human 
small intestine to the quercetin aglycone. It was determined that almost none or only trace 
amounts of both quercetin glucosides appeared in the ileostomy fluid, after the hydrolysis of 
onion flavonoids components with LPH (Walgren et al., 2000). In support of that, in the 
current in vitro study, quercetin 4́-glucoside and quercetin 3,4́-diglucoside were hydrolysed 
to free quercetin aglycone by β-galactosidase from Aspergillus oryzae. This was followed by 
incubation with Caco-2 cells to show the changes on glucose uptake, which modelled the 
effect of intestinal LPH on quercetin glucosides hydrolysis and glucose uptake. 
The β-glycosidase lactase phlorizin hydrolase (LPH) is responsible for hydrolysis on the 
luminal side of enterocytes (Day et al., 2000a). LPH is expressed in lactose-tolerant people 
but not in lactose-intolerant people. Hence, we hypothesised that quercetin glucosides may 
be less effective at blocking glucose uptake in lactose-tolerant people (because they can 
hydrolyse quercetin glucosides to the aglycone with LPH) compared to lactose-intolerant 
people. We tested this hypothesis using an onion meal, since onions are a rich source of 
quercetin glucosides (mainly quercetin 4́-glucoside and quercetin 3,4́-diglucoside), but 
contain very little free quercetin (Lombard et al., 2002). 
3.1.2. Aims 
 To investigate whether a food extract (onion solution) acts as inhibitors of the uptake 
of glucose in human subjects  
 To compare the glucose levels in lactose tolerant and intolerant subjects after intake 
of onion solution 
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3.2. Materials used in vivo study 
Consumables/Equipment 
Hydrogen breath analyser (Bedfont) 
Blood glucose analyser (EKF) 
Box of test strips 
Lancet (bunzlehealthcare) 
Non-sterile gloves 
Sharps container 
Multi standard 12mmol/L ready for use-2ml (EKF diagnostic) 
Biosen sensor test solution Glucose/Lactate 1ml tubes 
Glucose/Lactase haem solution tubes-20µl Capillary 
Biosen glucose/Lactate system solution 2.5L Can 
Table 3.1: Materials used in human physiology lab 
3.2. Methods 
3.2.1. Participants 
All 24 participants gave written consent and participant information was coded. Exclusion 
criteria: under 18 years old; history of blood disorder; pregnant; diabetic; data on 
contraceptive pill use was not collected. The protocol was approved by University of 
Hertfordshire Ethics Committee (Protocol cumber LMS/PG/UH/00187, Appendix 1 & 2) 
and all participants gave written consent (Appendix 3). 
 
24-Participants  
 
Age ± SD 
   Female 
 
Male 
P-value 
(Age) 
LT vs. LINT 
 
BMI 
(kg/m2)±SD 
P-value (BMI 
kg/m2) 
LT vs. LINT 
12-Lactose 
Tolerant (LT) 
27.6± 4.6 
       8 
4  
 
0.4 
22±3.4 
 
 
0.18 12-Lactose 
Intolerant 
(LINT) 
29.8±7.4 
  7 
5        
24.3±4.3 
Table 3.2: The mean and SD of Age and BMI (kg/m2) for 12 lactose-tolerant and 12 lactose-intolerant 
individuals at significance level of p < 0.05 
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3.2.2. Onion meal preparation 
Fresh red onions were purchased from Asda super market (10 fresh organic red onions in 
total, 500 grams). Onion bulbs had their dry skin peeled off to the first whole fresh scale, cut 
into 4-6 mm cubes and then 18-20g aliquots were left as raw. Afterwards, they were 
homogenised in water (25% w/v), boiled for 15 minutes, cooled to room temperature and 
filtered twice through a handheld baking sieve. Quercetin and quercetin glucosides were 
analysed by reverse phase HPLC (Lombard et al., 2002). 
3.2.3. Hydrogen breath test (Lactose-Intolerance Diagnosis) 
The Gastro+ Gastrolyzer (Bedfont product number GP0221400913) is a breath hydrogen 
monitor used to measure hydrogen levels in expired breath (Bedfont, 2016). It is intended for 
multi-patient use by healthcare professionals in a clinical environment. It can be used to 
indicate the following disorders, carbohydrates breakdown deficiency, carbohydrate 
malabsorption, lactose intolerance and bacterial overgrowth (Ghoshal, 2011).  
A Breath test was performed after an overnight fast. At the start of the test, fasting breath 
hydrogen was estimated 3 to 4 times and the average of these values was taken as the basal 
breath hydrogen.  
Operation of the Gastrolyzer is straightforward. A D-piece sampling system enabled end-
expired breath to be sampled easily and hygienically, using single-use disposable cardboard 
Faltpak mouthpieces and screen to ensure ease of operation. Also, the users can view results 
in a tabular or graphical format. Temperature may affect the accuracy of the Gastrolyzer. The 
instrument was calibrated at 21 °C (±4 °C). If the Gastrolyzer is used at a lower temperature 
than when it was calibrated, readings may be lower. When using at a higher temperature than 
calibrated, reading may be higher (Eisenmann et al., 2008).  
The participants were asked to inhale as deeply as possible and hold their breath throughout 
the on-screen sound during the last three seconds of the countdown. Then they were asked to 
exhale slowly but gently into the mouthpiece, aiming to empty the lungs as far as possible. 
Lactose intolerance was measured by using the hydrogen breath test analyser. Lactose (25g 
dissolved in 220 ml water) was given to subjects and breath hydrogen was measured over 2 
hours. Hydrogen levels 20 ppm above baseline were classified as lactose intolerance 
(Eisenmann et al., 2008). 
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Figure 3.1: Hydrogen breath analyser (Gastrolyzer). 
 
3.2.4. Blood Glucose measurement (finger prick) 
A self-monitoring or blood glucose monitoring by finger prick is a quick and easy method of 
identifying problems with blood sugar levels. EKF Diagnostics is a worldwide manufacturer 
of point of care equipment for the measurement of glucose, lactate, haemoglobin and glycated 
haemoglobin (HbA1C). EKF (Biosen S-Line Lab+ with catalogue number 5222-0123-6200) 
glucose analyser can test blood, plasma or serum to provide glucose and lactase values with 
excellent precision (less than >2% CV) over a wide measurement range. The figure below 
demonstrates the steps taken in the finger prick collection of blood and measurement of 
glucose levels (EKF, 2010). 
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Figure 3.2: EKF glucose analyser and steps involved in finger prick blood collection (EKF, 2010). 
3.2.5. Glucose tolerance test 
The participants were asked to avoid strenuous exercise and not intake alcohol or caffeine at 
night before the study day (Johnston et al., 2003). Finger prick capillary blood samples were 
obtained after an overnight fast and at 15, 30, 60, 90 and 120 minutes after drinking a glucose 
solution (50 g glucose dissolved in 220 ml water). The same blood collection regime was 
then repeated on a subsequent day after participants had consumed 220 ml of an onion meal 
(25% w/v) containing glucose (50 g). Glucose was measured with an EKF glucose analyser. 
The incremental area under the time glucose curve (AUC) was calculated using a linear 
trapezoidal method in Excel, taking the fasting blood glucose concentration as the baseline. 
The mean changes for peak glucose and blood glucose AUC were then compared between 
lactose-tolerant and lactose-intolerant groups in Excel by two-tailed t-tests and using two-
sample unequal variance. Quality of variance was tested for by an F test. 
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3.2.6. Statistical analysis (Clinical studies) 
Data are given as mean ± standard deviations (SD) from 24 participants. Changes in blood 
glucose concentrations from the baseline concentrations were measured by subtracting the 
fasting value from the highest value and were demonstrated as incremental (∆) 
concentrations. The incremental area under the curve (iAUC) for blood glucose was 
calculated from the incremental concentrations by using the trapezoid rule. Percentage 
changes in peak glucose and blood glucose AUC values were calculated for glucose control 
versus glucose plus onion with each participant acting as their own control. The mean 
changes for peak glucose and blood glucose AUC were then compared between lactose-
tolerant and lactose-intolerant groups in Excel by two-tailed t-tests and using two-sample 
unequal variance. Quality of variance was tested for by an F test. Analysis of variance 
(ANOVA) can determine whether the means of three or more groups are different. ANOVA 
uses F-tests to statistically test the equality of means. 
  
148 
 
3.3. Results 
The onion meal contained 1.7 µg/ml quercetin, 42.2 µg/ml quercetin 4'-glucoside and 31 
µg/ml quercetin 3,4'-diglucoside. Consuming an onion meal reduced the glycaemic response 
in both lactose-tolerant and lactose-intolerant people as determined by glucose AUC and 
peak blood glucose concentration.  
 
 
There was a statistically significant greater reduction in glycaemic response, as measured by 
changes in peak blood glucose, by the onion meal in lactose-intolerant people compared to 
lactose-tolerant people (44.19% and 19.28% respectively, p = 0.042) (Table 3.3). The onion 
meal also caused a greater reduction in blood glucose AUC in lactose-intolerant people 
compared to lactose-tolerant people, but this was not statistically significant (54.53% versus 
42.06% respectively, p = 0.425) (Table 3.3). 
Figure 3.3 below shows blood glucose concentrations following consumption of glucose or 
glucose plus an onion meal in 12 lactose-tolerant and lactose-intolerant adult participants. 
 AUC (mM x min) 
Reduction in 
AUC by onion 
Δ Blood glucose (mM)a 
Reduction in Δ 
glucose by 
onion 
 
Glucose 
Control 
Glucose + 
onion 
P % pb 
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Glucose 
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186.4 
(58.05) 
109.3 
(58.15) 
0.0037 
42.06 
(25.98) 
 
0.425 
3.06 
(1.18) 
2.24 
(0.93) 
0.083 19.28 
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130.2 
(49.22) 
57.1 
(55.48) 
0.0034 
54.53 
(44.05) 
3.03 
(0.90) 
1.77 
(0.93) 
0.0038 44.19 
Table 3.3: Effects of an onion meal on peak rise in blood glucose and incremental area under the blood 
glucose – time curve (AUC) in lactose-tolerant and lactose-intolerant adults. Values are expressed as means 
and s.d. a Peak glucose at 30 min minus fasting glucose. b Lactose-tolerant versus lactose-intolerant. 
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Figure 3.3: Blood glucose concentrations after consumption of glucose (●) or glucose plus an onion meal (■) 
in (a) lactose-tolerant adults and (b) lactose-intolerant adults. Data are means  SEM (n = 12) 
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3.4. Discussion 
The results of our pilot study indicate a more statistically significant reduction of peak 
glucose concentrations by an onion meal (solution) in lactose-intolerant people compared to 
lactose-tolerant people. This supports our hypothesis that LPH in lactose-tolerant people is 
hydrolysing quercetin glucosides in the onion meal and that this diminishes the quercetin 
glucosides ability to inhibit glucose uptake.  
In the current in vivo study, we have addressed the possible factors, which could have affected 
the antiglycaemic ability of flavonoids in onion in lactose-tolerant and intolerant people. 
Firstly, reduced glucose uptake in lactose-tolerant people may be related to inhibition of 
GLUT-2 by quercetin produced from the hydrolysis of quercetin glucosides by LPH. 
Quercetin has been shown to inhibit GLUT-2, and transport of glucose from the gut to the 
blood stream requires not only luminal glucose uptake into enterocytes via SGLT1, but also 
release from the basal membrane of enterocytes into the blood stream via GLUT- 2 (Johnston 
et al., 2005b) Secondly, both lactose-tolerant and intolerant people may express other 
glucosidases able to cleave quercetin glucosides. Thirdly, onions are rich in the soluble fibre 
inulin, and some types of dietary fibre reduce postprandial glycaemia.  
In order to use onions, it is important to consider the phenolic compositions of onion, which 
vary because of biological variations associated to cultivar, growing season, and 
environmental and agronomic conditions (Perez-Gregorio et al., 2010). Moreover, change in 
the content of flavonoids in onion depends on the availability of nutrients and water. It is 
believed that there is a strong phenotypic and genotypic correlation among the soluble solid 
contents, flavour and nutritional values of onions. In addition, harvesting at maturity stage is 
also a vital aspect when considering the chemical content and storage of the onion bulb 
(Slimestad et al., 2007). 
The flavonoids from onions have been described to have antidiabetic properties. These 
include mechanisms for improvement of insulin release and improved insulin sensitivity 
(Williamson, 2013). It is suggested that these compounds can modulate the postprandial rise 
in blood glucose levels due to an interaction with intestinal enzymes such as LPH and 
transporters that are responsible for the release and absorption of dietary glucose. 
Polyphenols are mainly consumed with a diet rich in fruits, vegetables, tea and other plant-
based food products and usually represent a versatile mixture of different components. They 
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can reach concentrations up to several hundred micromolar in the lumen of the human gut 
(Williamson, 2013); www.phenol-explorer.eu) and therefore may be able to reach intestinal 
glucose transporters and cause their inhibition. It is important to note that, participants in our 
pilot study were healthy (non-diabetic), and it has been suggested that GLUT-2 is 
permanently located at brush border membrane in insulin resistant individuals (but not 
healthy individuals) reducing higher levels of glucose and fructose absorption (Ait-Omar et 
al., 2011). Therefore, for the case of diabetic patients, onion could have a great antiglycaemic 
effect. 
Apart from glucose transporters in the intestine, it is important to consider the renal tubule 
which expresses in addition to SGLT-1, the SGLT-2 transporter with the latter, causing most 
of the renal glucose reabsorption. Both transporters possess the same affinities for glucose. 
Since quercetin is bioavailable and is filtered in kidneys, in a human study they tested 
whether the onion extract given to the human volunteers affected glucose disposal into urine 
after the OGTT. Such an effect was shown in a study after intake of an apple extract rich in 
phloridzin (Schulze et al., 2014). However, intake of the onion extract did not result in any 
changes in urinary glucose levels examined over 24 hours after the OGTT. Therefore, from 
our findings and these previous findings, further research is required to be carried out on 
urinary glucose levels after consumption of onion meals, in addition to blood glucose levels. 
Moreover, a new class of antidiabetic drug with partially similar structure with phloridzin 
inhibit SGLT-2 in the kidney, and demonstrated reduction in fasting plasma glucose levels 
and less postprandial glucose rates in patients with type 2 diabetes (List and Whaley, 2011). 
The effects of SGLT-2 inhibitors are linked with great glucose loss in renal sites by 
significant reduction of glucose re-uptake in S2 and S3 segments in kidney (Ferrannini et al., 
2010).  
 According to findings from several other human studies, in type 2 diabetic volunteers, 
quercetin (400 mg) given 30 min prior to an OGTT with 100 g glucose failed to change levels 
of blood glucose (Hussain et al., 2012), whereas onion extracts were shown to have an impact 
on the glucose plasma levels in patients with type 2 diabetes (Myint et al., 2009). This 
indicates more and other effects of the extract than that of quercetin and quercetin derivatives.  
Various herbs and dietary supplements, such as quercetin supplements, are known to alter β-
cell insulin output or peripheral insulin activity (Yeh et al., 2003). For quercetin, glucose-
induced insulin release from isolated rat pancreatic islets revealed an increase (Youl et al., 
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2010). As an example for effects in target tissues of insulin may be the recent in vitro study 
that revealed that extracts from vinification byproducts of Vitis vinifera with quercetin as the 
dominant constituent significantly inhibited glycogen phosphorylase (GP), an enzyme that 
catalyses the first step of intracellular degradation of glycogen to glucose-1-phosphate and 
the hepatic release of glucose (Kantsadi et al., 2014). GP inhibitors have been suggested as 
new hypoglycaemic agents for treatment of type 2 diabetes (Treadway et al., 2001) similar 
to inhibitors of hepatic glucose-6-phosphatase, an enzyme involved in the glucose release 
from glucose-6-phosphate as the final step in gluconeogenesis and glycogenolysis (Arion et 
al., 1997). Therefore, onion extracts or onion-derived polyphenols have the potential to affect 
physiological processes beyond intestinal glucose absorption and their effect will likely 
depend on dose and time. 
The glycaemic index (GI) of onion solution containing glucose can be measured to rank its 
glycaemic potency (Jenkins et al., 1981). GI is calculated as the incremental area under the 
curve (AUC) for blood glucose after intake of onion solution containing glucose, divided by 
the AUC of reference glucose solution. Therefore, for the case of mixed meals, i.e. onion 
with glucose, it is possible to rank order of the average glycaemic responses produced by 
onion meal eaten on multiple occasions over a period of time (15, 30, 45, 60, 80 and 120 
minutes). Our participants were given an onion solution containing glucose. It is important 
to note that, because of large between and within person variation of glycaemic responses, 
the amount cannot be used to predict the absolute glycaemic response of a person on a single 
occasion.  
However, accurate prediction of the relative glycaemic effect of onion meal is only possible 
in clinical settings if accurate values for GI of the onion and dietary glucose are known 
(Wolever et al., 2006). It is suggested that the GI of individual foods is lost when combined 
in a mixed meal (Hollenbeck et al., 1986). However, in another study, they showed the GI of 
individual foods is a significant determinant of the glycaemic effect of composite mixed 
meals (Wolever et al., 2006). Moreover, in our clinical study, the effects of protein and fat 
were not measured in the mean glycaemic response, which was in agreement with a previous 
study conducted by Wolever, et al. (2006). However, this is inconsistent with findings from 
other studies (Flint et al., 2004, Alfenas and Mattes, 2005). 
Consuming dietary flavonoid glucosides is an interesting approach to reducing the glycaemic 
response to a meal, and this aligns with a recent conclusion of the International Carbohydrate 
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Quality Consortium that overall diet, rather than just the GI values of individual foods, is 
important when evaluating the potential health risks of sugary foods consumed as part of a 
meal.(Augustin et al., 2015b). 
In support of current in vivo findings, several studies have reported the antidiabetic effects 
of various forms of onions, including aqueous onion extracts (El-Demerdash et al., 2005), 
dietary onions (Jelodar et al., 2005) and isolated or synthesised active compounds in onions 
(Kumari and Augusti, 2002, Sheela et al., 1995). All of these reports determined a great 
antihyperglycaemic effects of onions and its compounds in STZ-induced diabetic rats. 
Interestingly, in another research, they found that drinkable ripe onion juice, had a low 
hypoglycaemic activity in normal rats, while it caused antidiabetic effect in STZ-induced rats 
(Lee et al., 2013).  
Application of onion extract in mice fed with high fat diet resulted in lowering levels of 
postprandial blood glucose (Pereira et al., 2011). Similar findings were also detected in a 
study with type-2 diabetic patients (Myint et al., 2009). Here in our study, intake of 25% w/v 
onion solution containing 50g fresh red onion with 50g glucose (boiled 15min) resulted in a 
significant reduction in blood glucose concentrations at 45 minutes after the glucose load in 
lactose-intolerant individuals. Therefore, this result showed that the onion meal preparation 
worked on lowering levels of blood glucose in vivo study. Notably, in support of our current 
findings, an in vitro study illustrated an increased inhibitory potential for α-glucosidase and 
α-amylase inhibition in the presence of combinations (onion solution) compared to single 
compounds (quercetin) (Oboh et al., 2011). 
In the current clinical study, participants were given onion meal (boiled solution) rather than 
raw onion; therefore, the boiling condition could have altered the antiglycaemic effects of 
onion. Some clinical studies in humans have shown the hypoglycaemic activity of Allium 
cepa by showing that addition of raw onion to the diet for non-insulin-dependent diabetic 
people reduced the dose of antidiabetic medication needed for disease control (Bhushan, 
1984). According to several reports, onion acts as a hypoglycaemic agent through its effects 
on the small intestine, liver and muscles tissues, and changes the activities of the regulatory 
enzymes of glycolysis, gluconeogensesis and other pathways, such as reduction of ER stress, 
rather than increasing insulin levels and generating extra pancreatic effects (Taj Eldin et al., 
2010, Eldin et al., 2009). ER stress has been shown to have a crucial effect in the development 
of insulin resistance and diabetes by impairing insulin signalling (Fonseca et al., 2009, 
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Kaufman et al., 2010); therefore, effects of onion extracts or its components could retain the 
properties as strong antidiabetic agents by alleviating ER stress.  
It is important to take into consideration that some ingredients, in particular, volatile sulfur 
compounds including thiosulfonates and polysulfides for hypoglycemic activity might be lost 
during the preparation of onion meal or by passing over its best distribution period. Also, 
these sulfur compounds, available in onions in the form of cysteine derivatives, could be 
degraded during extraction by the enzyme allinase (El-Demerdash et al., 2005). Moreover, 
another study reported that S-methylcysteine sulfoxide isolated from onion has an 
antihyperglycaemic effect (Kumari and Augusti, 2002). Our observed increase in fasting 
blood glucose levels at both lactose-tolerant and lactose-intolerant groups during the first 30 
min after oral intake of onion meals containing glucose, in addition to glycaemic effect of 
glucose, is also thought to be attributed to the glucogenic effects of Allium cepa, which might 
be from the cysteine present in onion (Sheela et al., 1995). These glucogenic effects can 
counteract the common side effect (hypoglycaemia) of antidiabetic agents currently used if 
Allium cepa is taken concurrently as a food supplement. 
Further attention is required on the effect of cooking procedures on the content of flavonoids 
in onion. In fact, examining the following cooking methods: boiling, frying with oil or butter 
and microwave cooking. Previously, various cooking methods did not illustrate a consistent 
result on degradation of quercetin conjugates in onion. For instance, microwave cooking 
without water retained flavonoids, also frying did not affect flavonoid intake and viability 
(Loku et al., 2001). However, in agreement with our findings, the boiling of onion (onion 
solution) caused up to 30% loss of quercetin glycosides, which were transferred to the boiling 
water. The hydrolysis of quercetin glycosides for daily cooking might occur with the addition 
of seasonings such as glutamic acid. Additional ferrous ions could also accelerated the loss 
of flavonoids (Loku et al., 2001, Park, 1999). 
Our data indicates that different types of dietary polyphenols affect the intestinal glucose 
transport. Furthermore, these data suggest that foods rich in these dietary polyphenols might 
provide a dietary mechanism for the regulation of intestinal sugar absorption that is an 
important factor in the management of diabetes and in the long-term offer some protection 
against developing type-2 diabetes. Therefore, physiological and pharmacological health 
benefits of polyphenols cannot be side-lined. This would be helpful in reducing sudden 
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elevation in glucose and insulin levels in response. Hence, the need of time is to utilise these 
naturally occurring compounds for the health benefits.  
Although, in the current clinical study, onion meal resulted in reducing peak blood glucose 
levels in both lactose-tolerant (non-diabetic) and intolerant participants (non-diabetic), lower 
hypoglycaemic activity of onion meal in lactose-tolerant adults was observed. Further long 
term studies for the antiglycaemic effect of onion is required for healthy subjects with lactose 
intolerance condition. 
  
156 
 
4. CHAPTER FOUR - GENERAL DISCUSSION 
The principal quercetin compounds in onion are -glycosides quercetin 3,4́-diglucoside and 
quercetin 4́-glucoside. In current study, 3,4’-diglucoside and quercetin 4́-glucoside 
accounted for 31% and 43% of total concentrations of quercetin glucosides in onion, 
representing the combined value of up to 74%. Our findings agree with Lombard et al. (2002) 
and Price et al. (1997) who reported these two main quercetin glucosides conjugated together 
accounted for up to 80% of total flavonols content in onion. Moreover, in our study, quercetin 
4́-glucoside is found as the main quercetin glucoside in onion, agreeing with findings from 
Lombard et al. (2002) and Leighton et al. (1992). 
In our research, phloridzin, which is a known inhibitor of SGLT-1, was used as a positive 
control, and quercetin aglycone, quercetin 4́-glucoside, quercetin 3,4́-diglucoside, quercetin 
3-glucoside were tested on Caco-2 cells radiolabelled 3H-glucose uptake under both sodium-
dependent and independent conditions. The three quercetin glucosides caused a significant 
reduction on Caco-2 radiolabelled glucose levels under sodium-dependent conditions; also 
their inhibitory effect were found concentration dependent (Boyer et al., 2005). According 
to several other studies whose results correlate with ours, it is generally considered that 
flavonoid glucosides in onion such as phloridzin, quercetin 4́-glucoside, quercetin 3,4́-
diglucoside, quercetin 3-glucoside and onion extract are causing greater glucose inhibition 
under sodium dependent condition compared to sodium free condition (Walgren et al., 2000, 
Walle and Walle, 2003).  
However, under sodium-independent conditions, none of these quercetin glucosides showed 
a significant glucose inhibition, while only their aglycone form quercetin caused a great 
glucose inhibition. Aglycones such as quercetin, flavone and daidzein or genistein are 
absorbed by passive diffusion in the intestine through sodium-independent GLUT-2 due to 
their lipophilic characteristics (Kuo, 1998, Murota et al., 2002).  
In addition to flavonoids, inulin which is a soluble fibre is found in onions. According to a 
previous study several types of dietary fibre reduced postprandial glycaemia (Bonsu et al., 
2011), although, in the current study, inulin did not reduce the uptake of radiolabelled glucose 
in the presence and absence of sodium conditions. Therefore, the main inhibitory effect of 
the onion extract is suggested to be through flavonoids quercetin and its derivatives on 
SGLT-1 and GLUT-2 transporters (Cermak et al., 2004). However, in our experiments, the 
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main source of tested inulin was chicory not onion; therefore, this could be the reason for 
inconsistency of our data on low inhibitory effect of inulin on glucose uptake. 
We found that onion extract treated with Aspergillus oryzae β-galactosidase, had an increase 
on the levels of quercetin aglycone, with concomitant reductions in quercetin 3,4́-diglucoside 
and quercetin 4́-glucoside, and confirmed that β-galactosidase deglycosylated quercetin 4́-
glucoside and quercetin 3,4́-diglucoside to quercetin, respectively. These results were in 
accordance to research conducted by Cheng et al. (2011), In the current in vitro study, lower 
inhibitory effect of both onion and quercetin 3,4́-diglucoside were found after 60 minutes’ 
incubation with β-galactosidase Aspergillus oryzae on Caco-2 cells glucose uptake. 
Our data support the idea that -galactosidase is causing deglycosylation of quercetin 
glucosides (quercetin 4́-glucoside) which suggests that quercetin glucoside can no longer 
stay intact in the presence of -galactosidase, thus free quercetin will be released. Nemeth et 
al. (2003) have already published the substrate specificity of purified sheep LPH for the 
above quercetin glucosides, which is in line with our present findings quercetin 3,4́-
diglucoside, 4-glucoside and onion are suitable substrates for -galactosidase hydrolysis.  
The scientific evidence on the importance of polyphenol compounds to delay digestion and 
absorption of carbohydrate and to suppress hyperglycaemia in the postprandial state is 
promising, although it is mainly established on in vitro and animal studies. Evidence from 
human studies indicates that beverages such as apple juice, red wine and onion soup have 
glycaemic control effect (Johnston et al., 2002). Current in vitro studies were conducted to 
model or predict whether the in vivo study is likely to succeed or not. Thus, the in vitro study 
demonstrated quercetin glucosides and onion extract block glucose uptake, whereas free 
quercetin did not. Also, the in vivo study found that glucose uptake was blocked by the onion 
solution; therefore, it is possible, based on findings from the in vitro studies, that this could 
be due to the fact that in the absence of lactase, quercetin glucosides are not broken down 
and thus block the uptake of glucose.  
LPH-lactase is a membrane-bound enzyme present on the luminal side of the brush border 
and can therefore act on flavonoid glucosides before absorption. Another possibility is that 
enterocytes are constantly shed from the top of the intestinal villi into the lumen at a very 
high rate (Day et al., 2000a). Whether these enterocytes are viable or not, they may be capable 
of hydrolysing flavonoid glucosides present in the intestinal lumen -glucosidase activity 
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toward quercetin 4́-glucoside and other flavonoid glucosides have been detected in intestinal 
tissue from rats (Ioku et al., 1998) and humans (Walgren et al., 2000). The finding that 
ileostomy fluid had -glucosidase activity supports either mechanism. It is possible that some 
of the hydrolysis may have occurred in the ileostomy bag since a bacterial contamination of 
the ileostomy fluid from bacterial -glucosidase activity cannot be excluded. A variety of 
bacterial strains have high activity of this hydrolytic enzyme which can also lead to 
hydrolysis of these flavonoid glucosides (Walgren et al., 2000).  
In addition to the LPH expression in the enterocytes, the expression of other glucosidases 
such as α-glucosidases were possible in both lactose-tolerant and intolerant people, which 
could lead to deglycosylation of quercetin glycosides in the small intestine (Bonsu et al., 
2011). Our small pilot study requires a larger scale study to confirm if this benefit is greater 
in lactose-intolerant people compared to lactose-tolerant people.  
In addition, our study cannot rule out that other components in the onion meal are responsible 
for the reduced glucose uptake in the presence of onion. Nevertheless, our study does raise 
the possibility that a diet containing quercetin glucosides (and possibly other flavonoid 
glucosides hydrolysed by LPH) may be of greater benefit for glycaemic control in lactose-
intolerant people than for lactose-tolerant people.  
In order to optimise our pilot study, a higher number of participants are required to confirm 
if health benefits of onion remain greater in lactose-intolerant people compared to lactose-
tolerant adults. Moreover, our study illustrated that a diet containing quercetin glucoside may 
be of greater benefit for glycaemic control in lactose-intolerant people than for lactose-
tolerant people. Therefore, lactose tolerance could be a confounding factor in studies that 
compare glycaemic responses to diets between regions of the world where lactose tolerance 
is high, such as Northern Europe, with regions where lactose intolerance is high, such as the 
Mediterranean basin.   
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4.3. Conclusion 
According to our current findings from experimental work, a clear picture of how glucose 
transporters work and how much glucose uptake was obtained on the Caco-2 cell culture 
models in the presence of several most widely found flavonoids in onions. Caco-2 cell 
models demonstrated that phloridzin, quercetin 4́-glucoside, quercetin 3,4́-diglucoside and 
quercetin 3-glucoside inhibited sodium-dependent glucose uptake, whereas the aglycones 
quercetin inhibited sodium-independent glucose uptake. Quercetin glycosides inhibited this 
transfer from the apical to the basolateral side, primarily by inhibition of sodium independent 
GLUT-2 with less inhibition of sodium-dependent SGLT-1.  
Quercetin 4́-glucoside followed by quercetin 3,4́-diglucoside had the highest concentrations 
in the red onion extract. The assay of β-galactosidase from Aspergillus oryzae was conducted 
to model intestinal LPH, which showed the hydrolysis of quercetin 4́-glucoside and quercetin 
3,4-́diglucoside to free aglycones. In vitro experiments were useful on designing clinical 
studies, but they cannot be used to decisively conclude that the same results will occur in 
humans. This is because humans possess different enzymes and have different ways that 
lactase works in the body. This, however, still supports the notion that lactose intolerant 
people might be less prone to diabetes because they are more able to block dietary glucose. 
A human study was conducted in order to investigate, the antiglycaemic effects of flavonoids 
in onions, when lactose-tolerant and intolerant individuals consumed onion solution. There 
was a statistically significant higher decrease in glycaemic response, as determined by 
changes in peak blood glucose, by the onion meal in lactose-intolerant people compared to 
lactose-tolerant people. Although the number of participants in the human study groups was 
small, but it showed that onion (Allium cepa) in addition to its nutritional values has 
antiglycaemic effects that could be beneficial in management of blood glucose levels in 
adults and can possibly be in type 2 diabetic patients, mainly the level of its safety as revealed 
by its worldwide use as vegetable. 
We suggested that taking onion solution may reduce hyperglycaemia in lactose-intolerant 
participants more than lactose-tolerant people. In conclusion, the current research suggests 
that onion solution may be able to normalise the levels of blood glucose when doses are 
continuous for long periods. These findings provide a basis for the use of this drinkable onion 
product for the prevention of diabetic patients also. Therefore, we conclude that intake of this 
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product could be beneficial in prevention of type 2 diabetes mellitus, and lactose-intolerant 
people would benefit more from the antiglycaemic effect of onions compared to lactose-
tolerant adults. Of course, further studies for its long term effect for the prevention of diabetes 
and their link with lactose-intolerance are required. 
4.4. Future work 
Various cohort studies have shown an inverse relationship between flavonoids intake and 
diabetes. Flavonoids such as quercetin and its derivatives have received much attention on 
the literature over the past 10 years. However, most of the studies have been conducted in 
vitro; thus it is difficult to draw definite conclusion about usefulness of flavonoids in the diet. 
There is a need to improve analytical techniques to allow collection of more data in this 
aspect. 
Regarding the Caco-2 cell models, the efflux of polyphenolic compounds into the basolateral 
medium could be addressed by adding phloretin, which is a known inhibitor of GLUT-2 
mediated glucose transport on the basolateral membrane. Determining the exchange of 
glucose distribution between flavonoids will also help in showing the cooperation between 
cellular glucose levels and these compounds. Further research is required to determine the 
impacts of flavonoids on activation of carbohydrate response elements or protein trafficking.  
In addition to Caco-2 cell lines that expresses SGLT-1and GLUT-2 glucose transporters in 
the small intestine, it will be useful to consider the role of other transporters such as SGLT-
2 sodium-dependent glucose cotransporter, that is responsible for majority of glucose 
transport in kidney (Yi et al., 2013). Therefore, for future work use of CHO cell lines that 
express the human SGLT-2 transmembrane protein, along with a fluorescent glucose 
transporter assay that uses 2-NBDG as a glucose analog, a non-radioactive cell-based assay 
is suggested to be conducted for characterisation of SGLT-2 inhibitors (Blodgett et al., 2011).  
 To validate the effect of onion intake in vivo for future, the efficiency of onion extract is 
suggested to be compared with acarbose, a well-inhibitor of intestinal disaccharidases (Kang 
and Kim, 2010). In order to have a more consistent results from our clinical study, more 
participants and longer duration of the experiment is advised i.e. blood glucose levels are 
suggested be measured for 2-6 hours. Also, we elaborated that lactose-intolerant people 
would benefit more from the antiglycaemic effect of onions compared to lactose-tolerant 
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adults. However, more research for its long term beneficiary effects on type 2 diabetes and 
their link with lactose intolerance are required. 
In addition to Caco-2 cell models and human studies on antiglycaemic effects of flavonoids 
in onion on glucose levels, further research needs to be conducted on animal models such as 
rats. Also, a feeding study and oral glucose tolerance test in mice are recommended; which 
involves mice with 12 weeks of dietary intervention and collection of blood samples 15, 30, 
60, 90 and 120 min after glucose load with subsequent blood glucose measurements. 
Moreover, developing and validating an in situ closed loop perfusion method in rat colon is 
suggested, in order to compare with small intestine and Caco-2 cell models. Also, it is 
suggested that examination of interaction between onion extract and sodium-dependent 
glucose absorption, using isolated jejunal vesicles from rats and pigs be conducted by way 
of future research. 
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6. CHAPTER SIX – APPENDICES 
6.1. Appendix 1 
UNIVERSITY OF HERTFORDSHIRE 
FORM EC1: APPLICATION FOR ETHICAL APPROVAL 
OF A STUDY INVOLVING HUMAN PARTICIPANTS 
(See Guidance Notes) 
   
 
 
 
 
DECLARATIONS 
 
DECLARATION BY APPLICANT (See GN 2.1.3) 
 
(i) I undertake, to the best of my ability, to abide by accepted ethical principles in 
carrying out the study. 
 
(ii) I undertake to explain the nature of the study and all possible risks to potential 
participants, to the extent required to comply with both the letter and the spirit of 
my replies to the foregoing questions (including information contained in 
Appendices 1 & 2).  
 
(iii) Data relating to participants will be handled with great care. No data relating to 
named or identifiable participants will be passed on to others without the written 
Relevant ECDA: 
 
Science & Technology  
 
 
X 
 
OFFICE USE ONLY 
 
Protocol Number: 
 
 
Initial classification:  
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consent of the participants concerned, unless they have already consented to 
such sharing of data when they agreed to take part in the study.  
 
(iv) All participants will be informed (a) that they are not obliged to take part in the 
study, and (b) that they may withdraw at any time without disadvantage or having 
to give a reason. 
 
Where the participant is a minor or is otherwise unable, for any reason, to give full 
consent on their own, references here to participants being given an explanation or 
information, or being asked to give their consent, are to be understood as referring to 
the person giving consent on their behalf. (See Q 19 above; also GN Pt. 3, and 
especially 3.6 & 3.7 
Enter your name here   
 Golnaz Ranjbar……………………………………..Date…19/03/2014……………. 
 
If you are a member of staff, please obtain the signature of your line manager to 
indicate their agreement to this application: 
……………………………………………………      
………………………………………………………     
(Signature)                                      (Name in BLOCK CAPITALS and           position within 
the School) 
DECLARATION BY SUPERVISOR (see GN 2.1.3) 
 I confirm that the proposed study has been appropriately vetted within the School in 
respect of its aims and methods as a piece of research; that I have discussed this 
application for Ethics Committee approval with the applicant and approve its 
submission; and that I accept responsibility for guiding the applicant so as to ensure 
compliance with the terms of the protocol and with any applicable ethical code(s).  
Enter your name 
here………………………………………………………...Date……………… 
 
186 
 
THE STUDY 
 
 Q1. Please give the title (or provisional title) of the proposed study. (NB – you will be asked 
for further details later) 
Health Significance of Lactose Intolerance  
 
1. THE APPLICANT 
 
 
Q2. Please answer either Q2.1 or Q2.2 by providing the information requested.  Q2.1 should 
be answered by individual applicants, both staff and students, who require protocol 
approval for work which they themselves intend to carry out.  Q2.2 should be answered 
by academic staff requiring approval for standard protocols governing classroom 
practical work (or equivalent work) to be carried out by a specified group of students. 
(See GN 2.2.1 & 2.2.19) 
 Q2.1. Name of applicant/(principal) investigator  
Status:  
 
(a) undergraduate                   
                   
(b) postgraduate (taught/research)     
 
(c) academic staff          
 
   (d) other - please give details here         
  School/Department 
            School of Life and Medical Sciences 
 
X 
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            Department of Human and Environmental Sciences 
  Programme of study or award (e.g. BA/MSc/PhD/Staff research) 
              PhD 
E-mail address 
  g.ranjbar2@herts.ac.uk 
 
 
Name of supervisor 
Dr Richard Hoffman 
Supervisor’s contact details (email, extension number) 
             r.hoffman@herts.ac.uk  Extension number: 4526  
Q2.2. Class Protocol Applications Only.  
Name of applicant/(principal) investigator (member of staff) 
  School/Department 
  Programme of study or award (e.g. BSc/MA) 
Module Title 
  Year/group to be governed by the protocol 
Number of students conducting the study 
  Programme Tutor (if different from the applicant) 
E-mail address 
Please note: Risk Assessment Form EC5 is mandatory for all Class Protocol 
Applications and must accompany this application. 
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2. DETAILS OF THE PROPOSED STUDY 
 
 
Q3. (a) Is it likely that your application will require NHS approval? (See GN 2.2.2) 
 
              YES                                      NO 
 
        (If YES, please answer (b) & (c))               (If NO, please continue on to Q4) 
         
(b) Please confirm whether your research involves any of the following: 
  
 
NHS Patients 
Clinical trial of an investigational product 
Clinical trial of a medical device 
Exposure to any ionising radiation 
Adults who lack the capacity to consent 
Human Tissue 
 (c) Please confirm whether this study is considered to be a Clinical Trial of 
Investigational Medical Products (CTIMP) or Clinical Trial of Investigational 
Medical Devices. (See GN 2.2.2) 
 
              YES                                      NO 
 
 
X 
 
 
 
 
 
 
X  
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If YES, please indicate if the study involves any of the following categories: 
 
Children under 5 
 
 
Pregnant women 
 
 
A group of more than 5,000 people 
 
 
Study would be undertaken overseas 
If your study is likely to require NHS approval or is a Clinical Trial of Investigational 
Medical Products or Devices, DO NOT complete this form any further and submit it to 
your relevant ECDA at this stage. All NHS applications must be made on an IRAS form. 
If your study is a Clinical Trial of Investigational Medical Products or Devices involving 
one of the above specified categories, you will be contacted by the relevant ECDA 
with information on the next steps. Please note, you will be issues with a UH Protocol 
Number but this will not be valid until you have sent your relevant ECDA a copy of 
your NHS approval. 
Q4. Please give a short synopsis of your proposed study; stating its aims and highlighting, if 
appropriate, where these aims relate to the use of human participants. (See GN 2.2.3) 
Please enter details here. 
The aim is to investigate whether there is any difference in the uptake of glucose, 
when a food extract (onion) or other foods e.g. apple is consumed by lactose-tolerant 
and lactose-intolerant individuals. In this study, a hydrogen breath test will be 
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conducted for diagnosis of lactose tolerance and intolerance, and glucose levels will 
be measured by taking blood samples through finger pricks.  
Human participants are needed for part of this study, which cannot be performed in 
vitro or with animals. Details are described in the answer in Q5.  
Q5. Please give a brief explanation of the design of the study and the methods and 
procedures used, highlighting in particular where these involve the use of human 
participants. You should clearly state the nature of the involvement the human participants 
will have in your proposed study and the extent of their commitment. Thus you must complete 
and attach the Form EC6 (Participant Information Sheet) (see Appendix 2). Be sure to 
provide sufficient detail for the Committee to be clear what is involved in the proposed study, 
particularly in relation to the human participants. (See GN 2.2.4) 
I will provide a promotional poster in the CP snow building, and will invite students 
through study net. I will also ask the student union to advertise this study through the 
media available to them to obtain appropriate number of participants.  
In order to measure the glucose level among lactose tolerant and intolerant subjects, 
20 subjects will be recruited. Subjects will be excluded if they have had a significant 
current or previous medical history, such as diabetic patients, those who are/were 
receiving regular medication (apart from oral contraceptives) that may have affected 
gastrointestinal function, those with a history of fits, bleeding disorder (e.g. 
haemophilia) and pregnant women. Inclusion criteria (both groups): both sexes.  
The proposed study involves the use of a hydrogen breath test. The Gastrolyzer+ is 
a portable hand-held hydrogen breath tester, it is designed to aid in detection of 
gastro-intestinal disorders such as lactose intolerance. The hydrogen breath test 
involves 50 g of oral consumption of lactose, and then measuring the levels of 
hydrogen in breath (> 20 ppm) over the following 3-6 hours with levels above 20 
ppm showing lactose intolerance. Operation of the monitor is straightforward. A D-
piece sampling system enables end-expired breath to be sampled easily and 
hygienically, using single-use disposable cardboard FlatpakTM mouthpieces.  
After distinguishing lactose tolerant and intolerant individuals, will fast overnight for 
10-12 hours, a blood samples from human subjects will be drawn from a finger by 
pricking with a lancet (0 min) and collected into a capillary tube (10 μl samples). 
Each participant will then be given a solution of 50 g glucose in 220 ml water, then 
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blood samples will be taken at 15, 30, 60, 90 and 120 minutes. Each participant will 
then be given a solution of 50 g glucose in 220 ml water plus a portion of onion soup 
(mixture). Blood samples will again be taken by finger-prick at 0, 15, 30, 60, 90 and 
120 minutes. The sample is measured in an EKF glucose analyser by transferring into 
the EKF safe-lock cup prefilled with 0.5ml haemolysis solution, which reads the 
blood glucose level (mmol/L).  
Q6. Please give the starting date and finishing date. (For meaning of 
“starting date” and “finishing date”, see GN 2.2.5) 
Starting Date: June 2014  
Finishing Date: December 2014 
Q7. Where will the study take place? (If this is on UH Campus, who will permission be 
obtained from e.g. your Module Leader, Programme Tutor, Pro-Vice Chancellor 
(Student Experience) or the Dean of Students. If this is NOT on UH Campus, please 
attach a copy of the written permission, given by the proprietor, manager or other person 
with such authority over the premises, to use the premises for the purposes of carrying 
out this research (see Appendix 2)) (See GN 2.2.6) 
Please enter details here. 
University of Hertfordshire (College Lane Campus)- Human Physiology Lab and 
Diet Lab 
Permission has been obtained from both lab managers/technical staff (see attached). 
Q8. If the location is off campus, have you considered whether a risk assessment is 
necessary for the proposed location? (in respect of hazards/risks affecting both the 
participants and researchers) Please see Form EC5 (see Appendix 2, which is an 
example of a risk assessment form.) Please use this example if a risk assessment is 
necessary, and you have not been provided with a subject specific risk assessment 
form by your School or Supervisor.    
(See GN 2.2.7) 
Q9. (a) Will anyone other than yourself and the participants be present with you when 
conducting this study? (See GN 2.2.8)  
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              YES                                   NO 
If YES, please state the relationship between anyone else who is present other than the 
applicant and/or participants? (e.g. health professional, parent/guardian)  
 
(b) Will the proposed study be conducted in confidence? If NOT, what steps will be 
taken to ensure confidentiality of the participants’ information. (See GN 2.2.8)  
Yes  
  
X  
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3. HARMS, HAZARDS & RISKS 
 
 
Q10. Will this study involve invasive procedures on the human participants? (See GN 2.2.9) 
 
  Yes               No ARE YOU SURE? 
 
  (If YES, please fill out Appendix 1 –   (If NO, answer Q11, Q12, 
Q13 
   Increased Hazards and Risks.              & Q14)      
              Once this is complete, move on  
              to Q15)                
Q11, Q12, Q13 & Q14 - NON INVASIVE STUDIES ONLY 
Note: You are advised to read GN 2.2.10, 2.2.11, 2.2.12 & 2.2.13 carefully before you answer 
the following questions. 
 
Q11. Are there potential hazards to participant(s) and/or investigator(s) from the proposed 
study? (See 2.2.10)  
 
              YES                                    NO  
If YES, 
  Indicate their nature here. 
  Indicate here what precautions will be taken to avoid or minimise any adverse 
effects.  
 
Q12. Will or could the study cause discomfort or distress of a mental or emotional character 
to participants and/or investigator(s)? (See NG 2.2.11) 
 
             YES                                  NO  
X  
 
 
  
194 
 
 If YES, 
 Indicate its nature here. 
 
  Indicate here what precautions will be taken to avoid or minimise such adverse 
effects. 
 
Q13. Will or could medical or other aftercare and/or support be needed by participants and/or 
investigator(s) as a result of the study? (See GN 2.2.12)   
 
            YES                                   NO          
Q14. (a) If you have answered ‘YES’ to Q11, Q12 & Q13, please state here the previous 
experience (and/or any relevant training) of the supervisor (or academic member 
of staff applying for a standard protocol) of investigations involving the hazards, 
risks, discomfort or distress detailed in those answers. (See GN 2.2.13) 
 
(b) Please describe in appropriate detail what you would do should the adverse effects 
or events which you believe could arise from your study, and which you have 
mentioned in your replies to the previous questions, occur.  
(See UPR RE01, S 2.3 (ii) and GN 2.2.13) 
4. ABOUT YOUR PARTICIPANTS 
 
Q15. Please give a brief description of the kind of people you hope/intend to have as 
participants, for instance, a sample of the general population, University students, 
people affected by a particular medical condition, children aged 5 to 7, employees of 
a particular firm, people who support a particular political party. 
   Students and staff from the University of Hertfordshire  
Q16. Please state here approximately how many participants you hope will participate in 
your study. 
24 participants (12 lactose tolerant and 12 lactose intolerant) 
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Q17. By completing this form, you are indicating that you are reasonably sure that you will 
be successful in obtaining the number of participants which you hope/intend to recruit. 
Please outline here how you intend to recruit them. (See GN 2.2.14)  
I will produce a promotional poster and place copies of the poster on notice boards 
throughout the University of Hertfordshire. I will increase the number of participants 
through the assistance of the Nutrition and Dietetics’ programme tutor, who will 
inform the undergraduate students of this programme (permission letter attached). I 
will also seek permission from and the support of the students union to advertise this 
study through the media available to them in order to obtain appropriate number of 
participants (Promotional poster).  
 
5. CONFIDENTIALITY AND CONSENT 
 
[For guidance on issues relating to consent, see GN 2.2.15 & Pt. 3.] 
Q18. Is it intended to seek informed consent from the participants? 
 
              YES                                       NO  
(See UPR RE01, S 2.3 & 2.4 and GN 3.1) 
 
If NO, please explain why it is considered unnecessary or impossible or otherwise inappropriate 
to seek informed consent. 
If YES, please attach a copy of the Consent Form to be used (See Form EC3 & EC4 for reference 
and GN 3.2), or describe here how consent is to be obtained and recorded.  The information you 
give must be sufficient to enable the Committee to understand exactly what it is that prospective 
participants are being asked to agree to. 
 
X  
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Q19. If the participant is a minor (under 18 years of age), or is otherwise unable for any reason to give 
full consent on their own, state here whose consent will be obtained and how? (See especially 
GN 3.6 & 3.7 
One of the preconditions of selecting participants is that they should be 18 years old and  
older. Since the pool of selection for our participants is the campus of the University  
of Hertfordshire, it is likely that our volunteers will fit this criterion.  
Q20. Are personal data of any sort (such as name, age, gender, occupation, contact details or images) 
to be obtained from or in respect of any participant? (See GN 2.2.16). 
 
             YES                                       NO  
If YES, 
(a) Give details here of personal data to be gathered, and indicate how it will be stored. 
Standard questionnaire will be provided in order to collect participants’ names, ages, gender 
and contact details. Moreover, information regarding participants’ current or pervious medical 
histories, diabetes and those with history of blood disorder (i.e. haemophilia) will be gathered.  
 
(b) State here what steps will be taken to prevent or regulate access to personal data beyond 
the immediate investigative team? 
The data collected will be stored on a password-protected laptop. 
(c) Indicate here what assurances will be given to participants about the security of, and access 
to, personal data 
The same level of assurance provided in question (b) above will be provided to the participants 
in written format before they physically participate in the study. The notice will clearly state 
that I will be personally responsible for maintaining the security and confidentiality of such 
data. 
(d) State here, as far as you are able to do so, how long personal data collected during the 
study will be retained, and what arrangements have been made for its secure storage. 
The data will be held in a secure manner for at least the duration of my research project  
X  
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 and will be used as part of the findings of my PhD research project. After such period 
 when the PhD research project is completed, all the personal data will be destroyed.  
 
Q21. Is it intended (or possible) that data might be used beyond the present study? (See GN 2.2.16) 
 
               YES                                       NO  
 
If YES, please give here an indication of the kind of further use that is intended (or which may be 
possible). 
If NO, will the data be kept for a set period and then destroyed under secure conditions?    
 
               YES                                       NO  
 
If NO, please explain here why not. 
Q22. If your study involves work with children and/or vulnerable adults you will require a satisfactory 
Enhanced Criminal Records Bureau Disclosure. (See GN 2.2.17) Please indicate as appropriate: 
(a) CRB Disclosure not required 
 
 
(b) CRB Disclosure required and obtained                    
 
If a satisfactory CRB Disclosure is required, a copy of this must be attached to Appendix 2 in order for 
reviewers to be able to consider your application. 
 
 
 
 
X  
X  
X 
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6. REWARDS 
 
 
Q23. (a) Are you receiving any financial or other reward connected with this study? (See 
UPR RE01, 2.3)  
 
                 YES                                      NO   
 
If YES, give details here. 
(b) Are participants going to receive any financial or other reward connected with the 
study? 
 
                YES                                       NO 
 
If YES, give details here. 
(c) Will anybody else (including any other members of the investigative team) receive 
any  financial or other reward connected with this study? 
 
            YES                                      NO  
If YES, give details here 
 
7. OTHER RELEVANT MATTERS 
Q24. Enter here anything else you want to say in support of your application, or which you 
believe may assist the Committee in reaching its decision. 
 
 
 X 
 X 
 X 
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This section is to be completed if your answer to Q10 affirms the USE OF INVASIVE 
PROCEDURES in your study.  
Note: You are advised to read GN 2.2.10, 2.2.11, 2.2.12, 2.2.13 & 2.2.18 carefully before you 
answer the following questions. 
QA1. Please give details of the procedures to be used (e.g. injection of a substance, insertion 
of a catheter, taking of a blood or saliva sample), and any harm, discomfort or distress that 
their use may cause to participants and/or investigator(s). (See GN 2.2.10) 
 Clean the finger 
 Encourage blood flow (Keep finger warm) 
 Hold the lancet firmly against the finger and press the release bottom  
 Dispose of lancet into sharps bin 
 Wait 6 seconds to allow blood to flow and the bottom of the finger 
to the puncture site 
 Continue this process until a drop of blood is obtained from the 
puncture site 
 Load the blood into a10 l capillary tube 
 Wipe the puncture site with clean swab and apply pressure until the 
bleeding stops 
 Bruising and pain may arise on the side of the fingers 
 Bleeding may not stop immediately after collection of blood by 
capillary tube 
Indicate here what precautions will be taken to avoid or minimise any adverse 
effects.   
 The side of finger is generally less sensitive than the tip of a finger, therefore 
using side of finger will be used 
 Make sure that researcher’s hands are washed prior to the procedure 
 Keep the clean swab on the site of bleeding until it is completely stopped, to 
minimise the risk of any airborne infections 
 Dispose of lancet immediately after use (appropriate bins) to avoid cross 
contamination 
  
QA2. Will the study involve the administration of any substance(s)? (See GN 2.2.10) 
 
 YES NO 
If YES, 
 Give details here of the substance(s), the dose or amount to be given, likely effects 
(including duration) and any potential hazards to participant(s) and/or investigator(s). 
 
 Indicate here what precautions will be taken to avoid or minimise any adverse 
effects.  
 
After measuring the basal hydrogen concentration in the respiratory air of the 
 X 
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participants in the fasting state (which should not be higher than 5 ppm and at most 
10 ppm), the participant will be giving 25 g of lactose dissolved in 250 ml of water.  
It is recommended to dissolve lactose in warm water, as it dissolves better in warm 
water. The hydrogen values are measured at 0 minutes (before the load) as well as at 
15, 30, 60, 90 and 120 minutes after the lactose load.  
Following to the diagnosis of lactose tolerant and lactose intolerant individuals, each 
participant will be given a solution of 50 g glucose solution in 220ml water in 
addition to a portion of onion soup or other food products (e.g. apple). All blood 
samples will be taken immediately: before eating (0 min) and 15, 30, 45, 60, 90 and 
120 min after eating. The glucose levels will be measured at each time point by using 
EKF machine.  
QA3. Are there any potential hazards to participant(s) and/or investigator(s) arising from the 
use of the proposed invasive procedures? (See GN 2.2.10) 
 
             YES                                         NO 
If YES, 
 Indicate their nature here. 
 
Blood collection from fingertips may lead to: 
 Exposure to infectious agents 
 Blood cross-contamination 
 Bruising at sample size 
 
For hydrogen breath test monitor (Gastrolyzer): 
 People with lung disease or chest ailments may not be able to achieve the full 
breath-hold. Therefore, in such cases, this procedure may cause no harm 
however it may cause breathing discomfort in participants 
 Indicate here what precautions will be taken to avoid or minimise any adverse 
effects.  
 
For blood sample collection:  
 Laboratory coats and gloves should be worn throughout the experiments  
 Lancets must not be re-used  
 X 
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 If the blood drop is drawn directly onto a capillary tube, the tube must be 
removed from the analyser so that there is not potential for cross 
contamination 
 All disposable items should be placed immediately in the appropriate clinical 
waste containers 
 Any blood spills should be wiped up immediately 
  The EKF analyser should be cleaned regularly 
 Only minimal pressure should be used to encourage the formation of a blood 
drop  
 
For hydrogen breath test analyser: 
 Participants are advised to inhale and hold their breath for as long as possible 
when the breath test is started, and exhale, if necessary, before the countdown 
has completed. Alternatively, the user can use the face mask sampling mode 
 Under no circumstances should the Gastrolyzer be immersed or splashed with 
liquid  
 When cleaning the monitor, never use alcohol, cleaning agents containing 
alcohol, or other organic solvents, as these vapors will damage the H2 sensor 
inside. 
QA4. Will or could the study cause discomfort or distress of a mental or emotional character 
to participants and/or investigator(s)? (See GN 2.2.11) 
 
             YES                                  NO  
If YES, 
 
 Indicate its nature here 
 
Lancet stick injury, may lead to infection, however the probability is negligible. 
Moreover, bruising and painful lancet entry side, will result in participants’ 
discomfort. Incorrect blood collection may cause withdrawal of participants from the 
study, due to lack of confidence of the investigator. Participants may feel faint at the 
sight of blood drops.   
 Indicate here what precautions will be taken to avoid or minimise such adverse 
effects. 
 
Follow the detailed blood collection procedures for finger picks.  
X 
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The lancets for finger pricks are designed in such a way that they can only be used 
once, thereby minimising the possibility of cross contamination. 
If unable to draw blood, withdraw the lancet and apply light pressure to the site. 
Should not attempt to withdraw blood at the same site again. 
QA5. Medical or other aftercare and/or support must be made available for participants 
and/or investigator(s) who require it where invasive procedures have been used in the 
study. Please detail what aftercare and/or support will be available and in what 
circumstances it is intended to be used. (See UPR RE01, S 2.3 (ii) and GN 2.2.12) 
There could be a very small chance of fainting of participants, once blood is taken 
by finger-prick.  
If the participant fainted lie her/him down and stay with them until they have 
recovered. Little sips of water and a wet towel applied to the forehead. If 
complications arise contact the First Aid Officer. 
Plaster should be used on the site of sampling (tips of fingers)  
QA6. (a) Please state here previous experience (and/or any relevant training) of the 
supervisor (or academic member of staff applying for a standard protocol) of 
investigations involving hazards, risks, discomfort or distress as specified. (See GN 
2.2.13) 
Supervision of many project students 
 (b) Please describe in appropriate detail what you would do should the adverse effects 
or  events which you believe could arise from your study, and which you have 
mentioned in your replies to the previous questions, occur.  
Pain and bruising may arise while stabbing the lancet, therefore informing the 
participants prior to the use of lancet is recommended, followed by minimum 
pressure on the side of fingers to enhance the flow of blood drop. 
In the case of fainting, first aid officers will be asked to come for help and immediate 
treatment steps will be taken: 
 Loosen tight clothing around the neck 
 Raise person’s feet above the level of heart  
 Keep the participant lying down for at least 10 minutes, preferably in a cool 
and quiet space 
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QA7. In the event that the study reveals that a participant has a pre-existing medical 
condition (of which they may or may not be aware), and which could affect their 
present or future health or that of others, they should be informed of this in an 
appropriate manner and advised of follow-up action that they should take. (See GN 
2.2.18) Advice should be sought as to whether information should be passed to their 
GP and a decision taken whether they should be allowed to continue to take part in 
the study. If a potential participant is not willing to agree to such action being taken in 
these circumstances, they should not be allowed to take part in the study. Please 
indicate here what arrangements have been made for complying with these 
requirements. 
If the participant already knows that she/he is lactose intolerant, no additional action 
will be taken. If the participant being told she/he is lactose intolerant for the first 
time, the researcher has a duty of care, relevant information that is available in public 
domain (NHS website) will be provided for the participant. The researcher is not 
qualified to give dietary advise about lactose intolerance however if they have any 
concerns they should make an appointment to see their GP.  
In the case of abnormal blood glucose reading, if the blood sugar level is high 
(hyperglycaemia) or low (hypoglycaemia), the researcher will explain to the 
participants that it is not good for long-term health.  
Please revert to Q15. 
 
Please attach the following documents if you have affirmed possession of them in the relevant 
questions: 
(a) Permission from the location to be used to carry out this study (Q7) 
(This includes permission to use a location on UH Campus and any 
location off of UH Campus which requires permission to use.) 
 
(b) Risk assessment for off campus location (See Form EC5) (Q8) 
(c)  
(d) Copy of Consent Form (See Form EC3 & Form EC4) (Q18) 
(e)  
(f) Copy of Form EC6 (Participant Information Sheet) (Q5) 
 
(g) A copy of the proposed questionnaire and/or interview schedule (if appropriate for  
X 
X 
X 
X 
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6.2. Appendix 2                          
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6.3. Appendix 3 
                       University of Hertfordshire 
 
 
 CONSENT FORM FOR STUDIES INVOLVING HUMAN PARTICIPANTS 
 
  
I, the undersigned [please give your name here, in BLOCK CAPITALS] 
 
…………………………………………………………………………………………………………………………
. 
of [please give contact details here, sufficient to enable the investigator to get in touch with you, such as 
a postal or email address] 
 
…..…………………………………………………………………………………………………………………… 
.. 
hereby freely agree to take part in the study entitled [insert name of study here] 
 
…………………………………………………………………………………………………………………………
.  
 
 
1 I confirm that I have been given a Participant Information Sheet (a copy of which is attached to this form) 
giving particulars of the study, including its aim(s), methods and design, the names and contact details of 
key people and, as appropriate, the risks and potential benefits  
 
2 I have been assured that I may withdraw from the study at any time without disadvantage or having to 
give a reason. 
 
3 I have been given information about the risks of my suffering harm or adverse effects. 
 
4 I have been told how information relating to me (data obtained in the course of the study, and data 
provided by me about myself) will be handled: how it will be kept secure, who will have access to it, and 
how it will or may be used.  
 
 
5 I have been told that I may at some time in the future be contacted again in connection with this or 
another study. 
 
 
  
Signature of participant …………………………………………………………………………………… 
Date …………………………. 
 
 
 
Signature of (principal) investigator ……………………………………………………… 
Date ………………………… 
 
Name of (principal) investigator [in BLOCK CAPITALS please] 
…………………………………………………………………………………………………………………………
……... 
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6.4. Appendix 4 
FORM EC5 – STANDARD RISK ASSESSMENT FORM 
 
1. IDENTIFY HAZARDS 2. WHO COULD BE 
HARMED & HOW? 
3. EVALUATE THE RISKS 4. ACTION NEEDED 
Unintended stabbing by lancet 
 
 Participants  
 Inappropriate use of lancet 
One of the trained staff will be with 
the researcher on day of experiment 
Only retractable lancet devices 
should be used and lancets should be 
immediately disposed of in a sharps 
bin after use 
Exposure to infectious agents Participants 
Exposure to bacterial or fungous 
surface 
Hands should be washed before start 
of the experiment 
Any blood spills should be wiped off 
immediately 
Both subject and experimenter(s) 
hands should be washed prior to the 
experiment. Laboratory coats and 
gloves should be worn throughout the 
experiment. 
Bruising at sampling site 
 
Participants 
 On the site of the injection  
 Only minimal pressure should be 
used to encourage the formation of a 
blood drop 
Do not squeeze the site of injection 
Do not carry heavy bag straight after 
the blood test  
 Fainting Subjects may feel faint at the site of 
blood 
 
Do not panic at the time of fainting, 
since this can cause further 
complications  
Lie the patient down and stay with 
them until they have recovered. Little 
sips of water and a wet towel applied 
to the forehead. Verbal 
communication throughout the 
procedure will reassure the subject. If 
complications arise contact the First 
Aid Officer 
Incorrect blood collection procedure 
 
No blood drawn Lack of training may lead to an 
incomplete procedure 
Adequate training for researcher is 
essential, in order to be able to collect 
blood samples correctly  
NAME: Golnaz Ranjbar 
DATE: 20/01/2014 
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6.5. Appendix 5 
Participant Information Sheet 
Study Title 
Health Significance of Lactose Intolerance  
This study will investigate if there is a difference in the effects of onion or a similar food on 
glucose uptake in lactose tolerant compared to lactose intolerant people.  
Background: 
The study involves you taking a hydrogen breath test in order to establish if you are lactose 
tolerant or lactose intolerant. You will blow into the hydrogen breath tester. You will then 
consume 25 grams of lactose dissolved in 250 ml of water and blow into the hydrogen 
breath tester 15, 30, 60, 90 and 120 minutes after consuming lactose.  
You may then be selected for the next part of the experiment. This involves fasting 
overnight and then coming to the lab. A very small blood sample (10l) will be taken by 
pricking your fingertip with a lancet. You will then drink a solution of 50g glucose dissolved 
in 220ml water and blood samples will be taken by finger prick at 15, 30, 45, 60, 90 and 120 
minutes after drinking the glucose solution. This procedure is then repeated, but the second 
time you consume the glucose solution and an onion soup or similar food.  
Voluntary participation: 
There is no obligation for you to have these blood samples taken, which are being done for 
research purposes only. Your participation in this study is entirely voluntary and you may refuse 
to participate or discontinue participation at any time without penalty or loss of benefits to 
which you would normally be entitled. 
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6.6. Appendix 6 
Confidentiality of records: 
The samples will be destroyed soon after the results are available. You may have some 
minor discomfort associated with the collection of blood. For example, you may have 
pain or bruising due to the needle. Fainting may also occur when blood is taken, 
although this is rare. 
There is no cost to you nor will you receive any payment for taking part. In any medical 
research study certain benefits may be derived. Such benefits include the possibility that 
information learned during this study may help others in the future. It is possible that there will 
be no benefit to you for participating in this study. 
By signing this form, you authorize the use and disclosure of your protected information as 
necessary in order to carry out the research described in this document. Your personal identity 
will be kept confidential 
Your information will remain confidential. Golnaz Ranjbar as the main researcher the ethics 
committee may have direct access to your information collected. These individuals will do 
everything possible to protect your identity. 
INFORMED CONSENT 
I have read the information provided above. I have taken enough time to decide whether or not 
I would like to give permission to undertake the blood sampling for this pre-screening analysis. 
I authorize the use and disclosure (sharing) of my personal health information as described in 
this form. I have retained a signed copy of this form. 
Name of Participant:               Signature of Participant:                         Date: 
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6.7. Appendix 7 
Lactose Tolerant (LT) 
Participants Age yr Sex Height (cm) Weight (kg) BMI kg/m2 
1 26 
8
-F
em
al
e 
(6
7
%
) 
4
-M
al
e 
(3
3
%
) 
162 65 24.7 
2 29 173 71 20.7 
3 28 177 54 17.2 
4 29 177 78 24.9 
5 29 162 69 26.3 
6 32 167 52 18.6 
7 34 173 57 19.7 
8 31 167 77 27.6 
9 21 165 63 23.1 
10 21 177 57 18.1 
11 20 165 55 20.2 
12 31 174 70 23.1 
Average 27.583333   169.9167 64 22.01667 
SD 4.640892   5.853644 9.04534 3.411167 
 
Lactose Intolerant (LINT) 
Participants Age yr Sex Height (cm) Weight (kg) BMI kg/m2 
1 34 
7
-F
em
al
e 
(5
8
%
) 
5
-M
al
e 
(4
2
%
) 
171 82 28.7 
2 30 168 74 26.2 
3 32 175 69 22.5 
4 23 169 95 33.2 
5 27 179 85 26.5 
6 28 167 52 19.5 
7 37 173 80 26.7 
8 25 164 54 20 
9 21 169 62 20.7 
10 19 168 64 22.7 
11 44 172 75 25.3 
12 37 183 63 18.8 
Average 29.75   171.5 71.25 24.2333 
SD 7.39932   5.36826 12.9553 4.30926 
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Age (LT+LINT) 
p-Value t-test 0.39943 
p > 0.05 No statistically significant difference 
BMI (LT+LINT) 
p-Value t-test 0.1763 
p > 0.05 No statistically significant difference  
 
 
Lactose Tolerant Lactose Intolerant 
Participants 
Peak 
Gluc 
Peak 
(Gluc+On) 
Participants 
Peak 
Gluc 
Peak 
(Gluc+On) 
1 2.06 1.35 1 2.4 0.42 
2 1.99 2.89 2 2.9 1.72 
3 3.81 2.3 3 1.7 0.52 
4 3.18 2.1 4 3.81 2.3 
5 4.33 3.1 5 2.24 0.87 
6 4.61 3.87 6 2.44 1.55 
7 3.19 2.22 7 3.01 2.01 
8 3.92 0.89 8 3.57 1.31 
9 2.5 1.64 9 3.91 3.64 
10 2.11 2.36 10 5.14 3.23 
11 0.6 0.78 11 2.4 1.9 
12 4.46 3.4 12 2.9 1.77 
Mean 3.063 2.242 Mean 3.035 1.770 
SD 1.180 0.927 SD 0.899 0.933 
SE 0.340 0.260 SE 0.250 0.270 
p-value 0.083   p-value 0.004   
% Peak G+Go (Inhibition p=0.08) % peak G+Go (Inhibition p=0.0037) 
Peak 
(G+Go) 
73.18 26.82 
Peak 
(G+Go) 
58.32 41.68 
 
